WO2017222976A1 - Heterocyclic compounds as immunomodulators - Google Patents

Heterocyclic compounds as immunomodulators Download PDF

Info

Publication number
WO2017222976A1
WO2017222976A1 PCT/US2017/038120 US2017038120W WO2017222976A1 WO 2017222976 A1 WO2017222976 A1 WO 2017222976A1 US 2017038120 W US2017038120 W US 2017038120W WO 2017222976 A1 WO2017222976 A1 WO 2017222976A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
cycloalkyl
membered heterocycloalkyl
aryl
membered heteroaryl
Prior art date
Application number
PCT/US2017/038120
Other languages
French (fr)
Inventor
Kaijiong Xiao
Fenglei Zhang
Liangxing Wu
Wenqing Yao
Original Assignee
Incyte Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HRP20221030TT priority Critical patent/HRP20221030T1/en
Priority to SG11201811414TA priority patent/SG11201811414TA/en
Priority to MYPI2018002678A priority patent/MY197280A/en
Priority to DK17734589.9T priority patent/DK3472167T3/en
Priority to CN201780049752.9A priority patent/CN109890819B/en
Priority to JP2018566514A priority patent/JP7000357B2/en
Priority to EA201990074A priority patent/EA201990074A1/en
Priority to PL17734589.9T priority patent/PL3472167T3/en
Priority to SI201731245T priority patent/SI3472167T1/en
Priority to AU2017281285A priority patent/AU2017281285C1/en
Priority to EP22184212.3A priority patent/EP4137489A1/en
Priority to BR112018076534-1A priority patent/BR112018076534A2/en
Priority to UAA201900525A priority patent/UA125391C2/en
Priority to EP17734589.9A priority patent/EP3472167B1/en
Application filed by Incyte Corporation filed Critical Incyte Corporation
Priority to MA45392A priority patent/MA45392B1/en
Priority to CR20190028A priority patent/CR20190028A/en
Priority to RS20220907A priority patent/RS63673B1/en
Priority to MX2018016273A priority patent/MX2018016273A/en
Priority to ES17734589T priority patent/ES2927984T3/en
Priority to LTEPPCT/US2017/038120T priority patent/LT3472167T/en
Priority to CA3028685A priority patent/CA3028685A1/en
Priority to KR1020197001807A priority patent/KR102685249B1/en
Priority to IL263825A priority patent/IL263825B/en
Priority to MDE20190506T priority patent/MD3472167T2/en
Publication of WO2017222976A1 publication Critical patent/WO2017222976A1/en
Priority to PH12018502710A priority patent/PH12018502710A1/en
Priority to CONC2019/0000386A priority patent/CO2019000386A2/en
Priority to AU2021250978A priority patent/AU2021250978B2/en
Priority to JP2021209731A priority patent/JP7394824B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • the present application is concerned with pharmaceutically active compounds.
  • the disclosure provides compounds as well as their compositions and methods of use.
  • the compounds modulate PD-1/PD-L1 protein/protein interaction and are useful in the treatment of various diseases including infectious diseases and cancer.
  • the immune system plays an important role in controlling and eradicating diseases such as cancer.
  • cancer cells often develop strategies to evade or to suppress the immune system in order to favor their growth.
  • One such mechanism is altering the expression of co-stimulatory and co-inhibitory molecules expressed on immune cells (Postow et al, J. Clinical Oncology 2015, 1 -9).
  • Blocking the signaling of an inhibitory immune checkpoint, such as PD-1 has proven to be a promising and effective treatment modality.
  • PD-1 Programmed cell death-1
  • CD279 is a cell surface receptor expressed on activated T cells, natural killer T cells, B cells, and macrophages (Greenwald et al, Annu. Rev. Immunol 2005, 23 :515-548; Okazaki and Honjo, Trends Immunol 2006,
  • PD- 1 functions as an intrinsic negative feedback system to prevent the activation of T-cells, which in turn reduces autoimmunity and promotes self-tolerance.
  • PD- 1 is also known to play a critical role in the suppression of antigen-specific T cell response in diseases like cancer and viral infection (Sharpe et al, Nat Immunol 2007 8, 239-245; Postow et al, J. Clinical Oncol 2015, 1 -9).
  • the structure of PD-1 consists of an extracellular immunoglobulin variable-like domain followed by a transmembrane region and an intracellular domain (Parry et al, Mol Cell Biol 2005, 9543-9553).
  • the intracellular domain contains two phosphorylation sites located in an immunoreceptor tyrosine-based inhibitory motif and an immunoreceptor tyrosine-based switch motif, which suggests that PD-1 negatively regulates T cell receptor- mediated signals.
  • PD-1 has two ligands, PD-L1 and PD-L2 (Parry et al, Mol Cell Biol 2005, 9543-9553; Latchman et al, Nat Immunol 2001 , 2, 261-268), and they differ in their expression patterns.
  • PD-L1 protein is upregulated on macrophages and dendritic cells in response to lipopolysaccharide and GM-CSF treatment, and on T cells and B cells upon T cell receptor and B cell receptor signaling. PD-L1 is also highly expressed on almost all tumor cells, and the expression is further increased after IFN- ⁇ treatment (Iwai et al, PNAS2002, 99(19): 12293-7; Blank et al, Cancer Res 2004, 64(3): 1140-5).
  • tumor PD- Ll expression status has been shown to be prognostic in multiple tumor types (Wang et al, Eur J Surg Oncol 2015; Huang et al, Oncol Rep 2015; Sabatier et al, Oncotarget 2015, 6(7): 5449-5464).
  • PD-L2 expression in contrast, is more restricted and is expressed mainly by dendritic cells (Nakae et al, J Immunol 2006, 177:566-73).
  • Ligation of PD-1 with its ligands PD-L1 and PD-L2 on T cells delivers a signal that inhibits IL-2 and IFN- ⁇ production, as well as cell proliferation induced upon T cell receptor activation (Carter et al, Eur J Immunol 2002, 32(3):634-43; Freeman et al, J Exp Med 2000, 192(7): 1027-34).
  • the mechanism involves recruitment of SHP-2 or SHP-1 phosphatases to inhibit T cell receptor signaling such as Syk and Lck phosphorylation (Sharpe et al, Nat Immunol 2007, 8, 239-245).
  • Activation of the PD-1 signaling axis also attenuates PKC- ⁇ activation loop phosphorylation, which is necessary for the activation of NF- ⁇ and API pathways, and for cytokine production such as IL-2, IFN- ⁇ and TNF (Sharpe et al, Nat Immunol 2007, 8, 239-245; Carter et al, Eur J Immunol 2002, 32(3):634-43; Freeman et al, J Exp Med 2000,
  • PD-1 -deficient mice have been shown to develop lupus-like glomerulonephritis and dilated cardiomyopathy (Nishimura et al, Immunity 1999, 11 : 141-151; Nishimura et al, Science 2001, 291 :319-322).
  • LCMV model of chronic infection it has been shown that PD-1/PD-L1 interaction inhibits activation, expansion and acquisition of effector functions of virus-specific CD8 T cells (Barber et al, Nature 2006, 439, 682-7).
  • the present disclosure further provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of the disclosure, or a pharmaceutically acceptable salt or a stereoisomer thereof, and at least one pharmaceutically acceptable carrier or excipient.
  • the present disclosure further provides methods of modulating or inhibiting PD- 1/PD-Ll protein/protein interaction, which comprises administering to an individual a compound of the disclosure, or a pharmaceutically acceptable salt or a stereoisomer thereof.
  • the present disclosure further provides methods of treating a disease or disorder in a patient comprising administering to the patient a therapeutically effective amount of a compound of the disclosure, or a pharmaceutically acceptable salt or a stereoisomer thereof.
  • G 1 is NR 6 and G 2 is CPJR 7 ;
  • G 1 is CR 6 R 6 and G 2 is NR 7 ;
  • X 1 is N or CR 1 ;
  • X 2 is N or CR 2 ;
  • X 3 is N or CR 3 ;
  • Z is O, S, N, NR 4 or CR 4 ;
  • Y 1 and Y 2 are each independently N or C, provided Y 1 and Y 2 are not simultaneously
  • Cy is Ce- ⁇ aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R 8 substituents;
  • R 1 , R 2 and R 3 are each independently selected from H, C1-4 alkyl, C3-10 cycloalkyl, C3- 10 cycloalkyl-Ci-4 alkyl-, Ce- ⁇ oaryl, Ce- ⁇ aryl-Ci-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OR 10 , Ci-4 haloalkyl, Ci-4 haloalkoxy, NH 2 , -NHR 10 , -NR 10 R 10 , NHOR 10 , C(0)R 10 , C(O)NR 10 R 10 , C(0)OR 10 ,
  • each R 10 is independently selected from H, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkoxy, C3-10 cycloalkyl, C3-10 cycloalkyl-Ci-4 alkyl-, Ce- ⁇ aryl, Ce- ⁇ aryl-Ci-4 alkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4- 10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, Ci-4 alkoxy, C3-10 cycloalkyl, C3-io cycloalkyl-Ci-4
  • R 4 , R 5 , R 6 , R 7 and R 8 are each independently selected from H, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered
  • NR a C( NCN)NR a R a , NR a S(0)R a , NR a S(0) 2 R a , NR a S(0) 2 NR a R a , S(0)R a , S(0)NR a R a , S(0) 2 R a , and S(0) 2 NR a R a , wherein the Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-io aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R 4 , R 5 , R 6 , R 7 and R 8 are each optional
  • R 8 substituents on the Cy ring taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R B substituents;
  • R 5 substituents attached to the same carbon atom taken together with the carbon atom to which they are attached, form a C3-6 cycloalkyl ring or 4-, 5-, 6- or 7- membered heterocycloalkyl ring, wherein the C3-6 cycloalkyl ring and 4-, 5-, 6- or 7- membered heterocycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R B substituents;
  • R 9 is halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci- 4 alkyl-, CN, NO2, OR 11 , SR 1 1 , NH 2 , NHR 1 1 , NR N R N , NHOR 1 1 , C(0)R N , C(0)NR N R N , C(0)OR N , OC(0)R N , OC(0)NR N R N , NR N C(0)R N , NRHC ⁇ OR!! ⁇ RHC ⁇
  • each R 1 1 is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • each R A is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • heterocycloalkyl Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R a are each optionally substituted with 1 , 2 or 3 R d substituents;
  • each R c is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • Ci-e alkyl, Ci-e haloalkyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of R n is optionally substituted with 1, 2 or 3 R q substituents;
  • each R d is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, halo, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci- 4 alkyl-, CN, NH 2 , NHOR e , OR e , SR e , C(0)R e , C(0)NR e R e , C(0)OR e , OC(0)R e , OC(0)NR e R e , NHR e , NR e R e , NR e C(0)R e , NR e C(0)NR e R e , NR e
  • each R e is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • heterocycloalkyl Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R e are each optionally substituted with 1, 2 or 3 independently selected R f substituents;
  • each R g is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • R a substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 R h substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-7 membered heterocycloalkyl, Ce- ⁇ aryl, 5-6 membered heteroaryl, Ce- ⁇ aryl- C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-6 membered heteroaryl)-Ci-4 alkyl-, (4-7 membered heterocycloalkyl)-Ci-4 alkyl-, C 1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, halo, CN, OR 1 , SR NHOR 1 , C(0)R ⁇ C ⁇ NR , C(0)OR ⁇ OC(0)R ⁇
  • heterocycloalkyl)-Ci-4 alkyl- of R h are each optionally substituted by 1, 2, or 3 RJ substituents independently selected from C1-4 alkyl, C3-6 cycloalkyl, Ce- ⁇ aryl, 5- or 6-membered heteroaryl, 4-6 membered heterocycloalkyl, C 2 -4 alkenyl, C 2 -4 alkynyl, halo, Ci-4 haloalkyl, Ci-4haloalkoxy, CN, NHOR k , OR k , SR k , C(0)R k , C(0)NR k R k , C(0)OR k , OC(0)R k , OC(0)NR k R k , NHR k , NR k R k , NR k C(0)R k , NR k C(0)NR k R k , NR k C(0)OR k , NR k C(0)OR k , NR k C(0)
  • each R 1 or R k is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloal
  • R e substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 independently selected R h substituents;
  • R substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 independently selected R h substituents;
  • R 1 substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 independently selected R h substituents;
  • R k substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 independently selected R h substituents;
  • R° substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 independently selected R h substituents;
  • R r substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 independently selected R h substituents;
  • each R° or R r is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, Ce- ⁇ aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the C1-4 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, Ce- ⁇ aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C2-4 alkenyl, and C2-4 alkynyl of R 1 , R k , R° or R r are each optionally substituted with 1, 2 or 3 R q substituents;
  • each R 3 ⁇ 4 is independently selected from OH, CN, -COOH, NH2, halo, Ci-6 haloalkyl, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 haloalkoxy, Ci-6 alkylthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C3-6 cycloalkyl, NHR 12 and NR 12 R 12 , wherein the Ci-6 alkyl, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl of R q are each optionally substituted with halo, OH, CN, -COOH, NH2, C1-4 alkoxy, C1-4 haloalkyl, Ci-4 haloalkoxy, phenyl, C3-10 cycloalkyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl and each R 12 is independently Ci-6 alkyl
  • n is an integer of 1, 2, 3 or 4.
  • G 1 is NR 6 and G 2 is CR 7 R 7 ;
  • G 1 is CR 6 R 6 and G 2 is NR 7 ;
  • X 1 is N or CR 1 ;
  • X 2 is N or CR 2 ;
  • X 3 is N or CR 3 ;
  • Z is O, S, N, NR 4 or CR 4 ;
  • Y 1 and Y 2 are each independently N or C, provided Y 1 and Y 2 are not simultaneously
  • Cy is Ce- ⁇ aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R 8 substituents;
  • R 1 , R 2 and R 3 are each independently selected from H, C1-4 alkyl, C3-10 cycloalkyl, C3- 10 cycloalkyl-Ci-4 alkyl-, Ce- ⁇ aryl, Ce- ⁇ aryl-Ci-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OR 10 , Ci-4 haloalkyl, Ci-4 haloalkoxy, NH 2 , -NHR 10 , -NR 10 R 10 , NHOR 10 , C(0)R 10 , C(O)NR 10 R 10 , C(0)OR 10 ,
  • each R 10 is independently selected from H, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, Cw alkoxy, C3-10 cycloalkyl, C3-10 cycloalkyl-Ci-4 alkyl-, Ce- ⁇ aryl, Ce- ⁇ aryl-Ci-4 alkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4- 10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, Ci-4 alkoxy, C3-10 cycloalkyl, C3-10 cycloalkyl-Ci-4 alkyl-, wherein the C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, Ci-4 alkoxy, C3-10 cycloalkyl, C3-10 cycloalkyl
  • R 4 , R 5 , R 6 , R 7 and R 8 are each independently selected from H, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered
  • NR a C( NCN)NR a R a , NR a S(0)R a , NR a S(0) 2 R a , NR a S(0) 2 NR a R a , S(0)R a , S(0)NR a R a , S(0) 2 R a , and S(0) 2 NR a R a , wherein the Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-io aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R 4 , R 5 , R 6 , R 7 and R 8 are each optional
  • R 8 substituents on the Cy ring taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
  • R 9 is halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, (4-10 member
  • each R 11 is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • heterocycloalkyl Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-C 1-4 alkyl-, C3-io cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R 11 are each optionally substituted with 1 , 2 or 3 R b substituents;
  • each R a is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • heterocycloalkyl Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R a are each optionally substituted with 1 , 2 or 3 R d substituents;
  • each R c is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • each R d is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, halo, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci- 4 alkyl-, CN, NH 2 , NHOR e
  • each R e is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • heterocycloalkyl Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R e are each optionally substituted with 1, 2 or 3 independently selected R f substituents;
  • each R g is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • R a substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 R h substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-7 membered heterocycloalkyl, Ce- ⁇ aryl, 5-6 membered heteroaryl, Ce- ⁇ aryl- Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-6 membered heteroaryl)-Ci-4 alkyl-, (4-7 membered heterocycloalkyl)-Ci-4 alkyl-, C 1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, halo, CN, OR 1 , SR, NHOR, C(0)R, C C N , C(0)OR, OC(0)R,
  • heterocycloalkyl)-Ci-4 alkyl- of R h are each optionally substituted by 1, 2, or 3 Ri substituents independently selected from C1-4 alkyl, C3-6 cycloalkyl, Ce- ⁇ aryl, 5- or 6-membered heteroaryl, 4-6 membered heterocycloalkyl, C2-4 alkenyl, C2-4 alkynyl, halo, C1-4 haloalkyl, Ci-4haloalkoxy, CN, NHOR k , OR k , SR k , C(0)R k , C(0)NR k R k , C(0)OR k , OC(0)R k ,
  • each R 1 or R k is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalky
  • R e substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • R substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • R 1 substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • R k substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • R° substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • R r substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • each R° or R r is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, Ce- ⁇ aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the C1-4 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, Ce- ⁇ aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C2-4 alkenyl, and C2-4 alkynyl of R° or R r are each optionally substituted with 1, 2 or 3 R q substituents;
  • each R q is independently selected from OH, CN, -COOH, NH2, halo, C 1-6 haloalkyl, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 haloalkoxy, Ci-6 alkylthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C3-6 cycloalkyl, NHR 12 and NR 12 R 12 , wherein the Ci-6 alkyl, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl of R q are each optionally substituted with halo, OH, CN, -COOH, NH2, C1-4 alkoxy, C1-4 haloalkyl, Ci-4 haloalkoxy, phenyl, C3-10 cycloalkyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl and each R 12 is independently Ci-6 alkyl
  • n is an integer of 1, 2, 3 or 4.
  • G 1 is NR 6 and G 2 is CR 7 R 7 ;
  • G 1 is CR 6 R 6 and G 2 is NR 7 ;
  • X 1 is N or CR 1 ;
  • X 2 is N or CR 2 ;
  • X 3 is N or CR 3 ;
  • Z is O, S, N, NR 4 or CR 4 ;
  • Y 1 and Y 2 are each independently N or C, provided Y 1 and Y 2 are not simultaneously
  • Cy is Ce- ⁇ aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R 8 substituents;
  • R 1 , R 2 and R 3 are each independently selected from H, C1-4 alkyl, C3-10 cycloalkyl, C3- 10 cycloalkyl-Ci-4 alkyl-, Ce- ⁇ aryl, Ce- ⁇ aryl-Ci-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OR 10 , Ci-4 haloalkyl, Ci-4 haloalkoxy, NH 2 , -NHR 10 , -NR 10 R 10 , NHOR 10 , C(0)R 10 , C(O)NR 10 R 10 , C(0)OR 10 ,
  • each R 10 is independently selected from H, C1-4 alkyl, C 2 -4 alkenyl, C 2 -4 alkynyl, C1-4 alkoxy, C3-10 cycloalkyl, C3-10 cycloalkyl-Ci-4 alkyl-, Ce- ⁇ aryl, Ce- ⁇ aryl-Ci-4 alkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4- 10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the C1-4 alkyl, C 2 -4 alkenyl, C 2 -4 alkynyl, Ci-4 alkoxy, C3-10 cycloalkyl, C3-io cycl
  • R 4 , R 5 , R 6 , R 7 and R 8 are each independently selected from H, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered
  • R 8 substituents on the Cy ring taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
  • R 5 substituents attached to the same carbon atom taken together with the carbon atom to which they are attached, form a C3-6 cycloalkyl ring or 4-, 5-, 6- or 7- membered heterocycloalkyl ring, wherein the C3-6 cycloalkyl ring and 4-, 5-, 6- or 7- membered heterocycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
  • R 9 is halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci- 4 alkyl-, CN, NO2, OR 11 , SR 11 , NH2, NHR 11 , NR n R n , NHOR 11 , C(0)R n , C(0)NR n R n , C(0)OR n , OC(0)R n , OC(0)NR n R n , NR n C(0)R n , NR H C
  • each R 11 is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • heterocycloalkyl Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-C 1-4 alkyl-, C3-io cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R 11 are each optionally substituted with 1 , 2 or 3 R b substituents;
  • each R a is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • heterocycloalkyl Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R a are each optionally substituted with 1 , 2 or 3 R d substituents;
  • each R c is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • Ci-e alkyl, Ci-e haloalkyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of R n is optionally substituted with 1, 2 or 3 R q substituents;
  • each R d is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, halo, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci- 4 alkyl-, CN, NH2, NHOR e , OR e , SR e , C(0)R e , C(0)NR e R e , C(0)OR e , OC(0)R e , OC(0)NR e R e , NHR e , NR e R e , NR e C(0)R e , NR e C(0)NR e R e , NR e C(0)
  • each R e is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • heterocycloalkyl Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R e are each optionally substituted with 1, 2 or 3 independently selected R f substituents;
  • each R is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R p are each optionally substituted with 1, 2 or 3 R q substituents; or any two R a substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 R h substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-7 membered heterocycloalkyl, Ce- ⁇ aryl, 5-6 membered heteroaryl, Ce- ⁇ aryl- Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-6 membered heteroaryl)-Ci-4 alkyl-, (4-7 membered heterocycloal
  • heterocycloalkyl)-Ci-4 alkyl- of R h are each optionally substituted by 1, 2, or 3 RJ substituents independently selected from C1-4 alkyl, C3-6 cycloalkyl, Ce- ⁇ aryl, 5- or 6-membered heteroaryl, 4-6 membered heterocycloalkyl, C2-4 alkenyl, C2-4 alkynyl, halo, C1-4 haloalkyl, Ci-4haloalkoxy, CN, NHOR k , 0R k , SR k , C(0)R k , C(0)NR k R k , C(0)OR k , OC(0)R k ,
  • each R 1 or R k is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl
  • R e substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • R substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • R 1 substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents, or 1, 2, or 3 independently selected R q substituents; or any two R k substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents, or 1, 2, or 3 independently selected R q substituents; or any two R° substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents, or 1, 2, or 3 independently selected R q substituents; or any two R r substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycl
  • each R q is independently selected from OH, CN, -COOH, NH2, halo, C 1-6 haloalkyl, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 haloalkoxy, Ci-6 alkylthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C3-6 cycloalkyl, NHR 12 and NR 12 R 12 , wherein the Ci-6 alkyl, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl of R q are each optionally substituted with halo, OH, CN, -COOH, NH2, C1-4 alkoxy, C1-4 haloalkyl, Ci-4 haloalkoxy, phenyl, C3-10 cycloalkyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl and each R 12 is independently Ci-6 alkyl
  • G 1 is NR 6 and G 2 is CR 7 R 7 ;
  • G 1 is CR 6 R 6 and G 2 is NR 7 ;
  • X 1 is N or CR 1 ;
  • X 2 is N or CR 2 ;
  • X 3 is N or CR 3 ;
  • Z is O, S, N, NR 4 or CR 4 ;
  • Y 1 and Y 2 are each independently N or C, provided Y 1 and Y 2 are not simultaneously
  • Cy is Ce- ⁇ aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R 8 substituents;
  • each R 10 is independently selected from H and C1-4 alkyl optionally substituted with 1 or 2 groups independently selected from halo, OH, CN and C1-4 alkoxy; and wherein the C1-4 alkyl, C3-6 cycloalkyl, C 2 -4 alkenyl, C 2 -4 alkynyl and C1-4 alkoxy of R 1 , R 2 and R 3 are each optionally substituted with 1 or 2 substituents independently selected from halo, OH, CN and C1-4 alkoxy;
  • R 4 , R 5 , R 6 , R 7 and R 8 are each independently selected from H, halo, Ci-6 alkyl, C 2 -6 alkenyl, C 2 -6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered
  • R 8 substituents on the Cy ring taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
  • R 5 substituents attached to the same carbon atom taken together with the carbon atom to which they are attached, form a C3-6 cycloalkyl ring or 4-, 5-, 6- or 7- membered heterocycloalkyl ring, wherein the C3-6 cycloalkyl ring and 4-, 5-, 6- or 7- membered heterocycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
  • R 9 is halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci- 4 alkyl-, CN, N0 2 , OR 11 , SR.
  • each R 11 is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-C 1-4 alkyl-, C3-io cycloalkyl-Ci-4 alkyl-, (5-10 member
  • each R a is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • heterocycloalkyl Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R a are each optionally substituted with 1 , 2 or 3 R d substituents;
  • each R c is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • Ci-e alkyl, Ci-e haloalkyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of R n is optionally substituted with 1, 2 or 3 R q substituents;
  • each R d is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, halo, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci- 4 alkyl-, CN, NH 2 , NHOR e , OR e , SR e , C(0)R e , C(0)NR e R e , C(0)OR e , OC(0)R e , OC(0)NR e R e , NHR e , NR e R e , NR e C(0)R e , NR e C(0)NR e R e , NR e
  • each R e is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C 2 -6 alkenyl, C 2 -6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • heterocycloalkyl Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, Ci-6 haloalkyl, C 2 -6 alkenyl, C 2 -6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R e are each optionally substituted with 1, 2 or 3 independently selected R f substituents;
  • each R g is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • heterocycloalkyl Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R p is optionally substituted with 1, 2 or 3 R q substituents;
  • R a substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 R h substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-7 membered heterocycloalkyl, Ce- ⁇ aryl, 5-6 membered heteroaryl, C3-10 cycloalkyl-C 1-4 alkyl-, (5-6 membered heteroaryl)-C 1-4 alkyl-, (4-7 membered
  • R c substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • R e substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • R substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • R 1 substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • R k substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • R° substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • R r substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • each R 1 , R k , R° or R r is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, Ce- ⁇ aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C1-4 haloalkyl, C 2 -4 alkenyl, and C 2 -4 alkynyl, wherein the C1-4 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, Ce- ⁇ aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C2-4 alkenyl, and C2-4 alkynyl of R 1 , R k , R° or R r are each optionally substituted with 1, 2 or 3 R q substituents;
  • each R 3 ⁇ 4 is independently selected from OH, CN, -COOH, NH2, halo, Ci-6 haloalkyl, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 haloalkoxy, Ci-6 alkylthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C3-6 cycloalkyl, NHR 12 and NR 12 R 12 , wherein the Ci-6 alkyl, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl of R q are each optionally substituted with halo, OH, CN, -COOH, NH2, C1-4 alkoxy, C1-4 haloalkyl, Ci-4 haloalkoxy, phenyl, C3-10 cycloalkyl and 4-6 membered heterocycloalkyl and each R 12 is independently Ci-6 alkyl;
  • n is an integer of 1, 2, 3 or 4.
  • G 1 is NR 6 and G 2 is CR 7 R 7 ;
  • G 1 is CR 6 R 6 and G 2 is NR 7 ;
  • X 1 is N or CR 1 ;
  • X 2 is N or CR 2 ;
  • X 3 is N or CR 3 ;
  • Z is O, S, N, NR 4 or CR 4 ;
  • Y 1 and Y 2 are each independently N or C, provided Y 1 and Y 2 are not simultaneously
  • Cy is Ce- ⁇ aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R 8 substituents;
  • each R 10 is independently selected from H and C1-4 alkyl optionally substituted with 1 or 2 groups independently selected from halo, OH, CN and C1-4 alkoxy; and wherein the C1-4 alkyl, C3-6 cycloalkyl, C2-4 alkenyl, C2-4 alkynyl and C1-4 alkoxy of R 1 , R 2 and R 3 are each optionally substituted with 1 or 2 substituents independently selected from halo, OH, CN and C1-4 alkoxy;
  • R 4 , R 5 , R 6 , R 7 and R 8 are each independently selected from H, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered
  • NR a C( NCN)NR a R a , NR a S(0)R a , NR a S(0) 2 R a , NR a S(0) 2 NR a R a , S(0)R a , S(0)NR a R a , S(0)2R a , and S(0)2NR a R a , wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-io aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R 4 , R 5 , R 6 , R 7 and R 8 are each optionally substitute
  • R 8 substituents on the Cy ring taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
  • R 5 substituents attached to the same carbon atom taken together with the carbon atom to which they are attached, form a C3-6 cycloalkyl ring or 4-, 5-, 6- or 7- membered heterocycloalkyl ring, wherein the C3-6 cycloalkyl ring and 4-, 5-, 6- or 7- membered heterocycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
  • R 9 is halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci- 4 alkyl-, CN, NO2, OR 11 , SR 11 , NH2, NHR 11 , NR n R n , NHOR 11 , C(0)R n , C(0)NR n R n , C(0)OR n , OC(0)R n , OC(0)NR n R n , NR n C(0)R n , NRHC ⁇
  • each R 11 is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • heterocycloalkyl Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-C 1-4 alkyl-, C3-io cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R 11 are each optionally substituted with 1 , 2 or 3 R b substituents;
  • each R a is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • heterocycloalkyl Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R a are each optionally substituted with 1 , 2 or 3 R d substituents;
  • each R c is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • Ci-e alkyl, Ci-e haloalkyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of R n is optionally substituted with 1, 2 or 3 R q substituents;
  • each R d is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, halo, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci- 4 alkyl-, CN, NH2, NHOR e , OR e , SR e , C(0)R e , C(0)NR e R e , C(0)OR e , OC(0)R e , OC(0)NR e R e , NHR e , NR e R e , NR e C(0)R e , NR e C(0)NR e R e , NR e C(0)
  • each R e is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • heterocycloalkyl Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R e are each optionally substituted with 1, 2 or 3 independently selected R f substituents;
  • each R is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • heterocycloalkyl Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R p is optionally substituted with 1, 2 or 3 R q substituents;
  • R a substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 R h substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-7 membered heterocycloalkyl, Ce- ⁇ aryl, 5-6 membered heteroaryl, C3-10 cycloalkyl-C 1-4 alkyl-, (5-6 membered heteroaryl)-C 1-4 alkyl-, (4-7 membered
  • R c substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 independently selected R h substituents;
  • R e substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 independently selected R h substituents;
  • R substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 independently selected R h substituents;
  • R 1 substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 independently selected R h substituents, or 1 , 2, or 3 independently selected R q substituents; or any two R k substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents, or 1, 2, or 3 independently selected R q substituents; or any two R° substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents, or 1, 2, or 3 independently selected R q substituents; or any two R r substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-member
  • each R q is independently selected from OH, CN, -COOH, NH2, halo, C 1-6 haloalkyl, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 haloalkoxy, Ci-6 alkylthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C3-6 cycloalkyl, NHR 12 and NR 12 R 12 , wherein the Ci-6 alkyl, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl of R q are each optionally substituted with halo, OH, CN, -COOH, NH2, C1-4 alkoxy, C1-4 haloalkyl, Ci-4 haloalkoxy, phenyl, C3-10 cycloalkyl and 4-6 membered heterocycloalkyl and each R 12 is independently Ci-6 alkyl;
  • n is an integer of 1, 2, 3 or 4.
  • rovided herein is a compound having Formula (IV):
  • R 1 , R 2 and R 3 are each independently selected from H, Ci-4 alkyl, C3-6 cycloalkyl, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OH, C1-4 alkoxy, Ci-4 haloalkyl, Ci- 4 haloalkoxy, NH 2 , -NH-Ci-4 alkyl, -N(Ci- 4 alkyl) 2 , C(0)R 10 , C(O)NR 10 R 10 , C(0)OR 10 , OC(0)R 10 , OC(O)NR 10 R 10 , NR 10 C(O)R 10 , NR 10 C(O)OR 10 , NR 10 S(O)R 10 , NR 10 S(O) 2 R 10 , NR 10 S(O) 2 NR 10 R 10 , S(0)R 10 , S(O)NR 10 R 10 , S(0) 2 R 10 R 10 , and S(O) 2 NR 10 R 10 , wherein
  • R 1 , R 2 and R 3 are each independently selected from H, C1-4 alkyl, C3-6 cycloalkyl, C 2 -4 alkenyl, C 2 -4 alkynyl, halo, CN, OH, C1-4 alkoxy, Ci-4 haloalkyl, Ci- 4 haloalkoxy, NH 2 , -NH-Ci-4 alkyl, and -N(Ci-4 alkyl) 2 .
  • R 1 , R 2 and R 3 are each independently selected from H, C1-4 alkyl, C 2 -4 alkenyl, C 2 -4 alkynyl, halo, CN, OH, C1-4 alkoxy, Ci-4 haloalkyl, or C1-4 haloalkoxy.
  • R 1 is H
  • R 2 is H or halo
  • R 3 is H
  • R 1 , R 2 , and R 3 are H.
  • Cy is phenyl, 5- or 6-membered heteroaryl, C3-6 cycloalkyl or
  • 5- or 6-membered heterocycloalkyl each of which is optionally substituted with 1 to 5 independently selected R 8 substituents; or two adjacent R 8 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or
  • 6- membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R b substituents.
  • Cy is phenyl optionally substituted with 1 to 5 R 8 substituents.
  • Cy is 5- or 6-membered heteroaryl optionally substituted with 1 to 5 independently selected R 8 substituents.
  • Cy is C3-6 cycloalkyl optionally substituted with 1 to 5 independently selected R 8 substituents.
  • Cy is 5- or 6-membered heterocycloalkyl optionally substituted with 1 to 5 independently selected R 8 substituents.
  • Cy is phenyl, 2-thiophenyl, 3-thiophenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 3,6-dihydro-2H-pyran-4-yl, cyclohexyl, cyclohexenyl, 2,3-dihydro-l,4- benzodioxin-6-yl, l,3-benzodioxin-5-yl, 2-methylindazol-6-yl or 1 -methylindazol-4-yl, each of which is optionally substituted with 1 to 5 R 8 substituents.
  • R 9 is halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-e haloalkoxy, CN, NO2, OR 11 , SR 11 , NH2, NHR 11 , NR n R n , NHOR 11 , C(0)R n ,
  • Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, and Ci-6 haloalkoxy of R 9 are each optionally substituted with 1, 2 or 3 R b substituents.
  • R 9 is halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, CN, NO2, or NH2, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, and Ci-6 haloalkoxy of R 9 are each optionally substituted with 1, 2 or 3 R b substituents.
  • R 9 is halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, CN, NO2, and NH 2 .
  • R 9 is halo, Ci-6 alkyl, or CN.
  • R 9 is CH3, CN or halo. In some embodiments, R 9 is CH3. In other embodiments, R 9 is CN. Yet in certain embodiments, R 9 is halo such as F, CI or Br.
  • Z is S, CR 4 , NR 4 , or N and R 4 is independently H or Ci-6 alkyl.
  • Z is S, CH, NCH3 or N.
  • Z is S.
  • Z is CH.
  • Z is N(Ci-6 alkyl) such as NCH3.
  • Z is N.
  • Y 1 is C or N and Y 2 is C.
  • Y 1 is C and Y 2 is N.
  • Y 1 is C, Y 2 is N and Z is N;
  • Y 1 is C, Y 2 is N and Z is CR 4 ;
  • Y 1 is C, Y 2 is C and Z is S; or
  • Y 1 is C, Y 2 is C and Z is O.
  • Y 1 is N, Y 2 is C and Z is N. In certain embodiments, Y 1 is N, Y 2 is C and Z is CR 4 . In certain embodiments, Y 1 is C, Y 2 is N and Z is N. In some embodiments, Y 1 is C, Y 2 is N and Z is CR 4 . In some embodiments, Y 1 is C, Y 2 is C and Z is S. Yet in some embodiments, Y 1 is C, Y 2 is C and Z is O.
  • R 5 is H.
  • G 1 is NR 6 and G 2 is CR 7 R 7 . In some embodiments, G 1 is CR 6 R 6 and G 2 is NR 7 . In some embodiments, R 6 is H or Ci-6 alkyl optionally substituted with 1, 2 or 3 R b substituents. In some embodiments, R 7 is H or Ci-6 alkyl optionally substituted with 1, 2 or 3 R b substituents.
  • R b substituent is independently selected from halo, Ci-6 alkyl, Ci-6 haloalkyl, Ci-ehaloalkoxy, CN, OH, NH 2 , N0 2 , NHOR c , OR c , SR C , C(0)R c , C(0)NR c R c , C(0)OR c , OC(0)R c , OC(0)NR c R c , NHR C , NR C R C , NR c C(0)R c , NR c C(0)OR c , , c C(0)OR c ,
  • Ci-6 alkyl, Ci-6 haloalkyl, and Ci-6 haloalkoxy of R b are each further optionally substituted with 1-3 independently selected R d substituents.
  • R b substituent is independently selected from halo, Ci-6 alkyl, Ci-6 haloalkyl, Ci-ehaloalkoxy, CN, OH, NH2, NO2, OR c , SR C , C(0)R c , C(0)NR c R c , C(0)OR c , NHR C , NR C R C , and NR c C(0)R c ; wherein the Ci-e alkyl, Ci-e haloalkyl, and Ci-e haloalkoxy of R b are each further optionally substituted with 1-3 independently selected R d substituents.
  • R b substituent is independently selected from halo, Ci-6 alkyl, Ci-6 haloalkyl, Ci-e haloalkoxy, CN, OH, NH 2 , OR c , C(0)R c , C(0)NR c R c , and C(0)OR c .
  • R b substituent is independently selected from Ci-6 alkyl, CN, OH, and C(0)OR c .
  • R b is Ci-6 alkyl such as methyl.
  • R b is CN.
  • R b is OH.
  • R b is C(0)OR c such as C(0)OH or C(0)0(Ci-e alkyl).
  • provided herein is a compound of Formula I, or a
  • G 1 is NR 6 and G 2 is CR 7 R 7 ;
  • G 1 is CR 6 R 6 and G 2 is NR 7 ;
  • X 1 is N or CR 1 ;
  • X 2 is N or CR 2 ;
  • X 3 is N or CR 3 ;
  • Z is O, S, N, NR 4 or CR 4 ;
  • Y 1 and Y 2 are each independently N or C, provided Y 1 and Y 2 are not simultaneously N;
  • Cy is Ce-10 aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R 8 substituents;
  • R 1 , R 2 and R 3 are each independently selected from H, C1-4 alkyl, C3-6 cycloalkyl, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OH, Ci-4 alkoxy, Ci-4 haloalkyl, Ci-4 haloalkoxy, NH2, -NH- Ci-4 alkyl, -N(Ci- 4 alkyl) 2 , C(0)R 10 , C(O)NR 10 R 10 , C(0)OR 10 , OC(0)R 10 , OC(O)NR 10 R 10 , NR 10 C(O)R 10 , NR 10 C(O)OR 10 , NR 10 S(O)R 10 , NR 10 S(O) 2 R 10 , NR 10 S(O) 2 NR 10 R 10 , S(0)R 10 , S(O)NR 10 R 10 , S(0) 2 R 10 R 10 , and S(O) 2 NR 10 R 10 , wherein each R 10 is independently selected
  • R 4 , R 5 , R 6 , R 7 and R 8 are each independently selected from H, halo, Ci-6 alkyl, C 2 -6 alkenyl, C 2 -e alkynyl, Ci-e haloalkyl, Ci-e haloalkoxy, CN, N0 2 , OR a , SR a , C(0)R a , C(0)NR a R a , C(0)OR a , OC(0)R a , OC(0)NR a R a , NHR a , NR a R a , NR a C(0)R a , NR a C(0)OR a , NR a S(0)R a , NR a S(0) 2 R a , NR a S(0) 2 NR a R a , S(0)R a , S(0)NR a R a , S(0) 2 R a , and S(0) 2 NR a R a , wherein the Ci
  • R 8 substituents on the Cy ring taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
  • R 9 is halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, CN, N0 2 , OR 11 , SR 11 , NH 2 , NHR 11 , NR n R n , NHOR 11 , C(0)R n , C(0)NR n R n , C(0)OR n , OC(0)R n , OC(0)NR n R n , NR n C(0)R n , NR n C(0)OR n , NR ⁇ C ⁇ NR 11 !*.
  • Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, and Ci-6 haloalkoxy of R 9 are each optionally substituted with 1, 2 or 3 R b substituents;
  • each R 11 is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
  • each R a is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
  • each R b substituent is independently selected from halo, Ci-6 alkyl, Ci-6 haloalkyl, Ci- ehaloalkoxy, CN, OH, NH 2 , N0 2 , NHOR c , OR c , SR C , C(0)R c , C(0)NR c R c , C(0)OR c , OC(0)R c , OC(0)NR c R c , NHR C , NR C R C , NR c C(0)R c , NR c C(0)OR c , NR c C(0)NR c R c ,
  • Ci-6 alkyl, Ci-6 haloalkyl, and Ci-6 haloalkoxy of R b are each further optionally substituted with 1-3 independently selected R d substituents;
  • each R c is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl, wherein the Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl of R c are each optionally substituted with 1, 2 or 3 R f substituents independently selected from Ci-6 alkyl, Ci-e haloalkyl, C2-6 alkenyl, C2-6 alkynyl, halo, CN, OR g , SR g , C(0)R g , C(0)NR g R g , C(0)OR g , OC(0)R g , OC(0)NR g R g , NHR g , NR g R g , NR g C(0)R g , NR g C(0)NR g R g , NR g C(0)OR g , S(0)R g
  • each R d is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, halo, CN, NH 2 , OR e , SR e , C(0)R e , C(0)NR e R e , C(0)OR e , OC(0)R e , OC(0)NR e R e , NHR e , NR e R e , NR e C(0)R e , NR e C(0)NR e R e , NR e C(0)OR e , S(0)R e , S(0)NR e R e , S(0) 2 R e , NR e S(0) 2 R e , NR e S(0) 2 NR e R e , and S(0) 2 NR e R e ;
  • each R e is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • heterocycloalkyl Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-;
  • each R g is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • heterocycloalkyl Ce- ⁇ aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-;
  • z is a single bond or a double bond to maintain ring A being aromatic; and the subscript n is an integer of 1 , 2, 3 or 4.
  • provided herein is a compound of Formula I, or a
  • G 1 is NR 6 and G 2 is CR 7 R 7 ;
  • G 1 is CR 6 R 6 and G 2 is NR 7 ;
  • X 1 is N or CR 1 ;
  • X 2 is N or CR 2 ;
  • X 3 is N or CR 3 ;
  • Z is S, N, NR 4 or CR 4 ;
  • Y 1 and Y 2 are each independently N or C, provided Y 1 and Y 2 are not simultaneously
  • Cy is Ce- ⁇ aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R 8 substituents;
  • R 1 , R 2 and R 3 are each independently selected from H, C1-4 alkyl, C3-6 cycloalkyl, C 2 -4 alkenyl, C 2 -4 alkynyl, halo, CN, OH, Ci-4 alkoxy, Ci-4 haloalkyl, Ci-4 haloalkoxy, NH 2 , -NH- Ci-4 alkyl, and -N(Ci- 4 alkyl) 2 ;
  • R 4 , R 5 , R 6 , R 7 and R 8 are each independently selected from H, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, Ci-e haloalkoxy, CN, NO2, OR a , SR a , C(0)R a ,
  • Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl of R 4 , R 5 , R 6 , R 7 and R 8 are each optionally substituted with 1, 2, 3, 4 or 5 R b substituents;
  • R 8 substituents on the Cy ring taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R b substituents;
  • R 9 is halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, CN, NO2, or NH2, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, and Ci-6 haloalkoxy of R 9 are each optionally substituted with 1, 2 or 3 R b substituents;
  • each R a is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
  • each R b substituent is independently selected from halo, Ci-6 alkyl, Ci-6 haloalkyl, Ci- 6 haloalkoxy, CN, OH, NH2, NO2, OR c , SR C , C(0)R c , C(0)NR c R c , C(0)OR c , NHR C , NR C R C , and NR c C(0)R c ; wherein the Ci-6 alkyl, Ci-6 haloalkyl, and Ci-6 haloalkoxy of R b are each further optionally substituted with 1-3 independently selected R d substituents;
  • each R c is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
  • each R d is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, halo, CN, NH2, OR e , SR e , C(0)R e , C(0)NR e R e , C(0)OR e , NHR e , NR e R e , and NR e C(0)R e ;
  • each R e is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
  • n is an integer of 1 or 2.
  • provided herein is a compound of Formula I, or a
  • G 1 is NR 6 and G 2 is CR 7 R 7 ;
  • G 1 is CR 6 R 6 and G 2 is NR 7 ;
  • X 1 is N or CR 1 ;
  • X 2 is N or CR 2 ;
  • X 3 is N or CR 3 ;
  • Z is S, N, NR 4 or CR 4 ;
  • Y 1 and Y 2 are each independently N or C, provided Y 1 and Y 2 are not simultaneously
  • Cy is phenyl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R 8 substituents;
  • R 1 , R 2 and R 3 are each independently selected from H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OH, C1-4 alkoxy, Ci-4 haloalkyl, or Ci-4 haloalkoxy;
  • R 4 , R 5 , R 6 , R 7 and R 8 are each independently selected from H, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, Ci-e haloalkoxy, CN, NO2, OR a , and C(0)OR a , wherein the Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl of R 4 , R 5 , R 6 , R 7 and R 8 are each optionally substituted with 1 or 2 R b substituents;
  • R 8 substituents on the Cy ring taken together with the atoms to which they are attached, form a fused 5-, 6- or 7-membered heterocycloalkyl ring, or a fused 5- or 6-membered heteroaryl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring are each optionally substituted with 1 or 2 independently selected R b substituents;
  • R 9 is halo, Ci-e alkyl, or CN
  • each R a is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
  • each R b substituent is independently selected from halo, Ci-6 alkyl, Ci-6 haloalkyl, Ci- e haloalkoxy, CN, OH, NH2, OR c , C(0)R c , C(0)NR c R c , and C(0)OR c ;
  • each R c is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
  • n is an integer of 1 or 2.
  • compounds of Formula (I) or any subformulas as disclosed herein when Cy is phenyl, R 8 is not 4-aminopiperidin-l-yl, optionally substituted with 1-5 independently selected R b substituents. In some embodiments, compounds of Formula (I) or any subformulas as disclosed herein, when Cy is phenyl, R 8 is not -NHC(0)R a , wherein R a is 5- or 6-membered heteroaryl, or 2-pyridon-3-yl, each of which is optionally substituted with 1 -5 independently selected R d substituents.
  • R 8 is not (10-membered bicyclic heteroaryl)-NH-, optionally substituted with 1-5 independently selected R d substituents.
  • embodiments of the compounds of Formula (I) can be combined in any suitable combination.
  • Ci-6 alkyl is specifically intended to individually disclose (without limitation) methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl and Ce alkyl.
  • n-membered typically describes the number of ring-forming atoms in a moiety where the number of ring-forming atoms is n.
  • piperidinyl is an example of a 6-membered heterocycloalkyl ring
  • pyrazolyl is an example of a 5-membered heteroaryl ring
  • pyridyl is an example of a 6-membered heteroaryl ring
  • 1,2,3,4-tetrahydro-naphthalene is an example of a 10-membered cycloalkyl group.
  • each linking substituent include both the forward and backward forms of the linking substituent.
  • -NR(CR'R") n - includes both -NR(CR'R") n - and -(CR'R")nNR- and is intended to disclose each of the forms individually.
  • the Markush variables listed for that group are understood to be linking groups. For example, if the structure requires a linking group and the Markush group definition for that variable lists “alkyl” or "aryl” then it is understood that the "alkyl” or “aryl” represents a linking alkylene group or arylene group, respectively.
  • substituted means that an atom or group of atoms formally replaces hydrogen as a "substituent" attached to another group.
  • substituted refers to any level of substitution, e.g. , mono-, di-, tri-, tetra- or penta-substitution, where such substitution is permitted.
  • the substituents are independently selected, and substitution may be at any chemically accessible position. It is to be understood that substitution at a given atom is limited by valency. It is to be understood that substitution at a given atom results in a chemically stable molecule.
  • optionally substituted means unsubstituted or substituted.
  • substituted means that a hydrogen atom is removed and replaced by a substituent.
  • a single divalent substituent e.g., oxo, can replace two hydrogen atoms.
  • Cn-m indicates a range which includes the endpoints, wherein n and m are integers and indicate the number of carbons. Examples include Ci-4, Ci-6 and the like.
  • alkyl employed alone or in combination with other terms, refers to a saturated hydrocarbon group that may be straight-chained or branched.
  • Cn-m alkyl refers to an alkyl group having n to m carbon atoms.
  • An alkyl group formally corresponds to an alkane with one C-H bond replaced by the point of attachment of the alkyl group to the remainder of the compound.
  • the alkyl group contains from 1 to 6 carbon atoms, from 1 to 4 carbon atoms, from 1 to 3 carbon atoms, or 1 to 2 carbon atoms.
  • alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, ft-propyl, isopropyl, w-butyl, fert-butyl, isobutyl, sec-butyl; higher homologs such as 2- methyl-1 -butyl, w-pentyl, 3-pentyl, w-hexyl, 1 ,2,2-trimethylpropyl and the like.
  • alkenyl employed alone or in combination with other terms, refers to a straight-chain or branched hydrocarbon group corresponding to an alkyl group having one or more double carbon-carbon bonds.
  • An alkenyl group formally corresponds to an alkene with one C-H bond replaced by the point of attachment of the alkenyl group to the remainder of the compound.
  • Cn-m alkenyl refers to an alkenyl group having n to m carbons. In some embodiments, the alkenyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms.
  • Example alkenyl groups include, but are not limited to, ethenyl, w-propenyl, isopropenyl, n- butenyl, seobutenyl and the like.
  • alkynyl employed alone or in combination with other terms, refers to a straight-chain or branched hydrocarbon group corresponding to an alkyl group having one or more triple carbon-carbon bonds.
  • An alkynyl group formally corresponds to an alkyne with one C-H bond replaced by the point of attachment of the alkyl group to the remainder of the compound.
  • Cn-m alkynyl refers to an alkynyl group having n to m carbons.
  • Example alkynyl groups include, but are not limited to, ethynyl, propyn-l-yl, propyn-2-yl and the like.
  • the alkynyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms.
  • alkylene employed alone or in combination with other terms, refers to a divalent alkyl linking group.
  • An alkylene group formally corresponds to an alkane with two C-H bond replaced by points of attachment of the alkylene group to the remainder of the compound.
  • Cn-m alkylene refers to an alkylene group having n to m carbon atoms.
  • alkylene groups include, but are not limited to, ethan-l,2-diyl, propan-l ,3-diyl, propan-l,2-diyl, butan-l ,4-diyl, butan-l,3-diyl, butan-l,2-diyl, 2-methyl-propan-l,3-diyl and the like.
  • alkoxy employed alone or in combination with other terms, refers to a group of formula -O-alkyl, wherein the alkyl group is as defined above.
  • Cn-m alkoxy refers to an alkoxy group, the alkyl group of which has n to m carbons.
  • Example alkoxy groups include methoxy, ethoxy, propoxy (e.g. , w-propoxy and isopropoxy), i-butoxy and the like.
  • the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • amino refers to a group of formula -NH2.
  • cyano or "nitrile” refers to a group of formula -C ⁇ N, which also may be written as -CN.
  • halo refers to fluoro, chloro, bromo and iodo.
  • halo refers to a halogen atom selected from F, CI, or Br.
  • halo groups are F.
  • haloalkyl refers to an alkyl group in which one or more of the hydrogen atoms has been replaced by a halogen atom.
  • Cn-m haloalkyl refers to a Cn-m alkyl group having n to m carbon atoms and from at least one up to ⁇ 2(n to m)+l ⁇ halogen atoms, which may either be the same or different.
  • the halogen atoms are fluoro atoms.
  • the haloalkyl group has 1 to 6 or 1 to 4 carbon atoms.
  • Example haloalkyl groups include CF3, C2F5, CHF2, CCh, CHCI2, C2CI5 and the like.
  • the haloalkyl group is a fluoroalkyl group.
  • haloalkoxy refers to a group of formula -O-haloalkyl, wherein the haloalkyl group is as defined above.
  • Cn-m haloalkoxy refers to a haloalkoxy group, the haloalkyl group of which has n to m carbons.
  • Example haloalkoxy groups include trifluoromethoxy and the like. In some embodiments, the haloalkoxy group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • oxo refers to an oxygen atom as a divalent substituent, forming a carbonyl group when attached to carbon, or attached to a heteroatom forming a sulfoxide or sulfone group, or an N-oxide group.
  • aromatic refers to a carbocycle or heterocycle having one or more polyunsaturated rings having aromatic character (i. e. , having (4n + 2) delocalized ⁇ (pi) electrons where n is an integer).
  • aryl employed alone or in combination with other terms, refers to an aromatic hydrocarbon group, which may be monocyclic or poly cyclic (e.g. , having 2 fused rings).
  • Cn- m aryl refers to an aryl group having from n to m ring carbon atoms.
  • Aryl groups include, e.g. , phenyl, naphthyl, and the like. In some embodiments, aryl groups have from 6 to about 10 carbon atoms. In some embodiments aryl groups have 6 carbon atoms. In some embodiments aryl groups have 10 carbon atoms. In some embodiments, the aryl group is phenyl. In some embodiments, the aryl group is naphthyl.
  • heteroaryl or “heteroaromatic,” employed alone or in combination with other terms, refers to a monocyclic or poly cyclic aromatic heterocycle having at least one heteroatom ring member selected from sulfur, oxygen and nitrogen.
  • the heteroaryl ring has 1 , 2, 3 or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen.
  • any ring-forming ⁇ in a heteroaryl moiety can be an N-oxide.
  • the heteroaryl has 5-14 ring atoms including carbon atoms and 1 , 2, 3 or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen.
  • the heteroaryl has 5-10 ring atoms including carbon atoms and 1 , 2, 3 or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl has 5-6 ring atoms and 1 or 2 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl is a five-membered or six-membered heteroaryl ring. In other embodiments, the heteroaryl is an eight-membered, nine-membered or ten-membered fused bicyclic heteroaryl ring.
  • Example heteroaryl groups include, but are not limited to, pyridinyl (pyridyl), pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, azolyl, oxazolyl, thiazolyl, imidazolyl, furanyl, thiophenyl, quinolinyl, isoquinolinyl, naphthyridinyl (including 1,2-, 1,3-, 1,4-, 1,5-, 1,6-, 1,7-, 1,8-, 2,3- and 2,6-naphthyridine), indolyl, indazolyl, benzothiophenyl, benzofuranyl, benzisoxazolyl, imidazo[l,2-Z>]thiazolyl, purinyl, and the like.
  • pyridinyl pyridyl
  • pyrimidinyl pyrazinyl
  • a five-membered heteroaryl ring is a heteroaryl group having five ring atoms wherein one or more (e.g. , 1, 2 or 3) ring atoms are independently selected from N, O and S.
  • Exemplary five-membered ring heteroaryls include thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3- thiadiazolyl, 1,2,3-oxadiazolyl, 1 ,2,4-triazolyl, 1 ,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4- triazolyl, 1,3,4-thiadiazolyl and 1,3,4-oxadiazolyl.
  • a six-membered heteroaryl ring is a heteroaryl group having six ring atoms wherein one or more (e.g. , 1, 2 or 3) ring atoms are independently selected from N, O and S.
  • Exemplary six-membered ring heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl and pyridazinyl.
  • cycloalkyl employed alone or in combination with other terms, refers to a non-aromatic hydrocarbon ring system (monocyclic, bicyclic or poly cyclic), including cyclized alkyl and alkenyl groups.
  • Cn-m cycloalkyl refers to a cycloalkyl that has n to m ring member carbon atoms.
  • Cycloalkyl groups can include mono- or poly cyclic (e.g. , having 2, 3 or 4 fused rings) groups and spirocycles. Cycloalkyl groups can have 3, 4, 5, 6 or 7 ring-forming carbons (C3-7).
  • the cycloalkyl group has 3 to 6 ring members, 3 to 5 ring members, or 3 to 4 ring members. In some embodiments, the cycloalkyl group is monocyclic. In some embodiments, the cycloalkyl group is monocyclic or bicyclic. In some embodiments, the cycloalkyl group is a C3-6 monocyclic cycloalkyl group. Ring- forming carbon atoms of a cycloalkyl group can be optionally oxidized to form an oxo or sulfido group. Cycloalkyl groups also include cycloalkylidenes.
  • cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. Also included in the definition of cycloalkyl are moieties that have one or more aromatic rings fused (i.e. , having a bond in common with) to the cycloalkyl ring, e.g., benzo or thienyl derivatives of cyclopentane, cyclohexane and the like.
  • a cycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring.
  • cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcamyl, bicyclo[l . l . l]pentanyl, bicyclo[2.1.1]hexanyl, and the like.
  • the cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
  • heterocycloalkyl refers to a non-aromatic ring or ring system, which may optionally contain one or more alkenylene groups as part of the ring structure, which has at least one heteroatom ring member independently selected from nitrogen, sulfur oxygen and phosphorus, and which has 4-10 ring members, 4-7 ring members, or 4-6 ring members. Included within the term “heterocycloalkyl” are monocyclic 4-, 5-, 6- and 7-membered heterocycloalkyl groups. Heterocycloalkyl groups can include mono- or bicyclic (e.g., having two fused or bridged rings) ring systems.
  • the heterocycloalkyl group is a monocyclic group having 1, 2 or 3 heteroatoms independently selected from nitrogen, sulfur and oxygen. Ring- forming carbon atoms and heteroatoms of a heterocycloalkyl group can be optionally oxidized to form an oxo or sulfido group or other oxidized linkage (e.g., C(O), S(O), C(S) or S(0)2, N-oxide etc.) or a nitrogen atom can be quaternized.
  • the heterocycloalkyl group can be attached through a ring-forming carbon atom or a ring-forming heteroatom. In some embodiments, the heterocycloalkyl group contains 0 to 3 double bonds. In some
  • the heterocycloalkyl group contains 0 to 2 double bonds. Also included in the definition of heterocycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the heterocycloalkyl ring, e.g., benzo or thienyl derivatives of piperidine, morpholine, azepine, etc.
  • a heterocycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring.
  • heterocycloalkyl groups include azetidinyl, azepanyl, dihydrobenzofuranyl, dihydrofuranyl, dihydropyranyl, dihydrobenzodioxinyl, benzodioxinyl, morpholino, 3-oxa-9-azaspiro[5.5]undecanyl, l-oxa-8-azaspiro[4.5]decanyl, piperidinyl, piperazinyl, oxopiperazinyl, pyranyl, pyrrolidinyl, quinuclidinyl,
  • the definitions or embodiments refer to specific rings (e.g. , an azetidine ring, a pyridine ring, etc.). Unless otherwise indicated, these rings can be attached to any ring member provided that the valency of the atom is not exceeded. For example, an azetidine ring may be attached at any position of the ring, whereas an azetidin-3-yl ring is attached at the 3 -position.
  • the compounds described herein can be asymmetric (e.g. , having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated.
  • One method includes fractional recrystallization using a chiral resolving acid which is an optically active, salt-forming organic acid.
  • Suitable resolving agents for fractional recrystallization methods are, e.g. , optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids such as ⁇ - camphorsulfonic acid.
  • Other resolving agents suitable for fractional crystallization methods include stereoisomerically pure forms of a-methylbenzylamine (e.g.
  • Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine).
  • an optically active resolving agent e.g., dinitrobenzoylphenylglycine
  • Suitable elution solvent composition can be determined by one skilled in the art.
  • the compounds of the invention have the (i?)-configuration. In other embodiments, the compounds have the ( ⁇ -configuration. In compounds with more than one chiral centers, each of the chiral centers in the compound may be independently (R) or (S), unless otherwise indicated.
  • Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton.
  • Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge.
  • Example prototropic tautomers include ketone - enol pairs, amide - imidic acid pairs, lactam - lactim pairs, enamine - imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, e.g.
  • Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.
  • Compounds of the invention can also include all isotopes of atoms occurring in the intermediates or final compounds.
  • Isotopes include those atoms having the same atomic number but different mass numbers.
  • isotopes of hydrogen include tritium and deuterium.
  • One or more constituent atoms of the compounds of the invention can be replaced or substituted with isotopes of the atoms in natural or non-natural abundance.
  • the compound includes at least one deuterium atom.
  • one or more hydrogen atoms in a compound of the present disclosure can be replaced or substituted by deuterium.
  • the compound includes two or more deuterium atoms.
  • the compound includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 or 12 deuterium atoms. Synthetic methods for including isotopes into organic compounds are known in the art.
  • compound as used herein is meant to include all stereoisomers, geometric isomers, tautomers and isotopes of the structures depicted.
  • the term is also meant to refer to compounds of the inventions, regardless of how they are prepared, e.g., synthetically, through biological process (e.g., metabolism or enzyme conversion), or a combination thereof.
  • All compounds, and pharmaceutically acceptable salts thereof can be found together with other substances such as water and solvents (e.g. , hydrates and solvates) or can be isolated.
  • solvents e.g. , hydrates and solvates
  • the compounds described herein and salts thereof may occur in various forms and may, e.g. , take the form of solvates, including hydrates.
  • the compounds may be in any solid state form, such as a polymorph or solvate, so unless clearly indicated otherwise, reference in the specification to compounds and salts thereof should be understood as encompassing any solid state form of the compound.
  • the compounds of the invention, or salts thereof are substantially isolated.
  • substantially isolated is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected.
  • Partial separation can include, e.g. , a composition enriched in the compounds of the invention.
  • Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compounds of the invention, or salt thereof.
  • phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • ambient temperature and “room temperature,” as used herein, are understood in the art, and refer generally to a temperature, e.g. , a reaction temperature, that is about the temperature of the room in which the reaction is carried out, e.g. , a temperature from about 20 °C to about 30 °C.
  • the present invention also includes pharmaceutically acceptable salts of the compounds described herein.
  • pharmaceutically acceptable salts refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form.
  • examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • the pharmaceutically acceptable salts of the present invention include the non-toxic salts of the parent compound formed, e.g. , from non-toxic inorganic or organic acids.
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
  • such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, alcohols (e.g. , methanol, ethanol, iso-propanol or butanol) or acetonitrile (MeCN) are preferred.
  • non-aqueous media like ether, ethyl acetate, alcohols (e.g. , methanol, ethanol, iso-propanol or butanol) or acetonitrile (MeCN) are preferred.
  • suitable salts are found in Remington 's Pharmaceutical Sciences, 17 th Ed., (Mack Publishing Company, Easton, 1985), p. 1418, Berge et al, J. Pharm. Scl , 1977, 66( ⁇ ), 1 -19 and in Stahl et al
  • Suitable solvents can be substantially non-reactive with the starting materials (reactants), the intermediates or products at the temperatures at which the reactions are carried out, e.g. , temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature.
  • a given reaction can be carried out in one solvent or a mixture of more than one solvent.
  • suitable solvents for a particular reaction step can be selected by the skilled artisan.
  • Reactions can be monitored according to any suitable method known in the art.
  • product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g. , 3 ⁇ 4 or 1 C), infrared spectroscopy, spectrophotometry (e.g. , UV -visible), mass spectrometry or by chromatographic methods such as high performance liquid chromatography (HPLC) or thin layer chromatography (TLC).
  • spectroscopic means such as nuclear magnetic resonance spectroscopy (e.g. , 3 ⁇ 4 or 1 C), infrared spectroscopy, spectrophotometry (e.g. , UV -visible), mass spectrometry or by chromatographic methods such as high performance liquid chromatography (HPLC) or thin layer chromatography (TLC).
  • HPLC high performance liquid chromatography
  • TLC thin layer chromatography
  • Compound of formula 1-7 can be synthesized using a process shown in Scheme 1.
  • a palladium-catalyzed cross-coupling reaction of halo-substituted aromatic amine 1-1 with a suitable coupling reagent 1-2 (where M is, e.g., -B(OH)2) under standard conditions (such as Suzuki coupling reaction, e.g. , in the presence of a palladium catalyst and a suitable base) can produce compound 1-3.
  • M is, e.g., -B(OH)2
  • Suzuki coupling reaction e.g., in the presence of a palladium catalyst and a suitable base
  • the reaction of aromatic amine 1-3 with an acid of formula 1-4 using a coupling reagent such as, but not limited to, HATU can give the amide 1-5, which can be deprotected under acidic conditions (e.g.
  • the R 7 group can be introduced either by direct alkylation with an alkyl halide or reductive alkylation with an aldehyde or a ketone to give the desired product of formula 1-7.
  • compound of formula 2-7 can be synthesized using a process shown in Scheme 2.
  • the reaction of halo-substituted aromatic amine 2-1 with an ester of formula 2-2 in the presence of a suitable base such as, but not limited to, potassium fert-butoxide or sodium hydride can furnish the amide 2-3.
  • the Boc protecting group in compound 2-3 can be removed under acidic conditions (e.g., hydrochloric acid or trifluoroacetic acid) to provide the free amine of formula 2-4.
  • the Cy ring can be installed by the cross-coupling of compound 2-4 with a suitable coupling reagent 2-5 (where M is, e.g., -B(OH)2) under standard conditions (such as Suzuki coupling reaction, e.g.
  • R 7 group can be introduced either by direct alkylation with an alkyl halide or reductive alkylation with an aldehyde or a ketone to give the desired product of formula 2-7.
  • Ester of formula 3-3 can be synthesized using a process shown in Scheme 3.
  • the free amine group in compound 3-1 can be protected with Boc to give the compound of formula 3- 2.
  • Compound 3-2 can be deprotonated by a strong base such as, but not limited to, n-butyl lithium or lithium bis(trimethylsilyl)amide to generate the corresponding aryl lithium intermediate, which can further react with a chloroformate or carbon dioxide to give the desired ester or acid of formula 3-3.
  • a strong base such as, but not limited to, n-butyl lithium or lithium bis(trimethylsilyl)amide to generate the corresponding aryl lithium intermediate, which can further react with a chloroformate or carbon dioxide to give the desired ester or acid of formula 3-3.
  • Compounds of the present disclosure can inhibit the activity of PD-1/PD-L1 protein/protein interaction and, thus, are useful in treating diseases and disorders associated with activity of PD-1 and the diseases and disorders associated with PD-L1 including its interaction with other proteins such as PD-1 and B7-1 (CD80).
  • the compounds of the present disclosure demonstrate better efficacy and favorable safety and toxicity profiles in animal studies.
  • the compounds of the present disclosure, or pharmaceutically acceptable salts or stereoisomers thereof are useful for therapeutic administration to enhance, stimulate and/or increase immunity in cancer or chronic infection, including enhancement of response to vaccination.
  • the present disclosure provides a method for inhibiting or blocking the PD-1/PD-L1 protein/protein interaction.
  • the method includes administering to an individual or a patient a compound of Formula (I) or any of the formulas as described herein or of a compound as recited in any of the claims and described herein, or a pharmaceutically acceptable salt or a stereoisomer thereof.
  • the compounds of the present disclosure can be used alone, in combination with other agents or therapies or as an adjuvant or neoadjuvant for the treatment of diseases or disorders, including cancer or infection diseases.
  • any of the compounds of the disclosure including any of the embodiments thereof, may be used.
  • the compounds of the present disclosure inhibit the PD-1/PD-L1 protein/protein interaction, resulting in a PD-1 pathway blockade.
  • the blockade of PD-1 can enhance the immune response to cancerous cells and infectious diseases in mammals, including humans.
  • the present disclosure provides treatment of an individual or a patient in vivo using a compound of Formula (I) or a salt or stereoisomer thereof such that growth of cancerous tumors is inhibited.
  • a compound of Formula (I) or of any of the formulas as described herein, or a compound as recited in any of the claims and described herein, or a salt or stereoisomer thereof, can be used to inhibit the growth of cancerous tumors.
  • a compound of Formula (I) or of any of the formulas as described herein, or a compound as recited in any of the claims and described herein, or a salt or stereoisomer thereof can be used in conjunction with other agents or standard cancer treatments, as described below.
  • the present disclosure provides a method for inhibiting growth of tumor cells in vitro. The method includes contacting the tumor cells in vitro with a compound of Formula (I) or of any of the formulas as described herein, or of a compound as recited in any of the claims and described herein, or of a salt or stereoisomer thereof.
  • the present disclosure provides a method for inhibiting growth of tumor cells in an individual or a patient.
  • the method includes administering to the individual or patient in need thereof a therapeutically effective amount of a compound of Formula (I) or of any of the formulas as described herein, or of a compound as recited in any of the claims and described herein, or a salt or a stereoisomer thereof.
  • a method for treating cancer includes administering to a patient in need thereof, a therapeutically effective amount of a compound of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or a salt thereof.
  • cancers include those whose growth may be inhibited using compounds of the disclosure and cancers typically responsive to immunotherapy.
  • the present disclosure provides a method of enhancing, stimulating and/or increasing the immune response in a patient.
  • the method includes administering to the patient in need thereof a therapeutically effective amount of a compound of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or a salt thereof.
  • cancers that are treatable using the compounds of the present disclosure include, but are not limited to, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, endometrial cancer, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, non-Hodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemias including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leuk
  • cancers treatable with compounds of the present disclosure include melanoma (e.g., metastatic malignant melanoma), renal cancer (e.g. clear cell carcinoma), prostate cancer (e.g. hormone refractory prostate adenocarcinoma), breast cancer, colon cancer and lung cancer (e.g. non-small cell lung cancer). Additionally, the disclosure includes refractory or recurrent malignancies whose growth may be inhibited using the compounds of the disclosure.
  • melanoma e.g., metastatic malignant melanoma
  • renal cancer e.g. clear cell carcinoma
  • prostate cancer e.g. hormone refractory prostate adenocarcinoma
  • breast cancer e.g. hormone refractory prostate adenocarcinoma
  • colon cancer e.g. non-small cell lung cancer
  • lung cancer e.g. non-small cell lung cancer
  • cancers that are treatable using the compounds of the present disclosure include, but are not limited to, solid tumors (e.g. , prostate cancer, colon cancer, esophageal cancer, endometrial cancer, ovarian cancer, uterine cancer, renal cancer, hepatic cancer, pancreatic cancer, gastric cancer, breast cancer, lung cancer, cancers of the head and neck, thyroid cancer, glioblastoma, sarcoma, bladder cancer, etc.), hematological cancers (e.g.
  • lymphoma leukemia such as acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), DLBCL, mantle cell lymphoma, Non-Hodgkin lymphoma (including relapsed or refractory NHL and recurrent follicular), Hodgkin lymphoma or multiple myeloma) and combinations of said cancers.
  • ALL acute lymphoblastic leukemia
  • AML acute myelogenous leukemia
  • CLL chronic lymphocytic leukemia
  • CML chronic myelogenous leukemia
  • DLBCL mantle cell lymphoma
  • Non-Hodgkin lymphoma including relapsed or refractory NHL and recurrent follicular
  • Hodgkin lymphoma or multiple myeloma and combinations of said cancers.
  • PD-1 pathway blockade with compounds of the present disclosure can also be used for treating infections such as viral, bacteria, fungus and parasite infections.
  • the present disclosure provides a method for treating infections such as viral infections. The method includes administering to a patient in need thereof, a therapeutically effective amount of a compound of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, a salt thereof.
  • viruses causing infections treatable by methods of the present disclosure include, but are not limit to, human immunodeficiency virus, human papillomavirus, influenza, hepatitis A, B, C or D viruses, adenovirus, pox vims, herpes simpl ex viruses, human cytomegalovirus, severe acute respirator ⁇ ' syndrome virus, eboia virus, and measles virus.
  • viruses causing infections treatable by methods of the present disclosure include, but are not limit to, hepatitis (A, B, or C), herpes virus (e.g., VZV, HSV-1, HAV-6, HSV-II, and CMV, Epstein Barr virus), adenovirus, influenza virus, fiaviviruses, echovirus, rhinovirus, coxsackie virus, cornovirus, respiratory syncytial virus, mumpsvirus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus and arboviral encephalitis virus.
  • herpes virus e.g., VZV, HSV-1, HAV-6, HSV-II, and CMV, Epstein Barr virus
  • adenovirus e.g., adenovirus
  • influenza virus e.g., V
  • the present disclosure provides a method for treating bacterial infections.
  • the method includes administering to a patient in need thereof, a therapeutically effective amount of a compound of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or a salt thereof.
  • Non-limiting examples of pathogenic bacteria causing infections treatable by methods of the disclosure include chlamydia, rickettsial bacteria, mycobacteria, staphylococci, streptococci, pneumonococci, meningococci and conococci, klebsiella, proteus, serratia, pseudomonas, legionella, diphtheria, salmonella, bacilli, cholera, tetanus, botulism, anthrax, plague, leptospirosis, and Lyme's disease bacteria.
  • the present disclosure provides a method for treating fungus infections.
  • the method includes administering to a patient in need thereof, a therapeutically effective amount of a compound of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or a salt thereof.
  • pathogenic fungi causing infections treatable by methods of the disclosure include Candida (albicans, krusei, glabrata, tropicalis, etc.), Cryptococcus neoformans, Aspergillus
  • Genus Mucorales micor, absidia, rhizophus
  • Sporothrix schenkii Blastomyces dermatitidis
  • Paracoccidioides brasiliensis Coccidioides immitis
  • Histoplasma capsulatum Histoplasma capsulatum.
  • the present disclosure provides a method for treating parasite infections.
  • the method includes administering to a patient in need thereof, a therapeutically effective amount of a compound of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or a salt thereof.
  • Non-limiting examples of pathogenic parasites causing infections treatable by methods of the disclosure include Entamoeba histolytica, Balantidium coli, Naegleriafowleri, Acanthamoeba sp., Giardia lambia, Cryptosporidium sp., Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondi, and Nippostrongylus brasiliensis.
  • mice preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.
  • terapéuticaally effective amount refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
  • treating refers to one or more of (1) inhibiting the disease; e.g. , inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e. , arresting further development of the pathology and/or symptomatology); and (2) ameliorating the disease; e.g., ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e. , reversing the pathology and/or symptomatology) such as decreasing the severity of disease.
  • the compounds of the invention are useful in preventing or reducing the risk of developing any of the diseases referred to herein; e.g. , preventing or reducing the risk of developing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease.
  • Cancer cell growth and survival can be impacted by multiple signaling pathways.
  • Targeting more than one signaling pathway may reduce the likelihood of drug-resistance arising in a cell population, and/or reduce the toxicity of treatment.
  • the compounds of the present disclosure can be used in combination with one or more other enzyme/protein/receptor inhibitors for the treatment of diseases, such as cancer or infections.
  • diseases such as cancer or infections.
  • cancers include solid tumors and liquid tumors, such as blood cancers.
  • infections include viral infections, bacterial infections, fungus infections or parasite infections.
  • the compounds of the present disclosure can be combined with one or more inhibitors of the following kinases for the treatment of cancer: Aktl, Akt2, Akt3, TGF-PR, PKA, PKG, PKC, CaM-kinase, phosphorylase kinase, MEKK, ERK, MAPK, mTOR, EGFR, HER2, HER3, HER4, INS-R, IGF-1R, IR-R, PDGFaR, PDGFPR, CSFIR, KIT, FLK-II, KDR/FLK-1, FLK-4, flt-1, FGFR1, FGFR2, FGFR3, FGFR4, c-Met, Ron, Sea, TRKA, TRKB, TRKC, FLT3, VEGFR/Flt2, Flt4, EphAl, EphA2, EphA3, EphB2, EphB4, Tie2, Src, Fyn, Lck, Fgr, Btk, Fak, SYK,
  • the compounds of the present disclosure can be combined with one or more of the following inhibitors for the treatment of cancer or infections.
  • inhibitors that can be combined with the compounds of the present disclosure for treatment of cancer and infections include an FGFR inhibitor (FGFR1, FGFR2, FGFR3 or FGFR4, e.g., INCB54828, INCB62079 and INCB63904), a JAK inhibitor (JAK1 and/or JAK2, e.g., ruxolitinib, baricitinib or INCB39110), an IDO inhibitor (e.g., epacadostat and NLG919), an LSD1 inhibitor (e.g., INCB59872 and I CB60003), a TDO inhibitor, a PI3K-delta inhibitor (e.g., INCB50797 and I CB50465), a PI3K-gamma inhibitor such as a PI3K-gamma selective inhibitor, a Pirn inhibitor,
  • FGFR inhibitor FG
  • immune checkpoint inhibitors include inhibitors against immune checkpoint molecules such as CD27, CD28, CD40, CD122, CD96, CD73, CD47, OX40, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM, arginase, CD137 (also known as 4-1BB), ICOS, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, VISTA, PD-1 , PD-L1 and PD-L2.
  • immune checkpoint inhibitors include inhibitors against immune checkpoint molecules such as CD27, CD28, CD40, CD122, CD96, CD73, CD47, OX40, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM, arginase, CD137 (also known as 4-1BB), ICOS, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, LAG3,
  • the immune checkpoint molecule is a stimulatory checkpoint molecule selected from CD27, CD28, CD40, ICOS, OX40, GITR and CD137.
  • the immune checkpoint molecule is an inhibitory checkpoint molecule selected from A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD-1, TIM3, and VISTA.
  • the compounds provided herein can be used in combination with one or more agents selected from KIR inhibitors, TIGIT inhibitors, LAIRl inhibitors, CD 160 inhibitors, 2B4 inhibitors and TGFR beta inhibitors.
  • the inhibitor of an immune checkpoint molecule is anti-PDl antibody, anti-PD-Ll antibody, or anti-CTLA-4 antibody.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of PD-1 , e.g., an anti-PD-1 monoclonal antibody.
  • the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab (also known as MK-3475), pidilizumab, SHR-1210, PDR001 , or AMP-224.
  • the anti-PD-1 monoclonal antibody is nivolumab or pembrolizumab.
  • the anti-PDl antibody is pembrolizumab.
  • the anti PD-1 antibody is SHR-1210.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of PD-L1 , e.g., an anti-PD-Ll monoclonal antibody.
  • the anti-PD-Ll monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or MSB0010718C.
  • the anti-PD-Ll monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or MSB0010718C.
  • the anti-PD-Ll monoclonal antibody is
  • the inhibitor of an immune checkpoint molecule is an inhibitor of CTLA-4, e.g., an anti-CTLA-4 antibody.
  • the anti-CTLA-4 antibody is ipilimumab.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of LAG3, e.g., an anti-LAG3 antibody.
  • the anti-LAG3 antibody is BMS-986016 or LAG525.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of GITR, e.g., an anti-GITR antibody.
  • the anti-GITR antibody is TRX518 or MK-4166.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of OX40, e.g., an anti-OX40 antibody or OX40L fusion protein.
  • OX40 e.g., an anti-OX40 antibody or OX40L fusion protein.
  • the anti-OX40 antibody is MEDI0562.
  • the OX40L fusion protein is MEDI6383.
  • the agent is an alkylating agent, a proteasome inhibitor, a corticosteroid, or an immunomodulatory agent.
  • an alkylating agent include cyclophosphamide (CY), melphalan (MEL), and bendamustine.
  • the proteasome inhibitor is carfilzomib.
  • the corticosteroid is dexamethasone (DEX).
  • the immunomodulatory agent is lenalidomide (LEN) or pomalidomide (POM).
  • the compounds of the present disclosure can further be used in combination with other methods of treating cancers, for example by chemotherapy, irradiation therapy, tumor- targeted therapy, adjuvant therapy, immunotherapy or surgery.
  • immunotherapy include cytokine treatment (e.g., interferons, GM-CSF, G-CSF, IL-2), CRS-207
  • the compounds can be administered in combination with one or more anti-cancer drugs, such as a chemotherapeutics.
  • Example chemotherapeutics include any of: abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, anastrozole, arsenic trioxide, asparaginase, azacitidine, bevacizumab, bexarotene, baricitinib, bleomycin, bortezombi, bortezomib, busulfan intravenous, busulfan oral, calusterone, capecitabine, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, dalteparin sodium, dasatinib, daunorubicin, decitabine, denileukin, denileukin diftitox, dexrazox
  • anti-cancer agent(s) include antibody therapeutics such as trastuzumab (Herceptin), antibodies to costimulatory molecules such as CTLA-4 (e.g., ipilimumab), 4- 1BB, antibodies to PD-1 and PD-L1 , or antibodies to cytokines (IL-10, TGF- ⁇ , etc.).
  • Herceptin antibodies to costimulatory molecules
  • CTLA-4 e.g., ipilimumab
  • 4- 1BB antibodies to PD-1 and PD-L1
  • cytokines IL-10, TGF- ⁇ , etc.
  • antibodies to PD-1 and/or PD-L1 that can be combined with compounds of the present disclosure for the treatment of cancer or infections such as viral, bacteria, fungus and parasite infections include, but are not limited to, nivolumab, pembrolizumab, MPDL3280A, MEDI-4736 and SHR-1210.
  • the compounds of the present disclosure can further be used in combination with one or more anti-inflammatory agents, steroids, immunosuppressants or therapeutic antibodies.
  • the compounds of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or salts thereof can be combined with another immunogenic agent, such as cancerous cells, purified tumor antigens (including recombinant proteins, peptides, and carbohydrate molecules), cells, and cells transfected with genes encoding immune stimulating cytokines.
  • tumor vaccines include peptides of melanoma antigens, such as peptides of gplOO, MAGE antigens, Trp-2, MARTI and/or tyrosinase, or tumor cells transfected to express the cytokine GM-CSF.
  • tumor vaccines include the proteins from viruses implicated in human cancers such as Human Papilloma Viruses (HPV), Hepatitis Viruses (HBV and HCV) and Kaposi's Herpes Sarcoma Virus (KHSV).
  • HPV Human Papilloma Viruses
  • HBV and HCV Hepatitis Viruses
  • KHSV Kaposi's Herpes Sarcoma Virus
  • the compounds of the present disclosure can be used in combination with tumor specific antigen such as heat shock proteins isolated from tumor tissue itself.
  • the compounds of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or salts thereof can be combined with dendritic cells immunization to activate potent anti-tumor responses.
  • the compounds of the present disclosure can be used in combination with bispecific macrocyclic peptides that target Fe alpha or Fe gamma receptor-expressing effectors cells to tumor cells.
  • the compounds of the present disclosure can also be combined with macrocyclic peptides that activate host immune responsiveness.
  • the compounds of the present disclosure can be used in combination with bone marrow transplant for the treatment of a variety of tumors of hematopoietic origin.
  • the compounds of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or salts thereof can be used in combination with vaccines, to stimulate the immune response to pathogens, toxins, and self antigens.
  • pathogens for which this therapeutic approach may be particularly useful include pathogens for which there is currently no effective vaccine, or pathogens for which conventional vaccines are less than completely effective. These include, but are not limited to, HIV, Hepatitis (A, B, & C), Influenza, Herpes, Giardia, Malaria, Leishmania, Staphylococcus aureus, Pseudomonas Aeruginosa.
  • Viruses causing infections treatable by methods of the present disclosure include, but are not limit to human papillomavirus, influenza, hepatitis A, B, C or D viruses, adenovirus, poxvirus, herpes simplex viruses, human c tomegalovirus, severe acute respiratory syndrome virus, ebola virus, measles virus, herpes virus (e.g., VZV, HSV-1, HAV-6, HSV-II, and CMV, Epstein Barr virus), flaviviruses, echovirus, rhinovirus, coxsackie virus, cornovirus, respiratory syncytial virus, mumpsvirus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus and arboviral encephalitis virus.
  • human papillomavirus influenza, hepatitis A
  • Pathogenic bacteria causing infections treatable by methods of the disclosure include, but are not limited to, chlamydia, rickettsial bacteria, mycobacteria, staphylococci, streptococci, pneumonococci, meningococci and conococci, klebsiella, proteus, serratia, pseudomonas, legionella, diphtheria, salmonella, bacilli, cholera, tetanus, botulism, anthrax, plague, leptospirosis, and Lyme's disease bacteria.
  • Pathogenic fungi causing infections treatable by methods of the disclosure include, but are not limited to, Candida (albicans, krusei, glabrata, tropicalis, etc.), Cryptococcus neoformans, Aspergillus (fumigatus, niger, etc.), Genus Mucorales (mucor, absidia, rhizophus), Sporothrix schenkii, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Coccidioides immitis and Histoplasma capsulatum.
  • Candida albicans, krusei, glabrata, tropicalis, etc.
  • Cryptococcus neoformans Aspergillus (fumigatus, niger, etc.)
  • Genus Mucorales micor, absidia, rhizophus
  • Sporothrix schenkii Blastomyces dermatitidis
  • Paracoccidioides brasiliensis C
  • Pathogenic parasites causing infections treatable by methods of the disclosure include, but are not limited to, Entamoeba histolytica, Balantidium coli, Naegleriafowleri, Acanthamoeba sp., Giardia lambia, Cryptosporidium sp., Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondi, and Nippostrongylus brasiliensis.
  • more than one pharmaceutical agent When more than one pharmaceutical agent is administered to a patient, they can be administered simultaneously, separately, sequentially, or in combination (e.g. , for more than two agents).
  • the compounds of the present disclosure can be administered in the form of pharmaceutical compositions.
  • a composition comprising a compound of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or a pharmaceutically acceptable salt thereof, or any of the embodiments thereof, and at least one pharmaceutically acceptable carrier or excipient.
  • These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is indicated and upon the area to be treated.
  • Administration may be topical (including transdermal, epidermal, ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g. , by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal), oral or parenteral.
  • Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal intramuscular or injection or infusion; or intracranial, e.g. , intrathecal or intraventricular, administration.
  • Parenteral administration can be in the form of a single bolus dose, or may be, e.g. , by a continuous perfusion pump.
  • Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders.
  • compositions which contain, as the active ingredient, the compound of the present disclosure or a pharmaceutically acceptable salt thereof, in combination with one or more pharmaceutically acceptable carriers or excipients.
  • the composition is suitable for topical administration.
  • the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, e.g. , a capsule, sachet, paper, or other container.
  • the excipient when it serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient.
  • the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, e.g. , up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.
  • the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g., about 40 mesh.
  • the compounds of the invention may be milled using known milling procedures such as wet milling to obtain a particle size appropriate for tablet formation and for other formulation types.
  • Finely divided (nanoparticulate) preparations of the compounds of the invention can be prepared by processes known in the art see, e.g., WO 2002/000196.
  • excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup and methyl cellulose.
  • the formulations can additionally include: lubricating agents such as talc, magnesium stearate and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents.
  • the compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
  • the pharmaceutical composition comprises silicified microcrystalline cellulose (SMCC) and at least one compound described herein, or a pharmaceutically acceptable salt thereof.
  • SMCC silicified microcrystalline cellulose
  • the silicified microcrystalline cellulose comprises about 98% microcrystalline cellulose and about 2% silicon dioxide w/w.
  • the composition is a sustained release composition comprising at least one compound described herein, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.
  • the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and at least one component selected from microcrystalline cellulose, lactose monohydrate, hydroxypropyl methylcellulose and polyethylene oxide.
  • the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and microcrystalline cellulose, lactose monohydrate and hydroxypropyl methylcellulose.
  • the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and microcrystalline cellulose, lactose monohydrate and polyethylene oxide.
  • the composition further comprises magnesium stearate or silicon dioxide.
  • the microcrystalline cellulose is Avicel PH102TM.
  • the lactose monohydrate is Fast-flo 316TM.
  • the hydroxypropyl methylcellulose is hydroxypropyl methylcellulose 2208 K4M (e.g. , Methocel K4 M
  • the polyethylene oxide is polyethylene oxide WSR 1105 (e.g. , Poly ox WSR 1105TM).
  • a wet granulation process is used to produce the composition. In some embodiments, a dry granulation process is used to produce the composition.
  • compositions can be formulated in a unit dosage form, each dosage containing from about 5 to about 1,000 mg (1 g), more usually about 100 mg to about 500 mg, of the active ingredient. In some embodiments, each dosage contains about 10 mg of the active ingredient. In some embodiments, each dosage contains about 50 mg of the active ingredient. In some embodiments, each dosage contains about 25 mg of the active ingredient.
  • unit dosage forms refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable
  • the components used to formulate the pharmaceutical compositions are of high purity and are substantially free of potentially harmful contaminants (e.g., at least National Food grade, generally at least analytical grade, and more typically at least pharmaceutical grade).
  • the composition is preferably manufactured or formulated under Good Manufacturing Practice standards as defined in the applicable regulations of the U.S. Food and Drug Administration.
  • suitable formulations may be sterile and/or substantially isotonic and/or in full compliance with all Good
  • the active compound may be effective over a wide dosage range and is generally administered in a therapeutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms and the like.
  • the therapeutic dosage of a compound of the present invention can vary according to, e.g., the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician.
  • the compounds of the invention can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration.
  • Some typical dose ranges are from about 1 ⁇ g/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day.
  • the dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
  • the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention.
  • a solid preformulation composition containing a homogeneous mixture of a compound of the present invention.
  • the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
  • This solid preformulation is then subdivided into unit dosage forms of the type described above containing from, e.g., about 0.1 to about 1000 mg of the active ingredient of the present invention.
  • the tablets or pills of the present invention can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
  • the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
  • the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release.
  • enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
  • liquid forms in which the compounds and compositions of the present invention can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
  • compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
  • the liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra.
  • the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
  • Compositions can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face mask, tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner.
  • Topical formulations can contain one or more conventional carriers.
  • ointments can contain water and one or more hydrophobic carriers selected from, e.g., liquid paraffin, poly oxy ethylene alkyl ether, propylene glycol, white Vaseline, and the like.
  • Carrier compositions of creams can be based on water in combination with glycerol and one or more other components, e.g., glycerinemonostearate, PEG-glycerinemonostearate and cetylstearyl alcohol.
  • Gels can be formulated using isopropyl alcohol and water, suitably in combination with other components such as, e.g., glycerol, hydroxy ethyl cellulose, and the like.
  • topical formulations contain at least about 0.1, at least about 0.25, at least about 0.5, at least about 1, at least about 2 or at least about 5 wt % of the compound of the invention.
  • the topical formulations can be suitably packaged in tubes of, e.g., 100 g which are optionally associated with instructions for the treatment of the select indication, e.g. , psoriasis or other skin condition.
  • compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient and the like.
  • compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration.
  • the pH of the compound preparations typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers or stabilizers will result in the formation of pharmaceutical salts.
  • the therapeutic dosage of a compound of the present invention can vary according to, e.g., the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician.
  • the compounds of the invention can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration.
  • Some typical dose ranges are from about 1 ⁇ g/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day.
  • the dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
  • the compounds of the present disclosure can further be useful in investigations of biological processes in normal and abnormal tissues.
  • another aspect of the present invention relates to labeled compounds of the invention (radio-labeled, fluorescent-labeled, etc.) that would be useful not only in imaging techniques but also in assays, both in vitro and in vivo, for localizing and quantitating PD-1 or PD-Ll protein in tissue samples, including human, and for identifying PD-Ll ligands by inhibition binding of a labeled compound.
  • the present invention includes PD-1/PD-L1 binding assays that contain such labeled compounds.
  • the present invention further includes isotopically-substituted compounds of the disclosure.
  • An “isotopically-substituted” compound is a compound of the invention where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e. , naturally occurring). It is to be understood that a “radio-labeled” is a compound that has incorporated at least one isotope that is radioactive (e.g., radionuclide). Suitable
  • radionuclides that may be incorporated in compounds of the present invention include but are not limited to 3 ⁇ 4 (also written as T for tritium), n C, 1 C, 14 C, 1 N, 15 N, 15 0, 17 0, 18 0, 18 F, 35 S, 6C1, 82 Br, 75 Br, 76 Br, 77 Br, 12 I, 124 I, 125 I and 1 l l.
  • the radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio-labeled compound. For example, for in vitro PD-Ll protein labeling and competition assays, compounds that incorporate H, 14 C, 82 Br, 125 I, 1 1 1, 5 S or will generally be most useful.
  • n C, 18 F, 125 I, 12 I, 124 I, 1 X I, 75 Br, 76 Br or 77 Br will generally be most useful.
  • the radionuclide is selected from the group consisting of H, 14 C, 125 1, 5 S and 82 Br. Synthetic methods for incorporating radio-isotopes into organic compounds are known in the art.
  • a labeled compound of the invention can be used in a screening assay to identify and/or evaluate compounds.
  • a newly synthesized or identified compound i.e. , test compound
  • a test compound which is labeled can be evaluated for its ability to bind a PD- Ll protein by monitoring its concentration variation when contacting with the PD-Ll protein, through tracking of the labeling.
  • a test compound (labeled) can be evaluated for its ability to reduce binding of another compound which is known to bind to a PD-Ll protein (i.e., standard compound). Accordingly, the ability of a test compound to compete with the standard compound for binding to the PD-L1 protein directly correlates to its binding affinity.
  • the standard compound is labeled and test compounds are unlabeled. Accordingly, the concentration of the labeled standard compound is monitored in order to evaluate the competition between the standard compound and the test compound, and the relative binding affinity of the test compound is thus ascertained.
  • kits useful useful, e.g., in the treatment or prevention of diseases or disorders associated with the activity of PD-L1 including its interaction with other proteins such as PD-1 and B7-1 (CD80), such as cancer or infections, which include one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I), or any of the embodiments thereof.
  • kits can further include one or more of various conventional pharmaceutical kit components, such as, e.g. , containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to those skilled in the art.
  • Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, can also be included in the kit.
  • Step 2 tert-butyl 2-( ⁇ [2-cyano-3-(2, 3-dihydro-l, 4-benzodioxin-6- yl)phenyl]amino ⁇ carbonyl)- -dihydro[ 1, 3] thiazolo [5, 4-c]pyridine-5(4H)-carboxylate
  • Step 1 tert-butyl 2- ⁇ [(3-bromo-2-cyanophenyl)amino]carbonyl ⁇ -6, 7- dihydrof 1, 3 ] thiazolo [ 5, 4-c ]pyridine-5( 4H)-carboxylate
  • Step 3 N-(2-cyanobiphenyl-3-yl)-4, 5, 6, 7-tetrahydro[ 1, 3 Jthiazolof 5, 4-c ]pyridine-2- carboxamide
  • This compound was prepared using similar procedures as described for Example 1 with 5-(tert-butoxycarbonyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazine-2-carboxylic acid (AstaTech, Cat#: 74720) replacing 5-(tert-butoxycarbonyl)-4,5,6,7- tetrahydro[l,3]thiazolo[5,4-c]pyridine-2-carboxylic acid in Step 2.
  • Step 1 tert-butyl l-methyl-l, 4, 6, 7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate
  • Step 3 tert-butyl 2-( ⁇ [2-cyano-3-(2, 3-dihydro-l, 4-benzodioxin-6- yl)phenyl]amino ⁇ carbonyl)-l-methyl-l, 4, 6, 7-tetrahydro-5H-imidazo[4, 5-c]pyridine-5- carboxylate
  • Step 4 N-[2-cyano-3-(2, 3-dihydro-l, 4-benzodioxin-6-yl)phenyl]-l-methyl-4, 5, 6, 7- tetrahydro-lH-imidazo[ 4, 5-c Jpyridine-2-carboxamide
  • Step 1 3-(2, 3-dihydrobenzo [b ][ l,4]dioxin-6- l)-2-methylaniline
  • Step 2 tert-butyl 2-(3-(2, 3-dihydrobenzo[b] [l, 4]dioxin-6-yl)-2-methylphenylcarbamoyl)-6, 7- dihydrothiazolof 5,
  • Step 3 N-[3-(2, 3-dihydro-l,4-benzodioxin-6-yl)-2-methylphenyl]-4,5, 6, 7- tetrahydrof 1, 3 ] thiazolo [ 5, 4-c ]pyridine-2-carboxamide
  • This compound was prepared using similar procedures as described for Example 2 with 3-bromo-2-methylaniline replacing 2-amino-6-bromobenzonitrile in Step 1, and (2- fluoro-3-methoxyphenyl)boronic acid replacing phenylboronic acid in Step 3.
  • LC-MS calculated for C21H21FN3O2S (M+H) + : m/z 398.1; found 398.2.
  • This compound was prepared using similar procedures as described for Example 12, starting with 2'-fluoro-3'-methoxy-2-methylbiphenyl-3-amine, prepared using similar procedures for the synthesis of 2-amino-6-(2,3-dihydro-l,4-benzodioxin-6-yl)benzonitrile in Example 1, Step 1.
  • This compound was prepared using similar procedures as described for Example 2 with 3-bromo-2-methylaniline replacing 2-amino-6-bromobenzonitrile in Step 1, and (1- methyl- lH-indazol-4-yl)boronic acid ⁇ Combi-Blocks; cat#BB-9017) replacing phenylboronic acid in Step 3.
  • This compound was prepared using similar procedures as described for Example 2 with 3-bromo-2-methylaniline replacing 2-amino-6-bromobenzonitrile in Step 1, and [2- fluoro-3-(hydroxymethyl)phenyl]boronic acid ⁇ Combi-Blocks, Cat#: BB-6579) replacing phenylboronic acid in Step 3.
  • LC-MS calculated for C21H21FN3O2S (M+H) + : m/z 398.1; found 398.2.
  • This compound was prepared using similar procedures as described for Example 2 with 3-bromo-2-methylaniline replacing 2-amino-6-bromobenzonitrile in Step 1, and indazole-4-boronic acid hydrochloride ⁇ Aldrich, Cat#: 709379) replacing phenylboronic acid in Step 3.
  • LC-MS calculated for C21H20N5OS (M+H) + : m/z 390.1; found 390.2.
  • This compound was prepared using similar procedures as described for Example 2 with 3-bromo-2-methylaniline replacing 2-amino-6-bromobenzonitrile in Step 1, and 2- methyl-2H-indazol-6-ylboronic acid pinacol ester ⁇ Combi-Blocks, Cat#:PN-9131) replacing phenylboronic acid in Step 3.
  • LC-MS calculated for C22H22N5OS (M+H) + : m/z 404.2; found 404.2.
  • This compound was prepared using similar procedures as described for Example 2 with 3-bromo-2-methylaniline replacing 2-amino-6-bromobenzonitrile in Step 1, and 2- (cyanomethyl)phenylboronic acid ⁇ Combi-Blocks, Cat#:BB-2136) replacing phenylboronic acid in Step 3.
  • Step 1 tert-butyl 2-(3-bromo-2-chlorophenylcarbamoyl)-6, 7-dihydrothiazolo[5,4-c]pyridine- 5( 4H)-carboxylate
  • Step 2 N-( 3-bromo-2-chlorophenyl)-4, 5, 6, 7-tetrahydrothiazolo[ 5, 4-c ]pyridine-2- carboxamide
  • Ci3Hi 2 BrClN 3 OS (M+H) + : m/z 372.0; found 372.0.
  • Step 3 N-(2-chloro-2'-fluoro-3'-methoxybiphenyl-3-yl)-4, 5, 6, 7-tetrahydro[l, 3]thiazolo[5, 4- c ]pyridine-2-carboxamide
  • Example 1 This compound was prepared using similar procedures as described for Example 12, Step 3 to 4, starting with 5-tert-butyl 2-methyl l-methyl-6,7-dihydro-lH-imidazo[4,5- c]pyridine-2,5(4H)-dicarboxylate from Example 12, Step 2 and 2-amino-6-(l-methyl-lH- indazol-4-yl)benzonitrile, prepared using similar procedures for the synthesis of 2-amino-6- (2,3-dihydro-l,4-benzodioxin-6-yl)benzonitrile in.
  • the assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ⁇ . Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25° C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA.
  • Recombinant human PD-L1 protein (19-238) with a His- tag at the C-terminus was purchased from AcroBiosy stems (PD1-H5229).
  • Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from
  • PD-L1 and PD-1 proteins were diluted in the assay buffer and ⁇ 0 ⁇ . was added to the plate well. Plates were centrifuged and proteins were
  • Example 1 Data obtained for the Example compounds using the PD-l/PD-Ll homogenous time- resolved fluorescence (HTRF) binding assay described in Example A is provided in Table 1.
  • Table 1 Data obtained for the Example compounds using the PD-l/PD-Ll homogenous time- resolved fluorescence (HTRF) binding assay described in Example A is provided in Table 1.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

Description

HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS FIELD OF THE INVENTION
The present application is concerned with pharmaceutically active compounds. The disclosure provides compounds as well as their compositions and methods of use. The compounds modulate PD-1/PD-L1 protein/protein interaction and are useful in the treatment of various diseases including infectious diseases and cancer.
BACKGROUND OF THE INVENTION
The immune system plays an important role in controlling and eradicating diseases such as cancer. However, cancer cells often develop strategies to evade or to suppress the immune system in order to favor their growth. One such mechanism is altering the expression of co-stimulatory and co-inhibitory molecules expressed on immune cells (Postow et al, J. Clinical Oncology 2015, 1 -9). Blocking the signaling of an inhibitory immune checkpoint, such as PD-1 , has proven to be a promising and effective treatment modality.
Programmed cell death-1 (PD-1), also known as CD279, is a cell surface receptor expressed on activated T cells, natural killer T cells, B cells, and macrophages (Greenwald et al, Annu. Rev. Immunol 2005, 23 :515-548; Okazaki and Honjo, Trends Immunol 2006,
(4): 195-201). It functions as an intrinsic negative feedback system to prevent the activation of T-cells, which in turn reduces autoimmunity and promotes self-tolerance. In addition, PD- 1 is also known to play a critical role in the suppression of antigen-specific T cell response in diseases like cancer and viral infection (Sharpe et al, Nat Immunol 2007 8, 239-245; Postow et al, J. Clinical Oncol 2015, 1 -9).
The structure of PD-1 consists of an extracellular immunoglobulin variable-like domain followed by a transmembrane region and an intracellular domain (Parry et al, Mol Cell Biol 2005, 9543-9553). The intracellular domain contains two phosphorylation sites located in an immunoreceptor tyrosine-based inhibitory motif and an immunoreceptor tyrosine-based switch motif, which suggests that PD-1 negatively regulates T cell receptor- mediated signals. PD-1 has two ligands, PD-L1 and PD-L2 (Parry et al, Mol Cell Biol 2005, 9543-9553; Latchman et al, Nat Immunol 2001 , 2, 261-268), and they differ in their expression patterns. PD-L1 protein is upregulated on macrophages and dendritic cells in response to lipopolysaccharide and GM-CSF treatment, and on T cells and B cells upon T cell receptor and B cell receptor signaling. PD-L1 is also highly expressed on almost all tumor cells, and the expression is further increased after IFN-γ treatment (Iwai et al, PNAS2002, 99(19): 12293-7; Blank et al, Cancer Res 2004, 64(3): 1140-5). In fact, tumor PD- Ll expression status has been shown to be prognostic in multiple tumor types (Wang et al, Eur J Surg Oncol 2015; Huang et al, Oncol Rep 2015; Sabatier et al, Oncotarget 2015, 6(7): 5449-5464). PD-L2 expression, in contrast, is more restricted and is expressed mainly by dendritic cells (Nakae et al, J Immunol 2006, 177:566-73). Ligation of PD-1 with its ligands PD-L1 and PD-L2 on T cells delivers a signal that inhibits IL-2 and IFN-γ production, as well as cell proliferation induced upon T cell receptor activation (Carter et al, Eur J Immunol 2002, 32(3):634-43; Freeman et al, J Exp Med 2000, 192(7): 1027-34). The mechanism involves recruitment of SHP-2 or SHP-1 phosphatases to inhibit T cell receptor signaling such as Syk and Lck phosphorylation (Sharpe et al, Nat Immunol 2007, 8, 239-245).
Activation of the PD-1 signaling axis also attenuates PKC-Θ activation loop phosphorylation, which is necessary for the activation of NF-κΒ and API pathways, and for cytokine production such as IL-2, IFN-γ and TNF (Sharpe et al, Nat Immunol 2007, 8, 239-245; Carter et al, Eur J Immunol 2002, 32(3):634-43; Freeman et al, J Exp Med 2000,
192(7): 1027-34).
Several lines of evidence from preclinical animal studies indicate that PD-1 and its ligands negatively regulate immune responses. PD-1 -deficient mice have been shown to develop lupus-like glomerulonephritis and dilated cardiomyopathy (Nishimura et al, Immunity 1999, 11 : 141-151; Nishimura et al, Science 2001, 291 :319-322). Using an LCMV model of chronic infection, it has been shown that PD-1/PD-L1 interaction inhibits activation, expansion and acquisition of effector functions of virus-specific CD8 T cells (Barber et al, Nature 2006, 439, 682-7). Together, these data support the development of a therapeutic approach to block the PD-1 -mediated inhibitory signaling cascade in order to augment or "rescue" T cell response. Accordingly, there is a need for new compounds that block PD-1/PD-L1 protein/protein interaction.
SUMMARY
The present disclosure rovides, inter alia, a compound of Formula (I):
Figure imgf000003_0001
(I) or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein constituent variables are defined herein.
The present disclosure further provides a pharmaceutical composition comprising a compound of the disclosure, or a pharmaceutically acceptable salt or a stereoisomer thereof, and at least one pharmaceutically acceptable carrier or excipient.
The present disclosure further provides methods of modulating or inhibiting PD- 1/PD-Ll protein/protein interaction, which comprises administering to an individual a compound of the disclosure, or a pharmaceutically acceptable salt or a stereoisomer thereof.
The present disclosure further provides methods of treating a disease or disorder in a patient comprising administering to the patient a therapeutically effective amount of a compound of the disclosure, or a pharmaceutically acceptable salt or a stereoisomer thereof.
DETAILED DESCRIPTION
I. Compounds
The present disclosure rovides a compound of Formula (I):
Figure imgf000004_0001
or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
(i) G1 is NR6 and G2 is CPJR7; or
(ii) G1 is CR6R6 and G2 is NR7;
X1 is N or CR1;
X2 is N or CR2;
X3 is N or CR3;
Z is O, S, N, NR4 or CR4;
Y1 and Y2 are each independently N or C, provided Y1 and Y2 are not simultaneously
N;
Cy is Ce-ιο aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R8 substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C3-10 cycloalkyl, C3- 10 cycloalkyl-Ci-4 alkyl-, Ce-ι oaryl, Ce-ιο aryl-Ci-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OR10, Ci-4 haloalkyl, Ci-4 haloalkoxy, NH2, -NHR10, -NR10R10, NHOR10, C(0)R10, C(O)NR10R10, C(0)OR10,
OC(0)R10, OC(O)NR10R10, NR10C(O)R10, NR10C(O)OR10, NR10C(O)NR10R10, C(=NR10)R10, C(=NR10)NR10R10, NR10C(=NR10)NR10R10, NR10S(O)R10, NR10S(O)2R10,
NR10S(O)2NR10R10, S(0)R10, S(O)NR10R10, S(0)2R10, and S(O)2NR10R10, wherein each R10 is independently selected from H, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkoxy, C3-10 cycloalkyl, C3-10 cycloalkyl-Ci-4 alkyl-, Ce-ιο aryl, Ce-ιο aryl-Ci-4 alkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4- 10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, Ci-4 alkoxy, C3-10 cycloalkyl, C3-io cycloalkyl-Ci-4 alkyl-, Ce-ιο aryl, Ce-io aryl-Ci-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R1, R2, R3 and R10 are each optionally substituted with 1 , 2 or 3 independently selected Rd substituents;
R4, R5, R6, R7 and R8 are each independently selected from H, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, Ce-ιο aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered
heterocycloalkyl)-Ci-4 alkyl-, CN, NO2, ORa, SRa, NHORa, C(0)Ra, C(0)NRaRa, C(0)ORa, OC(0)Ra, OC(0)NRaRa, NHRa, NRaRa, NRaC(0)Ra, NRaC(0)ORa, NRaC(0)NRaRa, C(=NRa)Ra, C(=NRa)NRaRa, NRaC(=NRa)NRaRa, NRaC (=NOH)NRaRa,
NRaC(=NCN)NRaRa, NRaS(0)Ra, NRaS(0)2Ra, NRaS(0)2NRaRa, S(0)Ra, S(0)NRaRa, S(0)2Ra, and S(0)2NRaRa, wherein the Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-io aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R4, R5, R6, R7 and R8 are each optionally substituted with 1 , 2, 3, 4 or 5 Rb substituents;
or two adjacent R8 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected RB substituents;
or two R5 substituents attached to the same carbon atom, taken together with the carbon atom to which they are attached, form a C3-6 cycloalkyl ring or 4-, 5-, 6- or 7- membered heterocycloalkyl ring, wherein the C3-6 cycloalkyl ring and 4-, 5-, 6- or 7- membered heterocycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected RB substituents;
R9 is halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, Ce-ιο aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, NO2, OR11, SR1 1, NH2, NHR1 1, NRNRN, NHOR1 1, C(0)RN, C(0)NRNRN, C(0)ORN, OC(0)RN, OC(0)NRNRN, NRNC(0)RN, NRHC^OR!!^RHC^NRHR1 1, C(=NR1 1)R1 1, C(=NR1 1)NR1 1R1 1,
NR1 1C(=NR1 1)NR1 1R11, NR11C(=NOH)NR1 1R1 1, NR1 1C(=NCN)NR1 1R11, NRNS(0)RN, NRHS^R1 1, NRHS^NRHR1 1, S(0)RN, S(0)NRNRN, S(0)2RN, or S^NRHR1 1, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, C6-io aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R9 are each optionally substituted with 1 , 2 or 3 RB substituents;
each R1 1 is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-C 1-4 alkyl-, C3-io cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R1 1 are each optionally substituted with 1 , 2 or 3 RB substituents;
each RA is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Ra are each optionally substituted with 1 , 2 or 3 Rd substituents;
each Rb substituent is independently selected from halo, Ci-6 alkyl, Ci-6 haloalkyl, Ci- 6 haloalkoxy, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRcC(=NOH)NRcRc, NRCC(=NCN)NRCRC, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc,
S(0)NRcRc, S(0)2Rc and S(0)2NRcRc; wherein the Ci-e alkyl, Ci-e haloalkyl, Ci-e haloalkoxy, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- 10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-and (4- 10 membered heterocycloalkyl)-Ci-4 alkyl- of Rb are each further optionally substituted with 1-3 independently selected Rd substituents;
each Rc is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rc are each optionally substituted with 1 , 2 or 3 Rf substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10
cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, halo, CN, NHOR , ORg, SRg, C(0)Rg, C(0)NRgRg, C(0)ORg, OC(0)Rg, OC(0)NRgRg, NHRg, NRgRg, NRgC(0)Rg, NRgC(0)NRgRg, NRgC(0)ORg, C(=NR )NR R , NR C(=NR )NR R , NR C(=NOH)NR R , NR C (=NCN)NR R , S(0)Rg, S(0)NRgRg, S(0)2Rg, NRgS(0)2Rg, NRgS(0)2NRgRg, and S(0)2NRgRg; wherein the Ci-e alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rf are each optionally substituted with 1 , 2 or 3 Rn substituents independently selected from Ci-6 alkyl, C 1-6 haloalkyl, halo, CN, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, NHOR°, OR0, SR°, C(0)R°, C(0)NR°R°, C(0)OR°, OC(0)R°, OC(0)NR°R°, NHR°, NR°R°, NR°C(0)R°, NR°C(0)NR°R°, NR°C(0)OR°, C(=NR°)NR°R°, NR0C(=NR°)NR°R0, S(0)R°, S(0)NR°R°, S(0)2R°, NR°S(0)2R°,
NR0S(O)2NR0R°, and S(0)2NR°R°, wherein the Ci-e alkyl, Ci-e haloalkyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of Rn is optionally substituted with 1, 2 or 3 Rq substituents;
each Rd is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, halo, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, NH2, NHORe, ORe, SRe, C(0)Re, C(0)NReRe, C(0)ORe, OC(0)Re, OC(0)NReRe, NHRe, NReRe, NReC(0)Re, NReC(0)NReRe, NReC(0)ORe, C(=NRe)NReRe, NReC (=NRe)NReRe, NReC(=NOH)NReRe, NReC(=NCN)NReRe, S(0)Re, S(0)NReRe, S(0)2Re, NReS(0)2Re, NReS(0)2NReRe, and S(0)2NReRe, wherein the Ci-e alkyl, Ci-6 haloalkyl, Ce-ιο aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rd are each optionally substituted with 1-3 independently selected Rf substituents;
each Re is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Re are each optionally substituted with 1, 2 or 3 independently selected Rf substituents;
each Rg is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-C 1-4 alkyl-, C3-io cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rg are each optionally substituted with 1-3 Rp substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered
heterocycloalkyl)-Ci-4 alkyl-, halo, CN, NHORr, ORr, SRr, C(0)Rr, C(0)NRrRr, C(0)ORr, OC(0)Rr, OC(0)NRrRr, NHRr, NRrRr, NRrC(0)Rr, NRrC(0)NRrRr, NRrC(0)ORr,
C(=NRr)NRrRr, NRrC(=NRr)NRrRr, NRrC(=NOH)NRrRr, NRrC (=NCN)NRrRr, S(0)Rr, S(0)NRrRr, S(0)2Rr, NRrS(0)2Rr, NRrS(0)2NRrRr and S(0)2NRrRr, wherein the Ci-e alkyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rp are each optionally substituted with 1 , 2 or 3 Rq substituents;
or any two Ra substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 Rh substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-7 membered heterocycloalkyl, Ce-ιο aryl, 5-6 membered heteroaryl, Ce-ιο aryl- C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-6 membered heteroaryl)-Ci-4 alkyl-, (4-7 membered heterocycloalkyl)-Ci-4 alkyl-, C 1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, halo, CN, OR1, SR NHOR1, C(0)R\ C^NR , C(0)OR\ OC(0)R\ OC^NR , NHR1, NR'R1, NRiC(0)Ri, NR ^NRiR1, NR ^OR1, C^NR NR'R1, NR ^NR NR'R1,
NR ^NOI^NRiR1, NR ^NCN^R , S(0)R\ S^NR , δ(0)2^, NR^O^R1,
NR^O^NRiR1, and S O^NR'R1, wherein the Ci-e alkyl, Ci-e haloalkyl, C3-10 cycloalkyl, 4-7 membered heterocycloalkyl, Ce-ιο aryl, 5-6 membered heteroaryl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-6 membered heteroaryl)-C 1-4 alkyl-, (4-7 membered
heterocycloalkyl)-Ci-4 alkyl- of Rh are each optionally substituted by 1, 2, or 3 RJ substituents independently selected from C1-4 alkyl, C3-6 cycloalkyl, Ce-ιο aryl, 5- or 6-membered heteroaryl, 4-6 membered heterocycloalkyl, C2-4 alkenyl, C2-4 alkynyl, halo, Ci-4 haloalkyl, Ci-4haloalkoxy, CN, NHORk, ORk, SRk, C(0)Rk, C(0)NRkRk, C(0)ORk, OC(0)Rk, OC(0)NRkRk, NHRk, NRkRk, NRkC(0)Rk, NRkC(0)NRkRk, NRkC(0)ORk, C(=NRk)NRkRk, NRkC(=NRk)NRkRk, S(0)Rk, S(0)NRkRk, S(0)2Rk, NRkS(0)2Rk, NRkS(0)2NRkRk, and S(0)2NRkRk' wherein the C1-4 alkyl, C3-6 cycloalkyl, Ce-ιο aryl, 5- or 6-membered heteroaryl, 4-6 membered heterocycloalkyl, C2-4 alkenyl, C2-4 alkynyl, Ci-4 haloalkyl, and Ci-4haloalkoxy of Ri are each optionally substituted with 1, 2 or 3 Rq substituents;
or two Rh groups attached to the same carbon atom of the 4- to 10-membered heterocycloalkyl, taken together with the carbon atom to which they are attached, form a C3-6 cycloalkyl or 4- to 6-membered heterocycloalkyl having 1 -2 heteroatoms as ring members selected from O, N or S;
each R1 or Rk is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R1 or Rk are each optionally substituted with 1 -3 independently selected Rp substituents; or any two Rc substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 independently selected Rh substituents;
or any two Re substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 independently selected Rh substituents;
or any two R substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 independently selected Rh substituents;
or any two R1 substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 independently selected Rh substituents;
or any two Rk substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 independently selected Rh substituents;
or any two R° substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 independently selected Rh substituents;
or any two Rr substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 independently selected Rh substituents;
each R° or Rr is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, Ce-ιο aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the C1-4 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, Ce-ιο aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C2-4 alkenyl, and C2-4 alkynyl of R1, Rk, R° or Rr are each optionally substituted with 1, 2 or 3 Rq substituents;
each R¾ is independently selected from OH, CN, -COOH, NH2, halo, Ci-6 haloalkyl, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 haloalkoxy, Ci-6 alkylthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C3-6 cycloalkyl, NHR12 and NR12R12, wherein the Ci-6 alkyl, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl of Rq are each optionally substituted with halo, OH, CN, -COOH, NH2, C1-4 alkoxy, C1-4 haloalkyl, Ci-4 haloalkoxy, phenyl, C3-10 cycloalkyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl and each R12 is independently Ci-6 alkyl;
= is a single bond or a double bond to maintain ring A being aromatic; and the subscript n is an integer of 1, 2, 3 or 4.
In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
(i) G1 is NR6 and G2 is CR7R7; or
(ii) G1 is CR6R6 and G2 is NR7;
X1 is N or CR1;
X2 is N or CR2;
X3 is N or CR3;
Z is O, S, N, NR4 or CR4;
Y1 and Y2 are each independently N or C, provided Y1 and Y2 are not simultaneously
N;
Cy is Ce-ιο aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R8 substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C3-10 cycloalkyl, C3- 10 cycloalkyl-Ci-4 alkyl-, Ce-ιο aryl, Ce-ιο aryl-Ci-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OR10, Ci-4 haloalkyl, Ci-4 haloalkoxy, NH2, -NHR10, -NR10R10, NHOR10, C(0)R10, C(O)NR10R10, C(0)OR10,
OC(0)R10, OC(O)NR10R10, NR10C(O)R10, NR10C(O)OR10, NR10C(O)NR10R10, C(=NR10)R10, C(=NR10)NR10R10, NR10C(=NR10)NR10R10, NR10S(O)R10, NR10S(O)2R10,
NR10S(O)2NR10R10, S(0)R10, S(O)NR10R10, S(0)2R10, and S(O)2NR10R10, wherein each R10 is independently selected from H, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, Cw alkoxy, C3-10 cycloalkyl, C3-10 cycloalkyl-Ci-4 alkyl-, Ce-ιο aryl, Ce-ιο aryl-Ci-4 alkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4- 10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, Ci-4 alkoxy, C3-10 cycloalkyl, C3-10 cycloalkyl-Ci-4 alkyl-, Ce-ιο aryl, Ce-ιο aryl-Ci-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R1, R2, R3 and R10 are each optionally substituted with 1 , 2 or 3 independently selected Rd substituents;
R4, R5, R6, R7 and R8 are each independently selected from H, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, Ce-ιο aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered
heterocycloalkyl)-Ci-4 alkyl-, CN, NO2, ORa, SRa, NHORa, C(0)Ra, C(0)NRaRa, C(0)ORa, OC(0)Ra, OC(0)NRaRa, NHRa, NRaRa, NRaC(0)Ra, NRaC(0)ORa, NRaC(0)NRaRa, C(=NRa)Ra, C(=NRa)NRaRa, NRaC(=NRa)NRaRa, NRaC (=NOH)NRaRa,
NRaC(=NCN)NRaRa, NRaS(0)Ra, NRaS(0)2Ra, NRaS(0)2NRaRa, S(0)Ra, S(0)NRaRa, S(0)2Ra, and S(0)2NRaRa, wherein the Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-io aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R4, R5, R6, R7 and R8 are each optionally substituted with 1 , 2, 3, 4 or 5 Rb substituents;
or two adjacent R8 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
or two R5 substituents attached to the same carbon atom, taken together with the carbon atom to which they are attached, form a C3-6 cycloalkyl ring or 4-, 5-, 6- or 7- membered heterocycloalkyl ring, wherein the C3-6 cycloalkyl ring and 4-, 5-, 6- or 7- membered heterocycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents; R9 is halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, Ce-ιο aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, NO2, OR11, SR.11, NH2, NHR11, NRnRn, NHOR11, C(0)Rn, C(0)NRnRn, C(0)ORn, OC(0)Rn, OC(0)NRnRn, NRnC(0)Rn, NR11C(0)OR11, NR11C(0)NR11R11, C(=NR11)R11, C(=NR11)NR11R11,
NR11C(=NR11)NR11R11, NR11C(=NOH)NR11R11, NR11C(=NCN)NR11R11, NRnS(0)Rn, NRnS(0)2Rn, NR11 S(0)2NR1 XRX x, S(0)Rn, S(0)NRnRn, S(0)2Rn, or S^NRHR11, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, C6-io aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R9 are each optionally substituted with 1 , 2 or 3 Rb substituents;
each R11 is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-C 1-4 alkyl-, C3-io cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R11 are each optionally substituted with 1 , 2 or 3 Rb substituents;
each Ra is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Ra are each optionally substituted with 1 , 2 or 3 Rd substituents;
each Rb substituent is independently selected from halo, Ci-6 alkyl, Ci-6 haloalkyl, Ci- 6 haloalkoxy, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRcC(=NOH)NRcRc, NRCC(=NCN)NRCRC, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc,
S(0)NRcRc, S(0)2Rc and S(0)2NRcRc; wherein the Ci-e alkyl, Ci-e haloalkyl, Ci-e haloalkoxy, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- 10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-and (4- 10 membered heterocycloalkyl)-Ci-4 alkyl- of Rb are each further optionally substituted with 1-3 independently selected Rd substituents;
each Rc is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rc are each optionally substituted with 1, 2 or 3 Rf substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, halo, CN, NHOR , ORg, SRg, C(0)Rg, C(0)NRgRg, C(0)ORg, OC(0)Rg, OC(0)NRgRg, NHRg, NRgRg, NRgC(0)Rg, NRgC(0)NRgRg, NRgC(0)ORg, C(=NR )NR R , NR C(=NR )NR R , NR C(=NOH)NR R , NR C (=NCN)NR R , S(0)Rg, S(0)NRgRg, S(0)2Rg, NRgS(0)2Rg, NRgS(0)2NRgRg, and S(0)2NRgRg; wherein the Ci-e alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rf are each optionally substituted with 1, 2 or 3 Rn substituents independently selected from Ci-6 alkyl, C 1-6 haloalkyl, halo, CN, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, NHOR0, OR0, SR°, C(O)R0, C(O)NR0R°, C(O)OR0, OC(0)R°, OC(0)NR°R°, NHR°, NR°R°, NR0C(O)R°, NR0C(O)NR°R°, NR°C(0)OR°, C(=NR°)NR°R°, NR0C(=NR°)NR°R0, S(O)R0, S(O)NR0R°, S(O)2R0, NR0S(O)2R°,
NR°S(0)2NR°R°, and S(O)2NR0R°, wherein the Ci-e alkyl, Ci-e haloalkyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of Rn is optionally substituted with 1, 2 or 3 Rq substituents; each Rd is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, halo, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, NH2, NHORe, ORe, SRe, C(0)Re, C(0)NReRe, C(0)ORe, OC(0)Re, OC(0)NReRe, NHRe, NReRe, NReC(0)Re, NReC(0)NReRe, NReC(0)ORe, C(=NRe)NReRe, NReC (=NRe)NReRe, NReC(=NOH)NReRe, NReC(=NCN)NReRe, S(0)Re, S(0)NReRe, S(0)2Re, NReS(0)2Re, NReS(0)2NReRe, and S(0)2NReRe, wherein the Ci-e alkyl, Ci-6 haloalkyl, Ce-ιο aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rd are each optionally substituted with 1-3 independently selected Rf substituents;
each Re is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Re are each optionally substituted with 1, 2 or 3 independently selected Rf substituents;
each Rg is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-C 1-4 alkyl-, C3-io cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R are each optionally substituted with 1-3 Rp substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10
cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered
heterocycloalkyl)-Ci-4 alkyl-, halo, CN, NHORr, ORr, SRr, C(0)Rr, C(0)NRrRr, C(0)ORr, OC(0)Rr, OC(0)NRrRr, NHRr, NRrRr, NRrC(0)Rr, NRrC(0)NRrRr, NRrC(0)ORr,
C(=NRr)NRrRr, NRrC(=NRr)NRrRr, NRrC(=NOH)NRrRr, NRrC (=NCN)NRrRr, S(0)Rr, S(0)NRrRr, S(0)2Rr, NRrS(0)2Rr, NRrS(0)2NRrRr and S(0)2NRrRr, wherein the Ci-e alkyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rp are each optionally substituted with 1 , 2 or 3 Rq substituents;
or any two Ra substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 Rh substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-7 membered heterocycloalkyl, Ce-ιο aryl, 5-6 membered heteroaryl, Ce-ιο aryl- Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-6 membered heteroaryl)-Ci-4 alkyl-, (4-7 membered heterocycloalkyl)-Ci-4 alkyl-, C 1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, halo, CN, OR1, SR, NHOR, C(0)R, C C N , C(0)OR, OC(0)R, OC C N , NHR, NRR, N C C , N C C N , N C C O , C^NR N , NRC^NR NRR,
RiC(=NOH) RiRi, RiC(=NC )NRiRi, S(0)R, 8(0)ΝΚ¾', S(0)2R, NRS(0)2R, N S O^N , and S(0)2NRR, wherein the Ci-e alkyl, Ci-e haloalkyl, C3-10 cycloalkyl, 4-7 membered heterocycloalkyl, Ce-ιο aryl, 5-6 membered heteroaryl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-6 membered heteroaryl)-C 1-4 alkyl-, (4-7 membered
heterocycloalkyl)-Ci-4 alkyl- of Rh are each optionally substituted by 1, 2, or 3 Ri substituents independently selected from C1-4 alkyl, C3-6 cycloalkyl, Ce-ιο aryl, 5- or 6-membered heteroaryl, 4-6 membered heterocycloalkyl, C2-4 alkenyl, C2-4 alkynyl, halo, C1-4 haloalkyl, Ci-4haloalkoxy, CN, NHORk, ORk, SRk, C(0)Rk, C(0)NRkRk, C(0)ORk, OC(0)Rk,
OC(0)NRkRk, NHRk, NRkRk, NRkC(0)Rk, NRkC(0)NRkRk, NRkC(0)ORk, C(=NRk)NRkRk, NRkC(=NRk)NRkRk, S(0)Rk, S(0)NRkRk, S(0)2Rk, NRkS(0)2Rk, NRkS(0)2NRkRk, and S(0)2NRkRk' wherein the C1-4 alkyl, C3-6 cycloalkyl, Ce-ιο aryl, 5- or 6-membered heteroaryl, 4-6 membered heterocycloalkyl, C2-4 alkenyl, C2-4 alkynyl, C 1-4 haloalkyl, and Ci-4haloalkoxy of Ri are each optionally substituted with 1, 2 or 3 Rq substituents;
or two Rh groups attached to the same carbon atom of the 4- to 10-membered heterocycloalkyl, taken together with the carbon atom to which they are attached, form a C3-6 cycloalkyl or 4- to 6-membered heterocycloalkyl having 1 -2 heteroatoms as ring members selected from O, N or S;
each R1 or Rk is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R1 or Rk are each optionally substituted with 1-3 independently selected Rp substituents; or any two Rc substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Re substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R1 substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rk substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R° substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rr substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
each R° or Rr is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, Ce-ιο aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the C1-4 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, Ce-ιο aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C2-4 alkenyl, and C2-4 alkynyl of R° or Rr are each optionally substituted with 1, 2 or 3 Rq substituents;
each Rq is independently selected from OH, CN, -COOH, NH2, halo, C 1-6 haloalkyl, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 haloalkoxy, Ci-6 alkylthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C3-6 cycloalkyl, NHR12 and NR12R12, wherein the Ci-6 alkyl, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl of Rq are each optionally substituted with halo, OH, CN, -COOH, NH2, C1-4 alkoxy, C1-4 haloalkyl, Ci-4 haloalkoxy, phenyl, C3-10 cycloalkyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl and each R12 is independently Ci-6 alkyl;
= is a single bond or a double bond to maintain ring A being aromatic; and the subscript n is an integer of 1, 2, 3 or 4.
In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
(i) G1 is NR6 and G2 is CR7R7; or
(ii) G1 is CR6R6 and G2 is NR7;
X1 is N or CR1;
X2 is N or CR2;
X3 is N or CR3;
Z is O, S, N, NR4 or CR4;
Y1 and Y2 are each independently N or C, provided Y1 and Y2 are not simultaneously
N;
Cy is Ce-ιο aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R8 substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C3-10 cycloalkyl, C3- 10 cycloalkyl-Ci-4 alkyl-, Ce-ιο aryl, Ce-ιο aryl-Ci-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OR10, Ci-4 haloalkyl, Ci-4 haloalkoxy, NH2, -NHR10, -NR10R10, NHOR10, C(0)R10, C(O)NR10R10, C(0)OR10,
OC(0)R10, OC(O)NR10R10, NR10C(O)R10, NR10C(O)OR10, NR10C(O)NR10R10, C(=NR10)R10, C(=NR10)NR10R10, NR10C(=NR10)NR10R10, NR10S(O)R10, NR10S(O)2R10,
NR10S(O)2NR10R10, S(0)R10, S(O)NR10R10, S(0)2R10, and S(O)2NR10R10, wherein each R10 is independently selected from H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkoxy, C3-10 cycloalkyl, C3-10 cycloalkyl-Ci-4 alkyl-, Ce-ιο aryl, Ce-ιο aryl-Ci-4 alkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4- 10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, Ci-4 alkoxy, C3-10 cycloalkyl, C3-io cycloalkyl-Ci-4 alkyl-, Ce-ιο aryl, Ce-io aryl-Ci-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R1, R2, R3 and R10 are each optionally substituted with 1 , 2 or 3 independently selected Rd substituents;
R4, R5, R6, R7 and R8 are each independently selected from H, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, Ce-ιο aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered
heterocycloalkyl)-Ci-4 alkyl-, CN, NO2, ORa, SRa, NHORa, C(0)Ra, C(0)NRaRa, C(0)ORa, OC(0)Ra, OC(0)NRaRa, NHRa, NRaRa, NRaC(0)Ra, NRaC(0)ORa, NRaC(0)NRaRa, C(=NRa)Ra, C(=NRa)NRaRa, NRaC(=NRa)NRaRa, NRaC (=NOH)NRaRa,
NRaC(=NCN)NRaRa, NRaS(0)Ra, NRaS(0)2Ra, NRaS(0)2NRaRa, S(0)Ra, S(0)NRaRa,
S(0)2Ra, and S(0)2NRaRa, wherein the Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-io aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R4, R5, R6, R7 and R8 are each optionally substituted with 1 , 2, 3, 4 or 5 Rb substituents;
or two adjacent R8 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
or two R5 substituents attached to the same carbon atom, taken together with the carbon atom to which they are attached, form a C3-6 cycloalkyl ring or 4-, 5-, 6- or 7- membered heterocycloalkyl ring, wherein the C3-6 cycloalkyl ring and 4-, 5-, 6- or 7- membered heterocycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R9 is halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, Ce-ιο aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, NO2, OR11, SR11, NH2, NHR11, NRnRn, NHOR11, C(0)Rn, C(0)NRnRn, C(0)ORn, OC(0)Rn, OC(0)NRnRn, NRnC(0)Rn, NRHC^OR^ NRHC^NRHR11, C(=NR11)R11, C(=NR11)NR11R11, NR11C(=NR11)NR11R11, NR11C(=NOH)NR11R11, NR11C(=NCN)NR11R11, NRnS(0)Rn, NRHS^R11, NRHS^NRHR11, S(0)Rn, S(0)NRnRn, S(0)2Rn, or S^NRHR1 1, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, C6-io aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R9 are each optionally substituted with 1 , 2 or 3 Rb substituents;
each R11 is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-C 1-4 alkyl-, C3-io cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R11 are each optionally substituted with 1 , 2 or 3 Rb substituents;
each Ra is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Ra are each optionally substituted with 1 , 2 or 3 Rd substituents;
each Rb substituent is independently selected from halo, Ci-6 alkyl, Ci-6 haloalkyl, Ci- 6 haloalkoxy, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRcC(=NOH)NRcRc, NRCC(=NCN)NRCRC, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc,
S(0)NRcRc, S(0)2Rc and S(0)2NRcRc; wherein the Ci-e alkyl, Ci-e haloalkyl, Ci-e haloalkoxy, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- 10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-and (4- 10 membered heterocycloalkyl)-Ci-4 alkyl- of Rb are each further optionally substituted with 1-3 independently selected Rd substituents;
each Rc is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rc are each optionally substituted with 1, 2 or 3 Rf substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, halo, CN, NHOR , ORg, SRg, C(0)Rg, C(0)NRgRg, C(0)ORg, OC(0)Rg, OC(0)NRgRg, NHRg, NRgRg, NRgC(0)Rg, NRgC(0)NRgRg, NRgC(0)ORg, C(=NRg)NRgRg, NRgC(=NRg)NRgRg, NRgC(=NOH)NRgRg, NRgC(=NCN)NRgRg, S(0)Rg, S(0)NRgRg, S(0)2Rg, NRgS(0)2Rg, NRgS(0)2NRgRg, and S(0)2NRgRg; wherein the Ci-e alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rf are each optionally substituted with 1, 2 or 3 Rn substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, halo, CN, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, NHOR0, OR0, SR°, C(O)R0, C(O)NR0R°, C(O)OR0, OC(0)R°, OC(0)NR°R°, NHR°, NR°R°, NR0C(O)R°, NR0C(O)NR°R°, NR°C(0)OR°, C(=NR°)NR°R°, NR0C(=NR°)NR°R0, S(O)R0, S(O)NR0R°, S(O)2R0, NR0S(O)2R°,
NR0S(O)2NR0R°, and S(O)2NR0R°, wherein the Ci-e alkyl, Ci-e haloalkyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of Rn is optionally substituted with 1, 2 or 3 Rq substituents;
each Rd is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, halo, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, NH2, NHORe, ORe, SRe, C(0)Re, C(0)NReRe, C(0)ORe, OC(0)Re, OC(0)NReRe, NHRe, NReRe, NReC(0)Re, NReC(0)NReRe, NReC(0)ORe, C(=NRe)NReRe, NReC (=NRe)NReRe, NReC(=NOH)NReRe, NReC(=NCN)NReRe, S(0)Re, S(0)NReRe, S(0)2Re, NReS(0)2Re, NReS(0)2NReRe, and S(0)2NReRe, wherein the Ci-e alkyl, Ci-6 haloalkyl, Ce-ιο aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rd are each optionally substituted with 1-3 independently selected Rf substituents;
each Re is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Re are each optionally substituted with 1, 2 or 3 independently selected Rf substituents;
each R is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-C 1-4 alkyl-, C3-io cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R are each optionally substituted with 1-3 Rp substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10
cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered
heterocycloalkyl)-Ci-4 alkyl-, halo, CN, NHORr, ORr, SRr, C(0)Rr, C(0)NRrRr, C(0)ORr, OC(0)Rr, OC(0)NRrRr, NHRr, NRrRr, NRrC(0)Rr, NRrC(0)NRrRr, NRrC(0)ORr,
C(=NRr)NRrRr, NRrC(=NRr)NRrRr, NRrC(=NOH)NRrRr, NRrC (=NCN)NRrRr, S(0)Rr, S(0)NRrRr, S(0)2Rr, NRrS(0)2Rr, NRrS(0)2NRrRr and S(0)2NRrRr, wherein the Ci-e alkyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10
cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rp are each optionally substituted with 1, 2 or 3 Rq substituents; or any two Ra substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 Rh substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-7 membered heterocycloalkyl, Ce-ιο aryl, 5-6 membered heteroaryl, Ce-ιο aryl- Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-6 membered heteroaryl)-Ci-4 alkyl-, (4-7 membered heterocycloalkyl)-Ci-4 alkyl-, Ci-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, halo, CN, OR1, SR NHOR1, C(0)R 0(Ο)Ν^, 0(0)0^, 00(0)^, 00(0)Ν^^, NHR', NR'R1, NR'C C R1, Ν^0(Ο)Ν^^, NR'C^C OR1, C^NR NR'R1, NR'C^NR NR'R1,
NR'C^NOH^R'R1, NR'C^NCTvONR'R1, S^R1, S^N^R1, 8(0)Λ\ NR^O^R1, Ν^δ(0)2Ν^^, and S O^NR'R1, wherein the Ci-e alkyl, Ci-e haloalkyl, C3-10 cycloalkyl, 4-7 membered heterocycloalkyl, Ce-ιο aryl, 5-6 membered heteroaryl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-6 membered heteroaryl)-C 1-4 alkyl-, (4-7 membered
heterocycloalkyl)-Ci-4 alkyl- of Rh are each optionally substituted by 1, 2, or 3 RJ substituents independently selected from C1-4 alkyl, C3-6 cycloalkyl, Ce-ιο aryl, 5- or 6-membered heteroaryl, 4-6 membered heterocycloalkyl, C2-4 alkenyl, C2-4 alkynyl, halo, C1-4 haloalkyl, Ci-4haloalkoxy, CN, NHORk, 0Rk, SRk, C(0)Rk, C(0)NRkRk, C(0)ORk, OC(0)Rk,
OC(0)NRkRk, NHRk, NRkRk, NRkC(0)Rk, NRkC(0)NRkRk, NRkC(0)ORk, C(=NRk)NRkRk, NRkC(=NRk)NRkRk, S(0)Rk, S(0)NRkRk, S(0)2Rk, NRkS(0)2Rk, NRkS(0)2NRkRk, and S(0)2NRkRk- wherein the C1-4 alkyl, C3-6 cycloalkyl, Ce-ιο aryl, 5- or 6-membered heteroaryl, 4-6 membered heterocycloalkyl, C2-4 alkenyl, C2-4 alkynyl, C 1-4 haloalkyl, and Ci-4haloalkoxy of Ri are each optionally substituted with 1, 2 or 3 Rq substituents;
or two Rh groups attached to the same carbon atom of the 4- to 10-membered heterocycloalkyl, taken together with the carbon atom to which they are attached, form a C3-6 cycloalkyl or 4- to 6-membered heterocycloalkyl having 1 -2 heteroatoms as ring members selected from O, N or S;
each R1 or Rk is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R1 or Rk are each optionally substituted with 1 -3 independently selected Rp substituents; or any two Rc substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Re substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R1 substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents, or 1, 2, or 3 independently selected Rq substituents; or any two Rk substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents, or 1, 2, or 3 independently selected Rq substituents; or any two R° substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents, or 1, 2, or 3 independently selected Rq substituents; or any two Rr substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents, or 1, 2, or 3 independently selected Rq substituents; each R° or Rr is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, Ce-ιο aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the C1-4 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, Ce-ιο aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C2-4 alkenyl, and C2-4 alkynyl of R° or Rr are each optionally substituted with 1, 2 or 3 Rq substituents;
each Rq is independently selected from OH, CN, -COOH, NH2, halo, C 1-6 haloalkyl, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 haloalkoxy, Ci-6 alkylthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C3-6 cycloalkyl, NHR12 and NR12R12, wherein the Ci-6 alkyl, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl of Rq are each optionally substituted with halo, OH, CN, -COOH, NH2, C1-4 alkoxy, C1-4 haloalkyl, Ci-4 haloalkoxy, phenyl, C3-10 cycloalkyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl and each R12 is independently Ci-6 alkyl; ===== is a single bond or a double bond to maintain ring A being aromatic; and the subscript n is an integer of 1, 2, 3 or 4.
In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
(i) G1 is NR6 and G2 is CR7R7; or
(ii) G1 is CR6R6 and G2 is NR7;
X1 is N or CR1;
X2 is N or CR2;
X3 is N or CR3;
Z is O, S, N, NR4 or CR4;
Y1 and Y2 are each independently N or C, provided Y1 and Y2 are not simultaneously
N;
Cy is Ce-ιο aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R8 substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C3-6 cycloalkyl, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OH, Ci-4 alkoxy, Ci-4 haloalkyl, Ci-4 haloalkoxy, NH2, -NH- Ci-4 alkyl, -N(Ci-4 alkyl)2, NHOR10, C(0)R10, C(O)NR10R10, C(0)OR10, OC(0)R10, OC(O)NR10R10, NR10C(O)R10, NR10C(O)OR10, NR10C(O)NR10R10, C(=NR10)R10,
C(=NR10)NR10R10, NR10C(=NR10)NR10R10, NR10S(O)R10, NR10S(O)2R10,
NR10S(O)2NR10R10, S(0)R10, S(O)NR10R10, S(0)2R10, and S(O)2NR10R10, wherein each R10 is independently selected from H and C1-4 alkyl optionally substituted with 1 or 2 groups independently selected from halo, OH, CN and C1-4 alkoxy; and wherein the C1-4 alkyl, C3-6 cycloalkyl, C2-4 alkenyl, C2-4 alkynyl and C1-4 alkoxy of R1, R2 and R3 are each optionally substituted with 1 or 2 substituents independently selected from halo, OH, CN and C1-4 alkoxy;
R4, R5, R6, R7 and R8 are each independently selected from H, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, Ce-ιο aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered
heterocycloalkyl)-Ci-4 alkyl-, CN, N02, ORa, SRa, NHORa, C(0)Ra, C(0)NRaRa, C(0)ORa, OC(0)Ra, OC(0)NRaRa, NHRa, NRaRa, NRaC(0)Ra, NRaC(0)ORa, NRaC(0)NRaRa, C(=NRa)Ra, C(=NRa)NRaRa, NRaC(=NRa)NRaRa, NRaC (=NOH)NRaRa, NRaC(=NCN)NRaRa, NRaS(0)Ra, NRaS(0)2Ra, NRaS(0)2NRaRa, S(0)Ra, S(0)NRaRa, S(0)2Ra, and S(0)2NRaRa, wherein the Ci-e alkyl, C2-e alkenyl, C2-e alkynyl, Ce-io aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R4, R5, R6, R7 and R8 are each optionally substituted with 1 , 2, 3, 4 or 5 Rb substituents;
or two adjacent R8 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
or two R5 substituents attached to the same carbon atom, taken together with the carbon atom to which they are attached, form a C3-6 cycloalkyl ring or 4-, 5-, 6- or 7- membered heterocycloalkyl ring, wherein the C3-6 cycloalkyl ring and 4-, 5-, 6- or 7- membered heterocycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R9 is halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, Ce-ιο aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, N02, OR11, SR.11, NH2, NHR11, NRnRn, NHOR11, C(0)Rn, C(0)NRnRn, C(0)ORn, OC(0)Rn, OC(0)NRnRn, NRnC(0)Rn, NRnC(0)ORn, NR11C(0)NR11R11, C(=NR11)R11, C(=NR11)NR11R11,
NR11C(=NR11)NR11R11, NR11C(=NOH)NR11R11, NR11C(=NCN)NR11R11, NRnS(0)Rn, NRnS(0)2Rn, NR11 S(0)2NR1 Κη, S(0)Rn, S(0)NRnRn, S(0)2Rn, or S(0)2NRnRn, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, C6-io aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R9 are each optionally substituted with 1 , 2 or 3 Rb substituents;
each R11 is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-C 1-4 alkyl-, C3-io cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R11 are each optionally substituted with 1 , 2 or 3 Rb substituents;
each Ra is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Ra are each optionally substituted with 1 , 2 or 3 Rd substituents;
each Rb substituent is independently selected from halo, Ci-6 alkyl, Ci-6 haloalkyl, Ci- 6 haloalkoxy, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRcC(=NOH)NRcRc, NRCC(=NCN)NRCRC, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRCS(0)2RC, NRCS(0)2NRCRC, S(0)Rc,
S(0)NRcRc, S(0)2Rc and S(0)2NRcRc; wherein the Ci-e alkyl, Ci-e haloalkyl, Ci-e haloalkoxy, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- 10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-and (4- 10 membered heterocycloalkyl)-Ci-4 alkyl- of Rb are each further optionally substituted with 1-3 independently selected Rd substituents;
each Rc is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rc are each optionally substituted with 1 , 2 or 3 Rf substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered
heterocycloalkyl)-Ci-4 alkyl-, halo, CN, NHOR , ORg, SRg, C(0)Rg, C(0)NRgRg, C(0)ORg, OC(0)Rg, OC(0)NRgRg, NHRg, NRgRg, NRgC(0)Rg, NRgC(0)NRgRg, NRgC(0)ORg, C(=NR )NR R , NR C(=NR )NR R , NR C(=NOH)NR R , NR C (=NCN)NR R , S(0)Rg, S(0)NRgRg, S(0)2Rg, NRgS(0)2Rg, NRgS(0)2NRgRg, and S(0)2NRgRg; wherein the Ci-e alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rf are each optionally substituted with 1 , 2 or 3 Rn substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, halo, CN, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, NHOR0, OR0, SR°, C(O)R0, C(O)NR0R°, C(O)OR0, OC(0)R°, OC(0)NR°R°, NHR°, NR°R°, NR0C(O)R°, NR0C(O)NR°R°, NR°C(0)OR°, C(=NR°)NR°R°, NR0C(=NR°)NR°R0, S(O)R0, S(O)NR0R°, S(O)2R0, NR0S(O)2R°,
NR°S(0)2NR°R°, and S(O)2NR0R°, wherein the Ci-e alkyl, Ci-e haloalkyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of Rn is optionally substituted with 1, 2 or 3 Rq substituents;
each Rd is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, halo, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, NH2, NHORe, ORe, SRe, C(0)Re, C(0)NReRe, C(0)ORe, OC(0)Re, OC(0)NReRe, NHRe, NReRe, NReC(0)Re, NReC(0)NReRe, NReC(0)ORe, C(=NRe)NReRe, NReC (=NRe)NReRe, NReC(=NOH)NReRe, NReC(=NCN)NReRe, S(0)Re, S(0)NReRe, S(0)2Re, NReS(0)2Re, NReS(0)2NReRe, and S(0)2NReRe, wherein the Ci-e alkyl, Ci-6 haloalkyl, Ce-ιο aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rd are each optionally substituted with 1-3 independently selected Rf substituents;
each Re is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Re are each optionally substituted with 1, 2 or 3 independently selected Rf substituents;
each Rg is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-C 1-4 alkyl-, C3-io cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rg are each optionally substituted with 1-3 Rp substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-C 1-4 alkyl-, (4-10 membered heterocycloalkyl)-C 1-4 alkyl-, halo, CN, NHORr, ORr, SRr, C(0)Rr, C(0)NR¾r, C(0)ORr, OC(0)Rr, OC(0)NR¾r, NHRr, NRrRr, NRrC(0)Rr, NRrC(0)NRrRr, NRrC(0)ORr, C(=NRr)NRrRr, NRrC(=NRr)NRrRr, NRrC(=NOH)NRrRr, NRrC(=NCN)NRrRr, S(0)Rr, S(0)NRrRr, S(0)2Rr, NRrS(0)2Rr, NRrS(0)2NRrRr and S(0)2NRrRr, wherein the Ci-e alkyl, Ci-e haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rp is optionally substituted with 1, 2 or 3 Rq substituents;
or any two Ra substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 Rh substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-7 membered heterocycloalkyl, Ce-ιο aryl, 5-6 membered heteroaryl, C3-10 cycloalkyl-C 1-4 alkyl-, (5-6 membered heteroaryl)-C 1-4 alkyl-, (4-7 membered
heterocycloalkyl)-Ci-4 alkyl-, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, halo, CN, OR1, SR NHOR1, C(0)R C C NR'R1, 0(0)0^, ΟΟ(Ο)^, Ο0(Ο)Ν^^, NHR', NR'R1, NR^C R1, NR'C C NR'R1, NR'C^C OR1, C^NR NR'R1, NR'C^NR NR'R1, Ν^Ο(=ΝΟΗ)Ν^, Ν^Ο(=ΝΟΝ)Ν^^, S(0)R 8(0)Ν^^, 8(0)2^, NR^O^R1, Ν^8(0)2Ν^^, and
S(0)2NR1R1, wherein the Ci-6 alkyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-7 membered heterocycloalkyl, Ce-ιο aryl, 5-6 membered heteroaryl, C3-10 cycloalkyl-Ci-4 alkyl-, (5-6 membered heteroaryl)-Ci-4 alkyl-, (4-7 membered heterocycloalkyl)-Ci-4 alkyl- of Rh are each optionally substituted by 1, 2, or 3 RJ substituents independently selected from Ci-4 alkyl, C3-6 cycloalkyl, Ce-ιο aryl, 5- or 6-membered heteroaryl, C2-4 alkenyl, C2-4 alkynyl, halo, C1-4 haloalkyl, Ci-4haloalkoxy, CN, NHORk, ORk, SRk, C(0)Rk, C(0)NRkRk, C(0)ORk,
OC(0)Rk, OC(0)NRkRk, NHRk, NRkRk, NRkC(0)Rk, NRkC(0)NRkRk, NRkC(0)ORk, C(=NRk)NRkRk, NRkC(=NRk)NRkRk, S(0)Rk, S(0)NRkRk, S(0)2Rk, NRkS(0)2Rk,
NRkS(0)2NRkRk, and S(0)2NRkRk;
or two Rh groups attached to the same carbon atom of the 4- to 10-membered heterocycloalkyl, taken together with the carbon atom to which they are attached, form a C3-6 cycloalkyl or 4- to 6-membered heterocycloalkyl having 1-2 heteroatoms as ring members selected from O, N or S;
or any two Rc substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Re substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R1 substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rk substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R° substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rr substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
each R1, Rk, R° or Rr is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, Ce-ιο aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the C1-4 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, Ce-ιο aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C2-4 alkenyl, and C2-4 alkynyl of R1, Rk, R° or Rr are each optionally substituted with 1, 2 or 3 Rq substituents;
each R¾ is independently selected from OH, CN, -COOH, NH2, halo, Ci-6 haloalkyl, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 haloalkoxy, Ci-6 alkylthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C3-6 cycloalkyl, NHR12 and NR12R12, wherein the Ci-6 alkyl, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl of Rq are each optionally substituted with halo, OH, CN, -COOH, NH2, C1-4 alkoxy, C1-4 haloalkyl, Ci-4 haloalkoxy, phenyl, C3-10 cycloalkyl and 4-6 membered heterocycloalkyl and each R12 is independently Ci-6 alkyl;
= is a single bond or a double bond to maintain ring A being aromatic; and the subscript n is an integer of 1, 2, 3 or 4.
In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
(i) G1 is NR6 and G2 is CR7R7; or
(ii) G1 is CR6R6 and G2 is NR7;
X1 is N or CR1;
X2 is N or CR2;
X3 is N or CR3;
Z is O, S, N, NR4 or CR4;
Y1 and Y2 are each independently N or C, provided Y1 and Y2 are not simultaneously
N;
Cy is Ce-ιο aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R8 substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C3-6 cycloalkyl, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OH, Ci-4 alkoxy, Ci-4 haloalkyl, Ci-4 haloalkoxy, NH2, -NH- Ci-4 alkyl, -N(Ci-4 alkyl)2, NHOR10, C(0)R10, C(O)NR10R10, C(0)OR10, OC(0)R10, OC(O)NR10R10, NR10C(O)R10, NR10C(O)OR10, NR10C(O)NR10R10, C(=NR10)R10,
C(=NR10)NR10R10, NR10C(=NR10)NR10R10, NR10S(O)R10, NR10S(O)2R10,
NR10S(O)2NR10R10, S(0)R10, S(O)NR10R10, S(0)2R10, and S(O)2NR10R10, wherein each R10 is independently selected from H and C1-4 alkyl optionally substituted with 1 or 2 groups independently selected from halo, OH, CN and C1-4 alkoxy; and wherein the C1-4 alkyl, C3-6 cycloalkyl, C2-4 alkenyl, C2-4 alkynyl and C1-4 alkoxy of R1, R2 and R3 are each optionally substituted with 1 or 2 substituents independently selected from halo, OH, CN and C1-4 alkoxy;
R4, R5, R6, R7 and R8 are each independently selected from H, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, Ce-ιο aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered
heterocycloalkyl)-Ci-4 alkyl-, CN, NO2, ORa, SRa, NHORa, C(0)Ra, C(0)NRaRa, C(0)ORa, OC(0)Ra, OC(0)NRaRa, NHRa, NRaRa, NRaC(0)Ra, NRaC(0)ORa, NRaC(0)NRaRa, C(=NRa)Ra, C(=NRa)NRaRa, NRaC(=NRa)NRaRa, NRaC (=NOH)NRaRa,
NRaC(=NCN)NRaRa, NRaS(0)Ra, NRaS(0)2Ra, NRaS(0)2NRaRa, S(0)Ra, S(0)NRaRa, S(0)2Ra, and S(0)2NRaRa, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-io aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R4, R5, R6, R7 and R8 are each optionally substituted with 1 , 2, 3, 4 or 5 Rb substituents;
or two adjacent R8 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
or two R5 substituents attached to the same carbon atom, taken together with the carbon atom to which they are attached, form a C3-6 cycloalkyl ring or 4-, 5-, 6- or 7- membered heterocycloalkyl ring, wherein the C3-6 cycloalkyl ring and 4-, 5-, 6- or 7- membered heterocycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R9 is halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, Ce-ιο aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, NO2, OR11, SR11, NH2, NHR11, NRnRn, NHOR11, C(0)Rn, C(0)NRnRn, C(0)ORn, OC(0)Rn, OC(0)NRnRn, NRnC(0)Rn, NRHC^OR^ NRHC^NRHR11, C(=NR11)R11, C(=NR11)NR11R11,
NR11C(=NR11)NR11R11, NR11C(=NOH)NR11R11, NR11C(=NCN)NR11R11, NRnS(0)Rn, NRHSCCXhR11, NRHS^NRHR11, S(0)Rn, S(0)NRnRn, S(0)2Rn, or SCO^NR11^1, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, C6-io aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R9 are each optionally substituted with 1 , 2 or 3 Rb substituents;
each R11 is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-C 1-4 alkyl-, C3-io cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R11 are each optionally substituted with 1 , 2 or 3 Rb substituents;
each Ra is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Ra are each optionally substituted with 1 , 2 or 3 Rd substituents;
each Rb substituent is independently selected from halo, Ci-6 alkyl, Ci-6 haloalkyl, Ci- 6 haloalkoxy, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRcC(=NOH)NRcRc, NRCC(=NCN)NRCRC, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc,
S(0)NRcRc, S(0)2Rc and S(0)2NRcRc; wherein the Ci-e alkyl, Ci-e haloalkyl, Ci-e haloalkoxy, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- 10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-and (4- 10 membered heterocycloalkyl)-Ci-4 alkyl- of Rb are each further optionally substituted with 1-3 independently selected Rd substituents;
each Rc is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rc are each optionally substituted with 1 , 2 or 3 Rf substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered
heterocycloalkyl)-Ci-4 alkyl-, halo, CN, NHOR , ORg, SRg, C(0)Rg, C(0)NRgRg, C(0)ORg, OC(0)Rg, OC(0)NRgRg, NHRg, NRgRg, NRgC(0)Rg, NRgC(0)NRgRg, NRgC(0)ORg, C(=NRg)NRgRg, NRgC(=NRg)NRgRg, NRgC(=NOH)NRgRg, NRgC(=NCN)NRgRg, S(0)Rg, S(0)NRgRg, S(0)2Rg, NRgS(0)2Rg, NRgS(0)2NRgRg, and S(0)2NRgRg; wherein the Ci-e alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rf are each optionally substituted with 1 , 2 or 3 Rn substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, halo, CN, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, NHOR0, OR0, SR°, C(O)R0, C(O)NR0R°, C(O)OR0, OC(0)R°, OC(0)NR°R°, NHR°, NR°R°, NR0C(O)R°, NR0C(O)NR°R°, NR°C(0)OR°, C(=NR°)NR°R°, NR0C(=NR°)NR°R0, S(O)R0, S(O)NR0R°, S(O)2R0, NR0S(O)2R°,
NR0S(O)2NR0R°, and S(O)2NR0R°, wherein the Ci-e alkyl, Ci-e haloalkyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of Rn is optionally substituted with 1, 2 or 3 Rq substituents;
each Rd is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, halo, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, NH2, NHORe, ORe, SRe, C(0)Re, C(0)NReRe, C(0)ORe, OC(0)Re, OC(0)NReRe, NHRe, NReRe, NReC(0)Re, NReC(0)NReRe, NReC(0)ORe, C(=NRe)NReRe, NReC (=NRe)NReRe, NReC(=NOH)NReRe, NReC(=NCN)NReRe, S(0)Re, S(0)NReRe, S(0)2Re, NReS(0)2Re, NReS(0)2NReRe, and S(0)2NReRe, wherein the Ci-e alkyl, Ci-6 haloalkyl, Ce-ιο aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rd are each optionally substituted with 1-3 independently selected Rf substituents;
each Re is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Re are each optionally substituted with 1, 2 or 3 independently selected Rf substituents;
each R is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-C 1-4 alkyl-, C3-io cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R are each optionally substituted with 1-3 Rp substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, halo, CN, NHORr, ORr, SRr, C(0)Rr, C(0)NRrRr, C(0)ORr, OC(0)Rr, OC(0)NRrRr, NHRr, NRrRr, NRrC(0)Rr, NRrC(0)NRrRr, NRrC(0)ORr, C(=NRr)NRrRr, NRrC(=NRr)NRrRr, NRrC(=NOH)NRrRr, NRrC (=NCN)NRrRr, S(0)Rr, S(0)NRrRr, S(0)2Rr, NRrS(0)2Rr, NR'-S O^NR'R1' and S(0)2NRrRr, wherein the Ci-e alkyl, Ci-e haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rp is optionally substituted with 1, 2 or 3 Rq substituents;
or any two Ra substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 Rh substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-7 membered heterocycloalkyl, Ce-ιο aryl, 5-6 membered heteroaryl, C3-10 cycloalkyl-C 1-4 alkyl-, (5-6 membered heteroaryl)-C 1-4 alkyl-, (4-7 membered
heterocycloalkyl)-Ci-4 alkyl-, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, halo, CN, OR1, SR, NHOR, C(0)R, C C N , C(0)OR, OC(0)R, OC C N , NHR, NR'R1, NRiC(0)Ri, N C C N , N C C O , C(= Ri) RiRi, NRiC(=NR1)NRiRi, RiC(=NOH)]SrRiRi, RiC(=NC )NRiRi, S(0)R, S(0)NRR, S(0)2R, NRS(0)2R, N S O^N , and
S(0)2NR1R1, wherein the Ci-6 alkyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-7 membered heterocycloalkyl, Ce-ιο aryl, 5-6 membered heteroaryl, C3-10 cycloalkyl-Ci-4 alkyl-, (5-6 membered heteroaryl)-Ci-4 alkyl-, (4-7 membered heterocycloalkyl)-Ci-4 alkyl- of Rh are each optionally substituted by 1 , 2, or 3 Ri substituents independently selected from C1-4 alkyl, C3-6 cycloalkyl, Ce-ιο aryl, 5- or 6-membered heteroaryl, C2-4 alkenyl, C2-4 alkynyl, halo, C1-4 haloalkyl, Ci-4haloalkoxy, CN, NHORk, 0Rk, SRk, C(0)Rk, C(0)NRkRk, C(0)ORk,
OC(0)Rk, OC(0)NRkRk, NHRk, NRkRk, NRkC(0)Rk, NRkC(0)NRkRk, NRkC(0)ORk, C(=NRk)NRkRk, NRkC(=NRk)NRkRk, S(0)Rk, S(0)NRkRk, S(0)2Rk, NRkS(0)2Rk,
NRkS(0)2NRkRk, and S(0)2NRkRk;
or two Rh groups attached to the same carbon atom of the 4- to 10-membered heterocycloalkyl, taken together with the carbon atom to which they are attached, form a C3-6 cycloalkyl or 4- to 6-membered heterocycloalkyl having 1 -2 heteroatoms as ring members selected from O, N or S;
or any two Rc substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 independently selected Rh substituents;
or any two Re substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 independently selected Rh substituents;
or any two R substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 independently selected Rh substituents;
or any two R1 substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 independently selected Rh substituents, or 1 , 2, or 3 independently selected Rq substituents; or any two Rk substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents, or 1, 2, or 3 independently selected Rq substituents; or any two R° substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents, or 1, 2, or 3 independently selected Rq substituents; or any two Rr substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents, or 1, 2, or 3 independently selected Rq substituents; each R1, Rk, R° or Rr is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, Ce-ιο aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the C1-4 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, Ce-ιο aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C2-4 alkenyl, and C2-4 alkynyl of R1, Rk, R° or Rr are each optionally substituted with 1, 2 or 3 Rq substituents;
each Rq is independently selected from OH, CN, -COOH, NH2, halo, C 1-6 haloalkyl, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 haloalkoxy, Ci-6 alkylthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C3-6 cycloalkyl, NHR12 and NR12R12, wherein the Ci-6 alkyl, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl of Rq are each optionally substituted with halo, OH, CN, -COOH, NH2, C1-4 alkoxy, C1-4 haloalkyl, Ci-4 haloalkoxy, phenyl, C3-10 cycloalkyl and 4-6 membered heterocycloalkyl and each R12 is independently Ci-6 alkyl;
= is a single bond or a double bond to maintain ring A being aromatic; and the subscript n is an integer of 1, 2, 3 or 4.
In some embodiments provided herein is a compound having Formula (II):
Figure imgf000037_0001
or a pharmaceutically acceptable salt or a stereoisomer thereof.
In some embodiments, provided herein is a compound having Formula (III):
Figure imgf000038_0001
or a pharmaceutically acceptable salt or a stereoisomer thereof.
In some embodiment rovided herein is a compound having Formula (IV):
Figure imgf000038_0002
or a pharmaceutically acceptable salt or a stereoisomer thereof.
In some embodiments provided herein is a compound having Formula (V):
Figure imgf000038_0003
or a pharmaceutically acceptable salt or a stereoisomer thereof.
In some embodiments provided herein is a compound having Formula (VI):
Figure imgf000038_0004
or a pharmaceutically acceptable salt or a stereoisomer thereof.
In some embodiments, provided herein is a compound having Formula (VII):
Figure imgf000039_0001
or a pharmaceutically acceptable salt or a stereoisomer thereof.
In some embodiments, R1, R2 and R3 are each independently selected from H, Ci-4 alkyl, C3-6 cycloalkyl, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OH, C1-4 alkoxy, Ci-4 haloalkyl, Ci- 4 haloalkoxy, NH2, -NH-Ci-4 alkyl, -N(Ci-4 alkyl)2, C(0)R10, C(O)NR10R10, C(0)OR10, OC(0)R10, OC(O)NR10R10, NR10C(O)R10, NR10C(O)OR10, NR10S(O)R10, NR10S(O)2R10, NR10S(O)2NR10R10, S(0)R10, S(O)NR10R10, S(0)2R10, and S(O)2NR10R10, wherein each R10 is independently selected from H and C1-4 alkyl optionally substituted with 1 or 2 groups independently selected from halo, OH, CN and C1-4 alkoxy; and wherein the C1-4 alkyl, C3-6 cycloalkyl, C2-4 alkenyl, C2-4 alkynyl and C1-4 alkoxy of R1, R2 and R3 are each optionally substituted with 1 or 2 substituents independently selected from halo, OH, CN and C1-4 alkoxy.
In some embodiments, R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C3-6 cycloalkyl, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OH, C1-4 alkoxy, Ci-4 haloalkyl, Ci- 4 haloalkoxy, NH2, -NH-Ci-4 alkyl, and -N(Ci-4 alkyl)2.
In some embodiments, R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OH, C1-4 alkoxy, Ci-4 haloalkyl, or C1-4 haloalkoxy.
In some embodiments, R1 is H, R2 is H or halo, and R3 is H.
In some embodiments, R1, R2, and R3 are H.
In some embodiments, Cy is phenyl, 5- or 6-membered heteroaryl, C3-6 cycloalkyl or
5- or 6-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R8 substituents; or two adjacent R8 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or
6- membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents. In some embodiments, Cy is phenyl optionally substituted with 1 to 5 R8 substituents. In some embodiments, Cy is 5- or 6-membered heteroaryl optionally substituted with 1 to 5 independently selected R8 substituents. In some embodiments, Cy is C3-6 cycloalkyl optionally substituted with 1 to 5 independently selected R8 substituents. In some
embodiments, Cy is 5- or 6-membered heterocycloalkyl optionally substituted with 1 to 5 independently selected R8 substituents.
In some embodiments, Cy is phenyl, 2-thiophenyl, 3-thiophenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 3,6-dihydro-2H-pyran-4-yl, cyclohexyl, cyclohexenyl, 2,3-dihydro-l,4- benzodioxin-6-yl, l,3-benzodioxin-5-yl, 2-methylindazol-6-yl or 1 -methylindazol-4-yl, each of which is optionally substituted with 1 to 5 R8 substituents.
In some embodiments, R9 is halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-e haloalkoxy, CN, NO2, OR11, SR11, NH2, NHR11, NRnRn, NHOR11, C(0)Rn,
C(0)NRnRn, C(0)ORn, OC(0)Rn, OC(0)NRnRn, NRnC(0)Rn, NRnC(0)ORn,
NRHC^NRHR11, NRnS(0)Rn, NR^^R11, NRHS^NRHR11, S(0)Rn,
S(0)NRnRn, S(0)2Rn, or S(0)2NR11R11, wherein the Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, and Ci-6 haloalkoxy of R9 are each optionally substituted with 1, 2 or 3 Rb substituents.
In some embodiments, R9 is halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, CN, NO2, or NH2, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, and Ci-6 haloalkoxy of R9 are each optionally substituted with 1, 2 or 3 Rb substituents.
In some embodiments, R9 is halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, CN, NO2, and NH2.
In some embodiments, R9 is halo, Ci-6 alkyl, or CN.
In some embodiments, R9 is CH3, CN or halo. In some embodiments, R9 is CH3. In other embodiments, R9 is CN. Yet in certain embodiments, R9 is halo such as F, CI or Br.
In some embodiments, Z is S, CR4, NR4, or N and R4 is independently H or Ci-6 alkyl. In some embodiments, Z is S, CH, NCH3 or N. In certain embodiments, Z is S. In other embodiments, Z is CH. In some embodiments, Z is N(Ci-6 alkyl) such as NCH3. Yet in other embodiments, Z is N.
In some embodiments, Y1 is C or N and Y2 is C.
In some embodiments, Y1 is C and Y2 is N.
Figure imgf000041_0001
40 The moiety:
The moiety:
The moiety:
Figure imgf000042_0001
In some embodiments, (i) Y1 is N, Y2 is C and Z is N; (ii) Y1 is N, Y2 is C and Z is
CR4; (iii) Y1 is C, Y2 is N and Z is N; (iv) Y1 is C, Y2 is N and Z is CR4; (v) Y1 is C, Y2 is C and Z is S; or (vi) Y1 is C, Y2 is C and Z is O.
In some embodiments, Y1 is N, Y2 is C and Z is N. In certain embodiments, Y1 is N, Y2 is C and Z is CR4. In certain embodiments, Y1 is C, Y2 is N and Z is N. In some embodiments, Y1 is C, Y2 is N and Z is CR4. In some embodiments, Y1 is C, Y2 is C and Z is S. Yet in some embodiments, Y1 is C, Y2 is C and Z is O.
In some embodiments, R5 is H.
In some embodiments, G1 is NR6 and G2 is CR7R7. In some embodiments, G1 is CR6R6 and G2 is NR7. In some embodiments, R6 is H or Ci-6 alkyl optionally substituted with 1, 2 or 3 Rb substituents. In some embodiments, R7 is H or Ci-6 alkyl optionally substituted with 1, 2 or 3 Rb substituents.
In some embodiments, Rb substituent is independently selected from halo, Ci-6 alkyl, Ci-6 haloalkyl, Ci-ehaloalkoxy, CN, OH, NH2, N02, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc,
NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc, S(0)NRcRc, S(0)2Rc and S(0)2NRCRC; wherein the Ci-6 alkyl, Ci-6 haloalkyl, and Ci-6 haloalkoxy of Rb are each further optionally substituted with 1-3 independently selected Rd substituents.
In some embodiments, Rb substituent is independently selected from halo, Ci-6 alkyl, Ci-6 haloalkyl, Ci-ehaloalkoxy, CN, OH, NH2, NO2, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, NHRC, NRCRC, and NRcC(0)Rc; wherein the Ci-e alkyl, Ci-e haloalkyl, and Ci-e haloalkoxy of Rb are each further optionally substituted with 1-3 independently selected Rd substituents.
In some embodiments, Rb substituent is independently selected from halo, Ci-6 alkyl, Ci-6 haloalkyl, Ci-e haloalkoxy, CN, OH, NH2, ORc, C(0)Rc, C(0)NRcRc, and C(0)ORc.
In some embodiments, Rb substituent is independently selected from Ci-6 alkyl, CN, OH, and C(0)ORc. In certain embodiments, Rb is Ci-6 alkyl such as methyl. In certain embodiments, Rb is CN. In other embodiments, Rb is OH. In some embodiments, Rb is C(0)ORc such as C(0)OH or C(0)0(Ci-e alkyl).
In some embodiments, provided herein is a compound of Formula I, or a
pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
(i) G1 is NR6 and G2 is CR7R7; or
(ii) G1 is CR6R6 and G2 is NR7;
X1 is N or CR1;
X2 is N or CR2;
X3 is N or CR3;
Z is O, S, N, NR4 or CR4;
Y1 and Y2 are each independently N or C, provided Y1 and Y2 are not simultaneously N;
Cy is Ce-10 aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R8 substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C3-6 cycloalkyl, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OH, Ci-4 alkoxy, Ci-4 haloalkyl, Ci-4 haloalkoxy, NH2, -NH- Ci-4 alkyl, -N(Ci-4 alkyl)2, C(0)R10, C(O)NR10R10, C(0)OR10, OC(0)R10, OC(O)NR10R10, NR10C(O)R10, NR10C(O)OR10, NR10S(O)R10, NR10S(O)2R10, NR10S(O)2NR10R10, S(0)R10, S(O)NR10R10, S(0)2R10, and S(O)2NR10R10, wherein each R10 is independently selected from H and C1-4 alkyl optionally substituted with 1 or 2 groups independently selected from halo, OH, CN and C1-4 alkoxy; and wherein the C1-4 alkyl, C3-6 cycloalkyl, C2-4 alkenyl, C2-4 alkynyl and Ci-4 alkoxy of R1, R2 and R3 are each optionally substituted with 1 or 2 substituents independently selected from halo, OH, CN and C1-4 alkoxy;
R4, R5, R6, R7 and R8 are each independently selected from H, halo, Ci-6 alkyl, C2-6 alkenyl, C2-e alkynyl, Ci-e haloalkyl, Ci-e haloalkoxy, CN, N02, ORa, SRa, C(0)Ra, C(0)NRaRa, C(0)ORa, OC(0)Ra, OC(0)NRaRa, NHRa, NRaRa, NRaC(0)Ra, NRaC(0)ORa, NRaS(0)Ra, NRaS(0)2Ra, NRaS(0)2NRaRa, S(0)Ra, S(0)NRaRa, S(0)2Ra, and S(0)2NRaRa, wherein the Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl of R4, R5, R6, R7 and R8 are each optionally substituted with 1, 2, 3, 4 or 5 Rb substituents;
or two adjacent R8 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R9 is halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, CN, N02, OR11, SR11, NH2, NHR11, NRnRn, NHOR11, C(0)Rn, C(0)NRnRn, C(0)ORn, OC(0)Rn, OC(0)NRnRn, NRnC(0)Rn, NRnC(0)ORn, NR^C^NR11!*.11, NRnS(0)Rn, NRnS(0)2Rn, NR11 S(0)2NR1 XRX x, S(0)Rn, S(0)NRnRn, S(0)2Rn, or S(0)2NRnRn, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, and Ci-6 haloalkoxy of R9 are each optionally substituted with 1, 2 or 3 Rb substituents;
each R11 is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
each Ra is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
each Rb substituent is independently selected from halo, Ci-6 alkyl, Ci-6 haloalkyl, Ci- ehaloalkoxy, CN, OH, NH2, N02, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc,
NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc, S(0)NRcRc, S(0)2Rc and S(0)2NRcRc; wherein the Ci-6 alkyl, Ci-6 haloalkyl, and Ci-6 haloalkoxy of Rb are each further optionally substituted with 1-3 independently selected Rd substituents;
each Rc is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl, wherein the Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl of Rc are each optionally substituted with 1, 2 or 3 Rf substituents independently selected from Ci-6 alkyl, Ci-e haloalkyl, C2-6 alkenyl, C2-6 alkynyl, halo, CN, ORg, SRg, C(0)Rg, C(0)NRgRg, C(0)ORg, OC(0)Rg, OC(0)NRgRg, NHRg, NRgRg, NRgC(0)Rg, NRgC(0)NRgRg, NRgC(0)ORg, S(0)Rg, S(0)NRgRg, S(0)2Rg, NRgS(0)2Rg, NRgS(0)2NRgRg, and
S(0)2NRgRg;
each Rd is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, halo, CN, NH2, ORe, SRe, C(0)Re, C(0)NReRe, C(0)ORe, OC(0)Re, OC(0)NReRe, NHRe, NReRe, NReC(0)Re, NReC(0)NReRe, NReC(0)ORe, S(0)Re, S(0)NReRe, S(0)2Re, NReS(0)2Re, NReS(0)2NReRe, and S(0)2NReRe;
each Re is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-;
each Rg is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-;
z is a single bond or a double bond to maintain ring A being aromatic; and the subscript n is an integer of 1 , 2, 3 or 4.
In some embodiments, provided herein is a compound of Formula I, or a
pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
(i) G1 is NR6 and G2 is CR7R7; or
(ii) G1 is CR6R6 and G2 is NR7;
X1 is N or CR1;
X2 is N or CR2;
X3 is N or CR3;
Z is S, N, NR4 or CR4;
Y1 and Y2 are each independently N or C, provided Y1 and Y2 are not simultaneously
N;
Cy is Ce-ιο aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R8 substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C3-6 cycloalkyl, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OH, Ci-4 alkoxy, Ci-4 haloalkyl, Ci-4 haloalkoxy, NH2, -NH- Ci-4 alkyl, and -N(Ci-4 alkyl)2; R4, R5, R6, R7 and R8 are each independently selected from H, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, Ci-e haloalkoxy, CN, NO2, ORa, SRa, C(0)Ra,
C(0)NRaRa, and C(0)ORa, wherein the Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl of R4, R5, R6, R7 and R8 are each optionally substituted with 1, 2, 3, 4 or 5 Rb substituents;
or two adjacent R8 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R9 is halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, CN, NO2, or NH2, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, and Ci-6 haloalkoxy of R9 are each optionally substituted with 1, 2 or 3 Rb substituents;
each Ra is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
each Rb substituent is independently selected from halo, Ci-6 alkyl, Ci-6 haloalkyl, Ci- 6 haloalkoxy, CN, OH, NH2, NO2, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, NHRC, NRCRC, and NRcC(0)Rc; wherein the Ci-6 alkyl, Ci-6 haloalkyl, and Ci-6 haloalkoxy of Rb are each further optionally substituted with 1-3 independently selected Rd substituents;
each Rc is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
each Rd is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, halo, CN, NH2, ORe, SRe, C(0)Re, C(0)NReRe, C(0)ORe, NHRe, NReRe, and NReC(0)Re;
each Re is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
= is a single bond or a double bond to maintain ring A being aromatic; and the subscript n is an integer of 1 or 2.
In some embodiments, provided herein is a compound of Formula I, or a
pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
(i) G1 is NR6 and G2 is CR7R7; or
(ii) G1 is CR6R6 and G2 is NR7; X1 is N or CR1;
X2 is N or CR2;
X3 is N or CR3;
Z is S, N, NR4 or CR4;
Y1 and Y2 are each independently N or C, provided Y1 and Y2 are not simultaneously
N;
Cy is phenyl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R8 substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OH, C1-4 alkoxy, Ci-4 haloalkyl, or Ci-4 haloalkoxy;
R4, R5, R6, R7 and R8 are each independently selected from H, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, Ci-e haloalkoxy, CN, NO2, ORa, and C(0)ORa, wherein the Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl of R4, R5, R6, R7 and R8 are each optionally substituted with 1 or 2 Rb substituents;
or two adjacent R8 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused 5-, 6- or 7-membered heterocycloalkyl ring, or a fused 5- or 6-membered heteroaryl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring are each optionally substituted with 1 or 2 independently selected Rb substituents;
R9 is halo, Ci-e alkyl, or CN;
each Ra is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
each Rb substituent is independently selected from halo, Ci-6 alkyl, Ci-6 haloalkyl, Ci- e haloalkoxy, CN, OH, NH2, ORc, C(0)Rc, C(0)NRcRc, and C(0)ORc;
each Rc is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
= is a single bond or a double bond to maintain ring A being aromatic; and the subscript n is an integer of 1 or 2.
In some embodiments, compounds of Formula (I) or any subformulas as disclosed herein, when Cy is phenyl, R8 is not 4-aminopiperidin-l-yl, optionally substituted with 1-5 independently selected Rb substituents. In some embodiments, compounds of Formula (I) or any subformulas as disclosed herein, when Cy is phenyl, R8 is not -NHC(0)Ra, wherein Ra is 5- or 6-membered heteroaryl, or 2-pyridon-3-yl, each of which is optionally substituted with 1 -5 independently selected Rd substituents.
In some embodiments, compounds of Formula (I) or any subformulas as disclosed herein, when Cy is phenyl, R8 is not (10-membered bicyclic heteroaryl)-NH-, optionally substituted with 1-5 independently selected Rd substituents.
It is further appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment (while the embodiments are intended to be combined as if written in multiply dependent form). Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination. Thus, it is contemplated as features described as
embodiments of the compounds of Formula (I) can be combined in any suitable combination.
At various places in the present specification, certain features of the compounds are disclosed in groups or in ranges. It is specifically intended that such a disclosure include each and every individual subcombination of the members of such groups and ranges. For example, the term "Ci-6 alkyl" is specifically intended to individually disclose (without limitation) methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl and Ce alkyl.
The term "n-membered," where n is an integer, typically describes the number of ring-forming atoms in a moiety where the number of ring-forming atoms is n. For example, piperidinyl is an example of a 6-membered heterocycloalkyl ring, pyrazolyl is an example of a 5-membered heteroaryl ring, pyridyl is an example of a 6-membered heteroaryl ring and 1,2,3,4-tetrahydro-naphthalene is an example of a 10-membered cycloalkyl group.
At various places in the present specification, variables defining divalent linking groups may be described. It is specifically intended that each linking substituent include both the forward and backward forms of the linking substituent. For example, -NR(CR'R")n- includes both -NR(CR'R")n- and -(CR'R")nNR- and is intended to disclose each of the forms individually. Where the structure requires a linking group, the Markush variables listed for that group are understood to be linking groups. For example, if the structure requires a linking group and the Markush group definition for that variable lists "alkyl" or "aryl" then it is understood that the "alkyl" or "aryl" represents a linking alkylene group or arylene group, respectively. The term "substituted" means that an atom or group of atoms formally replaces hydrogen as a "substituent" attached to another group. The term "substituted", unless otherwise indicated, refers to any level of substitution, e.g. , mono-, di-, tri-, tetra- or penta-substitution, where such substitution is permitted. The substituents are independently selected, and substitution may be at any chemically accessible position. It is to be understood that substitution at a given atom is limited by valency. It is to be understood that substitution at a given atom results in a chemically stable molecule. The phrase "optionally substituted" means unsubstituted or substituted. The term "substituted" means that a hydrogen atom is removed and replaced by a substituent. A single divalent substituent, e.g., oxo, can replace two hydrogen atoms.
The term "Cn-m" indicates a range which includes the endpoints, wherein n and m are integers and indicate the number of carbons. Examples include Ci-4, Ci-6 and the like.
The term "alkyl" employed alone or in combination with other terms, refers to a saturated hydrocarbon group that may be straight-chained or branched. The term "Cn-m alkyl", refers to an alkyl group having n to m carbon atoms. An alkyl group formally corresponds to an alkane with one C-H bond replaced by the point of attachment of the alkyl group to the remainder of the compound. In some embodiments, the alkyl group contains from 1 to 6 carbon atoms, from 1 to 4 carbon atoms, from 1 to 3 carbon atoms, or 1 to 2 carbon atoms. Examples of alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, ft-propyl, isopropyl, w-butyl, fert-butyl, isobutyl, sec-butyl; higher homologs such as 2- methyl-1 -butyl, w-pentyl, 3-pentyl, w-hexyl, 1 ,2,2-trimethylpropyl and the like.
The term "alkenyl" employed alone or in combination with other terms, refers to a straight-chain or branched hydrocarbon group corresponding to an alkyl group having one or more double carbon-carbon bonds. An alkenyl group formally corresponds to an alkene with one C-H bond replaced by the point of attachment of the alkenyl group to the remainder of the compound. The term "Cn-m alkenyl" refers to an alkenyl group having n to m carbons. In some embodiments, the alkenyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms.
Example alkenyl groups include, but are not limited to, ethenyl, w-propenyl, isopropenyl, n- butenyl, seobutenyl and the like.
The term "alkynyl" employed alone or in combination with other terms, refers to a straight-chain or branched hydrocarbon group corresponding to an alkyl group having one or more triple carbon-carbon bonds. An alkynyl group formally corresponds to an alkyne with one C-H bond replaced by the point of attachment of the alkyl group to the remainder of the compound. The term "Cn-m alkynyl" refers to an alkynyl group having n to m carbons. Example alkynyl groups include, but are not limited to, ethynyl, propyn-l-yl, propyn-2-yl and the like. In some embodiments, the alkynyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms.
The term "alkylene", employed alone or in combination with other terms, refers to a divalent alkyl linking group. An alkylene group formally corresponds to an alkane with two C-H bond replaced by points of attachment of the alkylene group to the remainder of the compound. The term "Cn-m alkylene" refers to an alkylene group having n to m carbon atoms. Examples of alkylene groups include, but are not limited to, ethan-l,2-diyl, propan-l ,3-diyl, propan-l,2-diyl, butan-l ,4-diyl, butan-l,3-diyl, butan-l,2-diyl, 2-methyl-propan-l,3-diyl and the like.
The term "alkoxy", employed alone or in combination with other terms, refers to a group of formula -O-alkyl, wherein the alkyl group is as defined above. The term "Cn-m alkoxy" refers to an alkoxy group, the alkyl group of which has n to m carbons. Example alkoxy groups include methoxy, ethoxy, propoxy (e.g. , w-propoxy and isopropoxy), i-butoxy and the like. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
The term "amino" refers to a group of formula -NH2.
The term "carbonyl", employed alone or in combination with other terms, refers to a -C(=0)- group, which also may be written as C(O).
The term "cyano" or "nitrile" refers to a group of formula -C≡N, which also may be written as -CN.
The terms "halo" or "halogen", used alone or in combination with other terms, refers to fluoro, chloro, bromo and iodo. In some embodiments, "halo" refers to a halogen atom selected from F, CI, or Br. In some embodiments, halo groups are F.
The term "haloalkyl" as used herein refers to an alkyl group in which one or more of the hydrogen atoms has been replaced by a halogen atom. The term "Cn-m haloalkyl" refers to a Cn-m alkyl group having n to m carbon atoms and from at least one up to {2(n to m)+l } halogen atoms, which may either be the same or different. In some embodiments, the halogen atoms are fluoro atoms. In some embodiments, the haloalkyl group has 1 to 6 or 1 to 4 carbon atoms. Example haloalkyl groups include CF3, C2F5, CHF2, CCh, CHCI2, C2CI5 and the like. In some embodiments, the haloalkyl group is a fluoroalkyl group.
The term "haloalkoxy", employed alone or in combination with other terms, refers to a group of formula -O-haloalkyl, wherein the haloalkyl group is as defined above. The term "Cn-m haloalkoxy" refers to a haloalkoxy group, the haloalkyl group of which has n to m carbons. Example haloalkoxy groups include trifluoromethoxy and the like. In some embodiments, the haloalkoxy group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
The term "oxo" refers to an oxygen atom as a divalent substituent, forming a carbonyl group when attached to carbon, or attached to a heteroatom forming a sulfoxide or sulfone group, or an N-oxide group. In some embodiments, heterocyclic groups may be optionally substituted by 1 or 2 oxo (=0) substituents.
The term "sulfido" refers to a sulfur atom as a divalent substituent, forming a thiocarbonyl group (C=S) when attached to carbon.
The term "aromatic" refers to a carbocycle or heterocycle having one or more polyunsaturated rings having aromatic character (i. e. , having (4n + 2) delocalized π (pi) electrons where n is an integer).
The term "aryl," employed alone or in combination with other terms, refers to an aromatic hydrocarbon group, which may be monocyclic or poly cyclic (e.g. , having 2 fused rings). The term "Cn-m aryl" refers to an aryl group having from n to m ring carbon atoms. Aryl groups include, e.g. , phenyl, naphthyl, and the like. In some embodiments, aryl groups have from 6 to about 10 carbon atoms. In some embodiments aryl groups have 6 carbon atoms. In some embodiments aryl groups have 10 carbon atoms. In some embodiments, the aryl group is phenyl. In some embodiments, the aryl group is naphthyl.
The term "heteroaryl" or "heteroaromatic," employed alone or in combination with other terms, refers to a monocyclic or poly cyclic aromatic heterocycle having at least one heteroatom ring member selected from sulfur, oxygen and nitrogen. In some embodiments, the heteroaryl ring has 1 , 2, 3 or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, any ring-forming Ν in a heteroaryl moiety can be an N-oxide. In some embodiments, the heteroaryl has 5-14 ring atoms including carbon atoms and 1 , 2, 3 or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl has 5-10 ring atoms including carbon atoms and 1 , 2, 3 or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl has 5-6 ring atoms and 1 or 2 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl is a five-membered or six-membered heteroaryl ring. In other embodiments, the heteroaryl is an eight-membered, nine-membered or ten-membered fused bicyclic heteroaryl ring. Example heteroaryl groups include, but are not limited to, pyridinyl (pyridyl), pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, azolyl, oxazolyl, thiazolyl, imidazolyl, furanyl, thiophenyl, quinolinyl, isoquinolinyl, naphthyridinyl (including 1,2-, 1,3-, 1,4-, 1,5-, 1,6-, 1,7-, 1,8-, 2,3- and 2,6-naphthyridine), indolyl, indazolyl, benzothiophenyl, benzofuranyl, benzisoxazolyl, imidazo[l,2-Z>]thiazolyl, purinyl, and the like.
A five-membered heteroaryl ring is a heteroaryl group having five ring atoms wherein one or more (e.g. , 1, 2 or 3) ring atoms are independently selected from N, O and S.
Exemplary five-membered ring heteroaryls include thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3- thiadiazolyl, 1,2,3-oxadiazolyl, 1 ,2,4-triazolyl, 1 ,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4- triazolyl, 1,3,4-thiadiazolyl and 1,3,4-oxadiazolyl.
A six-membered heteroaryl ring is a heteroaryl group having six ring atoms wherein one or more (e.g. , 1, 2 or 3) ring atoms are independently selected from N, O and S.
Exemplary six-membered ring heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl and pyridazinyl.
The term "cycloalkyl," employed alone or in combination with other terms, refers to a non-aromatic hydrocarbon ring system (monocyclic, bicyclic or poly cyclic), including cyclized alkyl and alkenyl groups. The term "Cn-m cycloalkyl" refers to a cycloalkyl that has n to m ring member carbon atoms. Cycloalkyl groups can include mono- or poly cyclic (e.g. , having 2, 3 or 4 fused rings) groups and spirocycles. Cycloalkyl groups can have 3, 4, 5, 6 or 7 ring-forming carbons (C3-7). In some embodiments, the cycloalkyl group has 3 to 6 ring members, 3 to 5 ring members, or 3 to 4 ring members. In some embodiments, the cycloalkyl group is monocyclic. In some embodiments, the cycloalkyl group is monocyclic or bicyclic. In some embodiments, the cycloalkyl group is a C3-6 monocyclic cycloalkyl group. Ring- forming carbon atoms of a cycloalkyl group can be optionally oxidized to form an oxo or sulfido group. Cycloalkyl groups also include cycloalkylidenes. In some embodiments, cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. Also included in the definition of cycloalkyl are moieties that have one or more aromatic rings fused (i.e. , having a bond in common with) to the cycloalkyl ring, e.g., benzo or thienyl derivatives of cyclopentane, cyclohexane and the like. A cycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcamyl, bicyclo[l . l . l]pentanyl, bicyclo[2.1.1]hexanyl, and the like. In some embodiments, the cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
The term "heterocycloalkyl," employed alone or in combination with other terms, refers to a non-aromatic ring or ring system, which may optionally contain one or more alkenylene groups as part of the ring structure, which has at least one heteroatom ring member independently selected from nitrogen, sulfur oxygen and phosphorus, and which has 4-10 ring members, 4-7 ring members, or 4-6 ring members. Included within the term "heterocycloalkyl" are monocyclic 4-, 5-, 6- and 7-membered heterocycloalkyl groups. Heterocycloalkyl groups can include mono- or bicyclic (e.g., having two fused or bridged rings) ring systems. In some embodiments, the heterocycloalkyl group is a monocyclic group having 1, 2 or 3 heteroatoms independently selected from nitrogen, sulfur and oxygen. Ring- forming carbon atoms and heteroatoms of a heterocycloalkyl group can be optionally oxidized to form an oxo or sulfido group or other oxidized linkage (e.g., C(O), S(O), C(S) or S(0)2, N-oxide etc.) or a nitrogen atom can be quaternized. The heterocycloalkyl group can be attached through a ring-forming carbon atom or a ring-forming heteroatom. In some embodiments, the heterocycloalkyl group contains 0 to 3 double bonds. In some
embodiments, the heterocycloalkyl group contains 0 to 2 double bonds. Also included in the definition of heterocycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the heterocycloalkyl ring, e.g., benzo or thienyl derivatives of piperidine, morpholine, azepine, etc. A heterocycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring. Examples of heterocycloalkyl groups include azetidinyl, azepanyl, dihydrobenzofuranyl, dihydrofuranyl, dihydropyranyl, dihydrobenzodioxinyl, benzodioxinyl, morpholino, 3-oxa-9-azaspiro[5.5]undecanyl, l-oxa-8-azaspiro[4.5]decanyl, piperidinyl, piperazinyl, oxopiperazinyl, pyranyl, pyrrolidinyl, quinuclidinyl,
tetrahydrofuranyl, tetrahydropyranyl, 1,2,3,4-tetrahydroquinolinyl, tropanyl, and
thiomorpholino.
At certain places, the definitions or embodiments refer to specific rings (e.g. , an azetidine ring, a pyridine ring, etc.). Unless otherwise indicated, these rings can be attached to any ring member provided that the valency of the atom is not exceeded. For example, an azetidine ring may be attached at any position of the ring, whereas an azetidin-3-yl ring is attached at the 3 -position.
The compounds described herein can be asymmetric (e.g. , having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated. Compounds of the present invention that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from optically inactive starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Many geometric isomers of olefins, C=N double bonds and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms.
Resolution of racemic mixtures of compounds can be carried out by any of numerous methods known in the art. One method includes fractional recrystallization using a chiral resolving acid which is an optically active, salt-forming organic acid. Suitable resolving agents for fractional recrystallization methods are, e.g. , optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids such as β- camphorsulfonic acid. Other resolving agents suitable for fractional crystallization methods include stereoisomerically pure forms of a-methylbenzylamine (e.g. , S d R forms, or diastereomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N- methylephedrine, cyclohexylethylamine, 1,2-diaminocyclohexane and the like.
Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine). Suitable elution solvent composition can be determined by one skilled in the art.
In some embodiments, the compounds of the invention have the (i?)-configuration. In other embodiments, the compounds have the (^-configuration. In compounds with more than one chiral centers, each of the chiral centers in the compound may be independently (R) or (S), unless otherwise indicated.
Compounds of the invention also include tautomeric forms. Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton. Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge. Example prototropic tautomers include ketone - enol pairs, amide - imidic acid pairs, lactam - lactim pairs, enamine - imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, e.g. , 1H- and 3H-imidazole, 1H-, 2H- and 4H- 1,2,4- triazole, 1H- and 2H- isoindole and 1H- and 2H-pyrazole. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.
Compounds of the invention can also include all isotopes of atoms occurring in the intermediates or final compounds. Isotopes include those atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium. One or more constituent atoms of the compounds of the invention can be replaced or substituted with isotopes of the atoms in natural or non-natural abundance. In some embodiments, the compound includes at least one deuterium atom. For example, one or more hydrogen atoms in a compound of the present disclosure can be replaced or substituted by deuterium. In some embodiments, the compound includes two or more deuterium atoms. In some embodiments, the compound includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 or 12 deuterium atoms. Synthetic methods for including isotopes into organic compounds are known in the art.
The term, "compound," as used herein is meant to include all stereoisomers, geometric isomers, tautomers and isotopes of the structures depicted. The term is also meant to refer to compounds of the inventions, regardless of how they are prepared, e.g., synthetically, through biological process (e.g., metabolism or enzyme conversion), or a combination thereof.
All compounds, and pharmaceutically acceptable salts thereof, can be found together with other substances such as water and solvents (e.g. , hydrates and solvates) or can be isolated. When in the solid state, the compounds described herein and salts thereof may occur in various forms and may, e.g. , take the form of solvates, including hydrates. The compounds may be in any solid state form, such as a polymorph or solvate, so unless clearly indicated otherwise, reference in the specification to compounds and salts thereof should be understood as encompassing any solid state form of the compound.
In some embodiments, the compounds of the invention, or salts thereof, are substantially isolated. By "substantially isolated" is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected. Partial separation can include, e.g. , a composition enriched in the compounds of the invention. Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compounds of the invention, or salt thereof. The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
The expressions, "ambient temperature" and "room temperature," as used herein, are understood in the art, and refer generally to a temperature, e.g. , a reaction temperature, that is about the temperature of the room in which the reaction is carried out, e.g. , a temperature from about 20 °C to about 30 °C.
The present invention also includes pharmaceutically acceptable salts of the compounds described herein. The term "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the present invention include the non-toxic salts of the parent compound formed, e.g. , from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, alcohols (e.g. , methanol, ethanol, iso-propanol or butanol) or acetonitrile (MeCN) are preferred. Lists of suitable salts are found in Remington 's Pharmaceutical Sciences, 17th Ed., (Mack Publishing Company, Easton, 1985), p. 1418, Berge et al, J. Pharm. Scl , 1977, 66(\), 1 -19 and in Stahl et al., Handbook of Pharmaceutical Salts: Properties, Selection, and Use, (Wiley, 2002). In some embodiments, the compounds described herein include the N- oxide forms.
//. Synthesis
Compounds of the invention, including salts thereof, can be prepared using known organic synthesis techniques and can be synthesized according to any of numerous possible synthetic routes, such as those in the Schemes below. The reactions for preparing compounds of the invention can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially non-reactive with the starting materials (reactants), the intermediates or products at the temperatures at which the reactions are carried out, e.g. , temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected by the skilled artisan.
Preparation of compounds of the invention can involve the protection and
deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art. The chemistry of protecting groups is described, e.g., in Kocienski, Protecting Groups, (Thieme, 2007); Robertson, Protecting Group Chemistry, (Oxford University Press, 2000); Smith et al., March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 6th Ed. (Wiley, 2007); Peturssion et al, "Protecting Groups in Carbohydrate Chemistry," J. Chem. Educ, 1997, 74 \ 1), 1297; and Wuts et al., Protective Groups in Organic Synthesis, 4th Ed., (Wiley, 2006).
Reactions can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g. , ¾ or 1 C), infrared spectroscopy, spectrophotometry (e.g. , UV -visible), mass spectrometry or by chromatographic methods such as high performance liquid chromatography (HPLC) or thin layer chromatography (TLC).
The Schemes below provide general guidance in connection with preparing the compounds of the invention. One skilled in the art would understand that the preparations shown in the Schemes can be modified or optimized using general knowledge of organic chemistry to prepare various compounds of the invention.
Compounds of Formula (I) can be prepared, e.g. , using a process as illustrated in Schemes 1-3.
Compound of formula 1-7 can be synthesized using a process shown in Scheme 1. A palladium-catalyzed cross-coupling reaction of halo-substituted aromatic amine 1-1 with a suitable coupling reagent 1-2 (where M is, e.g., -B(OH)2) under standard conditions (such as Suzuki coupling reaction, e.g. , in the presence of a palladium catalyst and a suitable base) can produce compound 1-3. The reaction of aromatic amine 1-3 with an acid of formula 1-4 using a coupling reagent such as, but not limited to, HATU can give the amide 1-5, which can be deprotected under acidic conditions (e.g. , hydrochloric acid or trifluoroacetic acid) to provide the amine 1-6. The R7 group can be introduced either by direct alkylation with an alkyl halide or reductive alkylation with an aldehyde or a ketone to give the desired product of formula 1-7.
Scheme 1
Figure imgf000058_0001
1 -1 -3
deprotection
Figure imgf000058_0002
1 -6 1 -7
Alternatively, compound of formula 2-7 can be synthesized using a process shown in Scheme 2. The reaction of halo-substituted aromatic amine 2-1 with an ester of formula 2-2 in the presence of a suitable base such as, but not limited to, potassium fert-butoxide or sodium hydride can furnish the amide 2-3. The Boc protecting group in compound 2-3 can be removed under acidic conditions (e.g., hydrochloric acid or trifluoroacetic acid) to provide the free amine of formula 2-4. The Cy ring can be installed by the cross-coupling of compound 2-4 with a suitable coupling reagent 2-5 (where M is, e.g., -B(OH)2) under standard conditions (such as Suzuki coupling reaction, e.g. , in the presence of a palladium catalyst and a suitable base) to give compound of formula 2-6. Finally, the R7 group can be introduced either by direct alkylation with an alkyl halide or reductive alkylation with an aldehyde or a ketone to give the desired product of formula 2-7.
Scheme 2
Figure imgf000059_0001
-— Cy-M→ or /V-alkylation
Figure imgf000059_0002
2-6 2-7
Ester of formula 3-3 can be synthesized using a process shown in Scheme 3. The free amine group in compound 3-1 can be protected with Boc to give the compound of formula 3- 2. Compound 3-2 can be deprotonated by a strong base such as, but not limited to, n-butyl lithium or lithium bis(trimethylsilyl)amide to generate the corresponding aryl lithium intermediate, which can further react with a chloroformate or carbon dioxide to give the desired ester or acid of formula 3-3.
heme 3
Figure imgf000059_0003
Compound of formula 4 can be synthesized in accordance with the synthetic protocols set forth in Schemes 1-3, using the appropriate starting materials.
Figure imgf000059_0004
III. Uses of the Compounds
Compounds of the present disclosure can inhibit the activity of PD-1/PD-L1 protein/protein interaction and, thus, are useful in treating diseases and disorders associated with activity of PD-1 and the diseases and disorders associated with PD-L1 including its interaction with other proteins such as PD-1 and B7-1 (CD80). Advantageously, the compounds of the present disclosure demonstrate better efficacy and favorable safety and toxicity profiles in animal studies. In certain embodiments, the compounds of the present disclosure, or pharmaceutically acceptable salts or stereoisomers thereof, are useful for therapeutic administration to enhance, stimulate and/or increase immunity in cancer or chronic infection, including enhancement of response to vaccination. In some embodiments, the present disclosure provides a method for inhibiting or blocking the PD-1/PD-L1 protein/protein interaction. The method includes administering to an individual or a patient a compound of Formula (I) or any of the formulas as described herein or of a compound as recited in any of the claims and described herein, or a pharmaceutically acceptable salt or a stereoisomer thereof. The compounds of the present disclosure can be used alone, in combination with other agents or therapies or as an adjuvant or neoadjuvant for the treatment of diseases or disorders, including cancer or infection diseases. For the uses described herein, any of the compounds of the disclosure, including any of the embodiments thereof, may be used.
The compounds of the present disclosure inhibit the PD-1/PD-L1 protein/protein interaction, resulting in a PD-1 pathway blockade. The blockade of PD-1 can enhance the immune response to cancerous cells and infectious diseases in mammals, including humans. In some embodiments, the present disclosure provides treatment of an individual or a patient in vivo using a compound of Formula (I) or a salt or stereoisomer thereof such that growth of cancerous tumors is inhibited. A compound of Formula (I) or of any of the formulas as described herein, or a compound as recited in any of the claims and described herein, or a salt or stereoisomer thereof, can be used to inhibit the growth of cancerous tumors. Alternatively, a compound of Formula (I) or of any of the formulas as described herein, or a compound as recited in any of the claims and described herein, or a salt or stereoisomer thereof, can be used in conjunction with other agents or standard cancer treatments, as described below. In one embodiment, the present disclosure provides a method for inhibiting growth of tumor cells in vitro. The method includes contacting the tumor cells in vitro with a compound of Formula (I) or of any of the formulas as described herein, or of a compound as recited in any of the claims and described herein, or of a salt or stereoisomer thereof. In another embodiment, the present disclosure provides a method for inhibiting growth of tumor cells in an individual or a patient. The method includes administering to the individual or patient in need thereof a therapeutically effective amount of a compound of Formula (I) or of any of the formulas as described herein, or of a compound as recited in any of the claims and described herein, or a salt or a stereoisomer thereof. In some embodiments, provided herein is a method for treating cancer. The method includes administering to a patient in need thereof, a therapeutically effective amount of a compound of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or a salt thereof. Examples of cancers include those whose growth may be inhibited using compounds of the disclosure and cancers typically responsive to immunotherapy.
In some embodiments, the present disclosure provides a method of enhancing, stimulating and/or increasing the immune response in a patient. The method includes administering to the patient in need thereof a therapeutically effective amount of a compound of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or a salt thereof.
Examples of cancers that are treatable using the compounds of the present disclosure include, but are not limited to, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, endometrial cancer, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, non-Hodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemias including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumors of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney or urethra, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T -cell lymphoma, environmentally induced cancers including those induced by asbestos, and combinations of said cancers. The compounds of the present disclosure are also useful for the treatment of metastatic cancers, especially metastatic cancers that express PD-L1.
In some embodiments, cancers treatable with compounds of the present disclosure include melanoma (e.g., metastatic malignant melanoma), renal cancer (e.g. clear cell carcinoma), prostate cancer (e.g. hormone refractory prostate adenocarcinoma), breast cancer, colon cancer and lung cancer (e.g. non-small cell lung cancer). Additionally, the disclosure includes refractory or recurrent malignancies whose growth may be inhibited using the compounds of the disclosure.
in some embodiments, cancers that are treatable using the compounds of the present disclosure include, but are not limited to, solid tumors (e.g. , prostate cancer, colon cancer, esophageal cancer, endometrial cancer, ovarian cancer, uterine cancer, renal cancer, hepatic cancer, pancreatic cancer, gastric cancer, breast cancer, lung cancer, cancers of the head and neck, thyroid cancer, glioblastoma, sarcoma, bladder cancer, etc.), hematological cancers (e.g. , lymphoma, leukemia such as acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), DLBCL, mantle cell lymphoma, Non-Hodgkin lymphoma (including relapsed or refractory NHL and recurrent follicular), Hodgkin lymphoma or multiple myeloma) and combinations of said cancers.
PD-1 pathway blockade with compounds of the present disclosure can also be used for treating infections such as viral, bacteria, fungus and parasite infections. The present disclosure provides a method for treating infections such as viral infections. The method includes administering to a patient in need thereof, a therapeutically effective amount of a compound of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, a salt thereof. Examples of viruses causing infections treatable by methods of the present disclosure include, but are not limit to, human immunodeficiency virus, human papillomavirus, influenza, hepatitis A, B, C or D viruses, adenovirus, pox vims, herpes simpl ex viruses, human cytomegalovirus, severe acute respirator}' syndrome virus, eboia virus, and measles virus. In some embodiments, viruses causing infections treatable by methods of the present disclosure include, but are not limit to, hepatitis (A, B, or C), herpes virus (e.g., VZV, HSV-1, HAV-6, HSV-II, and CMV, Epstein Barr virus), adenovirus, influenza virus, fiaviviruses, echovirus, rhinovirus, coxsackie virus, cornovirus, respiratory syncytial virus, mumpsvirus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus and arboviral encephalitis virus.
The present disclosure provides a method for treating bacterial infections. The method includes administering to a patient in need thereof, a therapeutically effective amount of a compound of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or a salt thereof. Non-limiting examples of pathogenic bacteria causing infections treatable by methods of the disclosure include chlamydia, rickettsial bacteria, mycobacteria, staphylococci, streptococci, pneumonococci, meningococci and conococci, klebsiella, proteus, serratia, pseudomonas, legionella, diphtheria, salmonella, bacilli, cholera, tetanus, botulism, anthrax, plague, leptospirosis, and Lyme's disease bacteria.
The present disclosure provides a method for treating fungus infections. The method includes administering to a patient in need thereof, a therapeutically effective amount of a compound of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or a salt thereof. Non-limiting examples of pathogenic fungi causing infections treatable by methods of the disclosure include Candida (albicans, krusei, glabrata, tropicalis, etc.), Cryptococcus neoformans, Aspergillus
(fumigatus, niger, etc.), Genus Mucorales (mucor, absidia, rhizophus), Sporothrix schenkii, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Coccidioides immitis and
Histoplasma capsulatum.
The present disclosure provides a method for treating parasite infections. The method includes administering to a patient in need thereof, a therapeutically effective amount of a compound of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or a salt thereof. Non-limiting examples of pathogenic parasites causing infections treatable by methods of the disclosure include Entamoeba histolytica, Balantidium coli, Naegleriafowleri, Acanthamoeba sp., Giardia lambia, Cryptosporidium sp., Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondi, and Nippostrongylus brasiliensis.
The terms "individual" or "patient," used interchangeably, refer to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.
The phrase "therapeutically effective amount" refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
As used herein, the term "treating" or "treatment" refers to one or more of (1) inhibiting the disease; e.g. , inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e. , arresting further development of the pathology and/or symptomatology); and (2) ameliorating the disease; e.g., ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e. , reversing the pathology and/or symptomatology) such as decreasing the severity of disease.
In some embodiments, the compounds of the invention are useful in preventing or reducing the risk of developing any of the diseases referred to herein; e.g. , preventing or reducing the risk of developing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease.
Combination Therapies
Cancer cell growth and survival can be impacted by multiple signaling pathways.
Thus, it is useful to combine different enzyme/protein/receptor inhibitors, exhibiting different preferences in the targets which they modulate the activities of, to treat such conditions. Targeting more than one signaling pathway (or more than one biological molecule involved in a given signaling pathway) may reduce the likelihood of drug-resistance arising in a cell population, and/or reduce the toxicity of treatment.
The compounds of the present disclosure can be used in combination with one or more other enzyme/protein/receptor inhibitors for the treatment of diseases, such as cancer or infections. Examples of cancers include solid tumors and liquid tumors, such as blood cancers. Examples of infections include viral infections, bacterial infections, fungus infections or parasite infections. For example, the compounds of the present disclosure can be combined with one or more inhibitors of the following kinases for the treatment of cancer: Aktl, Akt2, Akt3, TGF-PR, PKA, PKG, PKC, CaM-kinase, phosphorylase kinase, MEKK, ERK, MAPK, mTOR, EGFR, HER2, HER3, HER4, INS-R, IGF-1R, IR-R, PDGFaR, PDGFPR, CSFIR, KIT, FLK-II, KDR/FLK-1, FLK-4, flt-1, FGFR1, FGFR2, FGFR3, FGFR4, c-Met, Ron, Sea, TRKA, TRKB, TRKC, FLT3, VEGFR/Flt2, Flt4, EphAl, EphA2, EphA3, EphB2, EphB4, Tie2, Src, Fyn, Lck, Fgr, Btk, Fak, SYK, FRK, JAK, ABL, ALK and B-Raf. In some embodiments, the compounds of the present disclosure can be combined with one or more of the following inhibitors for the treatment of cancer or infections. Non-limiting examples of inhibitors that can be combined with the compounds of the present disclosure for treatment of cancer and infections include an FGFR inhibitor (FGFR1, FGFR2, FGFR3 or FGFR4, e.g., INCB54828, INCB62079 and INCB63904), a JAK inhibitor (JAK1 and/or JAK2, e.g., ruxolitinib, baricitinib or INCB39110), an IDO inhibitor (e.g., epacadostat and NLG919), an LSD1 inhibitor (e.g., INCB59872 and I CB60003), a TDO inhibitor, a PI3K-delta inhibitor (e.g., INCB50797 and I CB50465), a PI3K-gamma inhibitor such as a PI3K-gamma selective inhibitor, a Pirn inhibitor, a CSF1R inhibitor, a TAM receptor tyrosine kinases (Tyro-3, Axl, and Mer), an angiogenesis inhibitor, an interleukin receptor inhibitor, bromo and extra terminal family members inhibitors (for example, bromodomain inhibitors or BET inhibitors such as INCB54329 and INCB57643) and an adenosine receptor antagonist or combinations thereof.
Compounds of the present disclosure can be used in combination with one or more immune checkpoint inhibitors. Exemplary immune checkpoint inhibitors include inhibitors against immune checkpoint molecules such as CD27, CD28, CD40, CD122, CD96, CD73, CD47, OX40, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM, arginase, CD137 (also known as 4-1BB), ICOS, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, VISTA, PD-1 , PD-L1 and PD-L2. In some embodiments, the immune checkpoint molecule is a stimulatory checkpoint molecule selected from CD27, CD28, CD40, ICOS, OX40, GITR and CD137. In some embodiments, the immune checkpoint molecule is an inhibitory checkpoint molecule selected from A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD-1, TIM3, and VISTA. In some embodiments, the compounds provided herein can be used in combination with one or more agents selected from KIR inhibitors, TIGIT inhibitors, LAIRl inhibitors, CD 160 inhibitors, 2B4 inhibitors and TGFR beta inhibitors.
In some embodiments, the inhibitor of an immune checkpoint molecule is anti-PDl antibody, anti-PD-Ll antibody, or anti-CTLA-4 antibody.
In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-1 , e.g., an anti-PD-1 monoclonal antibody. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab (also known as MK-3475), pidilizumab, SHR-1210, PDR001 , or AMP-224. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab or pembrolizumab. In some embodiments, the anti-PDl antibody is pembrolizumab. In some embodiments, the anti PD-1 antibody is SHR-1210.
In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-L1 , e.g., an anti-PD-Ll monoclonal antibody. In some embodiments, the anti-PD-Ll monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or MSB0010718C. In some embodiments, the anti-PD-Ll monoclonal antibody is
MPDL3280A or MEDI4736.
In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of CTLA-4, e.g., an anti-CTLA-4 antibody. In some embodiments, the anti-CTLA-4 antibody is ipilimumab. In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of LAG3, e.g., an anti-LAG3 antibody. In some embodiments, the anti-LAG3 antibody is BMS-986016 or LAG525.
In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of GITR, e.g., an anti-GITR antibody. In some embodiments, the anti-GITR antibody is TRX518 or MK-4166.
In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of OX40, e.g., an anti-OX40 antibody or OX40L fusion protein. In some embodiments, the anti-OX40 antibody is MEDI0562. In some embodiments, the OX40L fusion protein is MEDI6383.
Compounds of the present disclosure can be used in combination with one or more agents for the treatment of diseases such as cancer. In some embodiments, the agent is an alkylating agent, a proteasome inhibitor, a corticosteroid, or an immunomodulatory agent. Examples of an alkylating agent include cyclophosphamide (CY), melphalan (MEL), and bendamustine. In some embodiments, the proteasome inhibitor is carfilzomib. In some embodiments, the corticosteroid is dexamethasone (DEX). In some embodiments, the immunomodulatory agent is lenalidomide (LEN) or pomalidomide (POM).
The compounds of the present disclosure can further be used in combination with other methods of treating cancers, for example by chemotherapy, irradiation therapy, tumor- targeted therapy, adjuvant therapy, immunotherapy or surgery. Examples of immunotherapy include cytokine treatment (e.g., interferons, GM-CSF, G-CSF, IL-2), CRS-207
immunotherapy, cancer vaccine, monoclonal antibody, adoptive T cell transfer, oncolytic virotherapy and immunomodulating small molecules, including thalidomide or JAK1/2 inhibitor and the like. The compounds can be administered in combination with one or more anti-cancer drugs, such as a chemotherapeutics. Example chemotherapeutics include any of: abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, anastrozole, arsenic trioxide, asparaginase, azacitidine, bevacizumab, bexarotene, baricitinib, bleomycin, bortezombi, bortezomib, busulfan intravenous, busulfan oral, calusterone, capecitabine, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, dalteparin sodium, dasatinib, daunorubicin, decitabine, denileukin, denileukin diftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolone propionate, eculizumab, epirubicin, erlotinib, estramustine, etoposide phosphate, etoposide, exemestane, fentanyl citrate, filgrastim, floxuridine, fludarabine, fluorouracil, fulvestrant, gefitinib, gemcitabine, gemtuzumab ozogamicin, goserelin acetate, histrelin acetate, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib mesylate, interferon alfa 2a, irinotecan, lapatinib ditosylate, lenalidomide, letrozole, leucovorin, leuprolide acetate, levamisole, lomustine, meclorethamine, megestrol acetate, melphalan, mercaptopurine, methotrexate, methoxsalen, mitomycin C, mitotane, mitoxantrone, nandrolone phenpropionate, nelarabine, nofetumomab, oxaliplatin, paclitaxel, pamidronate, panitumumab, pegaspargase, pegfilgrastim, pemetrexed disodium, pentostatin, pipobroman, plicamycin, procarbazine, quinacrine, rasburicase, rituximab, ruxolitinib, sorafenib, streptozocin, sunitinib, sunitinib maleate, tamoxifen, temozolomide, teniposide, testolactone, thalidomide, thioguanine, thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine, vorinostat and zoledronate.
Other anti-cancer agent(s) include antibody therapeutics such as trastuzumab (Herceptin), antibodies to costimulatory molecules such as CTLA-4 (e.g., ipilimumab), 4- 1BB, antibodies to PD-1 and PD-L1 , or antibodies to cytokines (IL-10, TGF-β, etc.).
Examples of antibodies to PD-1 and/or PD-L1 that can be combined with compounds of the present disclosure for the treatment of cancer or infections such as viral, bacteria, fungus and parasite infections include, but are not limited to, nivolumab, pembrolizumab, MPDL3280A, MEDI-4736 and SHR-1210.
The compounds of the present disclosure can further be used in combination with one or more anti-inflammatory agents, steroids, immunosuppressants or therapeutic antibodies.
The compounds of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or salts thereof can be combined with another immunogenic agent, such as cancerous cells, purified tumor antigens (including recombinant proteins, peptides, and carbohydrate molecules), cells, and cells transfected with genes encoding immune stimulating cytokines. Non-limiting examples of tumor vaccines that can be used include peptides of melanoma antigens, such as peptides of gplOO, MAGE antigens, Trp-2, MARTI and/or tyrosinase, or tumor cells transfected to express the cytokine GM-CSF.
The compounds of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or salts thereof can be used in combination with a vaccination protocol for the treatment of cancer. In some embodiments, the tumor cells are transduced to express GM-CSF. In some embodiments, tumor vaccines include the proteins from viruses implicated in human cancers such as Human Papilloma Viruses (HPV), Hepatitis Viruses (HBV and HCV) and Kaposi's Herpes Sarcoma Virus (KHSV). In some embodiments, the compounds of the present disclosure can be used in combination with tumor specific antigen such as heat shock proteins isolated from tumor tissue itself. In some embodiments, the compounds of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or salts thereof can be combined with dendritic cells immunization to activate potent anti-tumor responses.
The compounds of the present disclosure can be used in combination with bispecific macrocyclic peptides that target Fe alpha or Fe gamma receptor-expressing effectors cells to tumor cells. The compounds of the present disclosure can also be combined with macrocyclic peptides that activate host immune responsiveness.
The compounds of the present disclosure can be used in combination with bone marrow transplant for the treatment of a variety of tumors of hematopoietic origin.
The compounds of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or salts thereof can be used in combination with vaccines, to stimulate the immune response to pathogens, toxins, and self antigens. Examples of pathogens for which this therapeutic approach may be particularly useful, include pathogens for which there is currently no effective vaccine, or pathogens for which conventional vaccines are less than completely effective. These include, but are not limited to, HIV, Hepatitis (A, B, & C), Influenza, Herpes, Giardia, Malaria, Leishmania, Staphylococcus aureus, Pseudomonas Aeruginosa.
Viruses causing infections treatable by methods of the present disclosure include, but are not limit to human papillomavirus, influenza, hepatitis A, B, C or D viruses, adenovirus, poxvirus, herpes simplex viruses, human c tomegalovirus, severe acute respiratory syndrome virus, ebola virus, measles virus, herpes virus (e.g., VZV, HSV-1, HAV-6, HSV-II, and CMV, Epstein Barr virus), flaviviruses, echovirus, rhinovirus, coxsackie virus, cornovirus, respiratory syncytial virus, mumpsvirus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus and arboviral encephalitis virus.
Pathogenic bacteria causing infections treatable by methods of the disclosure include, but are not limited to, chlamydia, rickettsial bacteria, mycobacteria, staphylococci, streptococci, pneumonococci, meningococci and conococci, klebsiella, proteus, serratia, pseudomonas, legionella, diphtheria, salmonella, bacilli, cholera, tetanus, botulism, anthrax, plague, leptospirosis, and Lyme's disease bacteria.
Pathogenic fungi causing infections treatable by methods of the disclosure include, but are not limited to, Candida (albicans, krusei, glabrata, tropicalis, etc.), Cryptococcus neoformans, Aspergillus (fumigatus, niger, etc.), Genus Mucorales (mucor, absidia, rhizophus), Sporothrix schenkii, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Coccidioides immitis and Histoplasma capsulatum.
Pathogenic parasites causing infections treatable by methods of the disclosure include, but are not limited to, Entamoeba histolytica, Balantidium coli, Naegleriafowleri, Acanthamoeba sp., Giardia lambia, Cryptosporidium sp., Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondi, and Nippostrongylus brasiliensis.
When more than one pharmaceutical agent is administered to a patient, they can be administered simultaneously, separately, sequentially, or in combination (e.g. , for more than two agents).
IV. Formulation, Dosage Forms and Administration
When employed as pharmaceuticals, the compounds of the present disclosure can be administered in the form of pharmaceutical compositions. Thus the present disclosure provides a composition comprising a compound of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or a pharmaceutically acceptable salt thereof, or any of the embodiments thereof, and at least one pharmaceutically acceptable carrier or excipient. These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is indicated and upon the area to be treated. Administration may be topical (including transdermal, epidermal, ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g. , by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal intramuscular or injection or infusion; or intracranial, e.g. , intrathecal or intraventricular, administration. Parenteral administration can be in the form of a single bolus dose, or may be, e.g. , by a continuous perfusion pump. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders.
Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. This invention also includes pharmaceutical compositions which contain, as the active ingredient, the compound of the present disclosure or a pharmaceutically acceptable salt thereof, in combination with one or more pharmaceutically acceptable carriers or excipients. In some embodiments, the composition is suitable for topical administration. In making the compositions of the invention, the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, e.g. , a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, e.g. , up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.
In preparing a formulation, the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g., about 40 mesh.
The compounds of the invention may be milled using known milling procedures such as wet milling to obtain a particle size appropriate for tablet formation and for other formulation types. Finely divided (nanoparticulate) preparations of the compounds of the invention can be prepared by processes known in the art see, e.g., WO 2002/000196.
Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents. The compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
In some embodiments, the pharmaceutical composition comprises silicified microcrystalline cellulose (SMCC) and at least one compound described herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the silicified microcrystalline cellulose comprises about 98% microcrystalline cellulose and about 2% silicon dioxide w/w.
In some embodiments, the composition is a sustained release composition comprising at least one compound described herein, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient. In some embodiments, the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and at least one component selected from microcrystalline cellulose, lactose monohydrate, hydroxypropyl methylcellulose and polyethylene oxide. In some embodiments, the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and microcrystalline cellulose, lactose monohydrate and hydroxypropyl methylcellulose. In some embodiments, the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and microcrystalline cellulose, lactose monohydrate and polyethylene oxide. In some
embodiments, the composition further comprises magnesium stearate or silicon dioxide. In some embodiments, the microcrystalline cellulose is Avicel PH102™. In some embodiments, the lactose monohydrate is Fast-flo 316™. In some embodiments, the hydroxypropyl methylcellulose is hydroxypropyl methylcellulose 2208 K4M (e.g. , Methocel K4 M
Premier™) and/or hydroxypropyl methylcellulose 2208 K100LV (e.g., Methocel K00LV™). In some embodiments, the polyethylene oxide is polyethylene oxide WSR 1105 (e.g. , Poly ox WSR 1105™).
In some embodiments, a wet granulation process is used to produce the composition. In some embodiments, a dry granulation process is used to produce the composition.
The compositions can be formulated in a unit dosage form, each dosage containing from about 5 to about 1,000 mg (1 g), more usually about 100 mg to about 500 mg, of the active ingredient. In some embodiments, each dosage contains about 10 mg of the active ingredient. In some embodiments, each dosage contains about 50 mg of the active ingredient. In some embodiments, each dosage contains about 25 mg of the active ingredient. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable
pharmaceutical excipient.
The components used to formulate the pharmaceutical compositions are of high purity and are substantially free of potentially harmful contaminants (e.g., at least National Food grade, generally at least analytical grade, and more typically at least pharmaceutical grade). Particularly for human consumption, the composition is preferably manufactured or formulated under Good Manufacturing Practice standards as defined in the applicable regulations of the U.S. Food and Drug Administration. For example, suitable formulations may be sterile and/or substantially isotonic and/or in full compliance with all Good
Manufacturing Practice regulations of the U.S. Food and Drug Administration.
The active compound may be effective over a wide dosage range and is generally administered in a therapeutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms and the like.
The therapeutic dosage of a compound of the present invention can vary according to, e.g., the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of a compound of the invention in a
pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g. , hydrophobicity), and the route of administration. For example, the compounds of the invention can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1 μg/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention. When referring to these preformulation compositions as homogeneous, the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation is then subdivided into unit dosage forms of the type described above containing from, e.g., about 0.1 to about 1000 mg of the active ingredient of the present invention.
The tablets or pills of the present invention can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
The liquid forms in which the compounds and compositions of the present invention can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face mask, tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner.
Topical formulations can contain one or more conventional carriers. In some embodiments, ointments can contain water and one or more hydrophobic carriers selected from, e.g., liquid paraffin, poly oxy ethylene alkyl ether, propylene glycol, white Vaseline, and the like. Carrier compositions of creams can be based on water in combination with glycerol and one or more other components, e.g., glycerinemonostearate, PEG-glycerinemonostearate and cetylstearyl alcohol. Gels can be formulated using isopropyl alcohol and water, suitably in combination with other components such as, e.g., glycerol, hydroxy ethyl cellulose, and the like. In some embodiments, topical formulations contain at least about 0.1, at least about 0.25, at least about 0.5, at least about 1, at least about 2 or at least about 5 wt % of the compound of the invention. The topical formulations can be suitably packaged in tubes of, e.g., 100 g which are optionally associated with instructions for the treatment of the select indication, e.g. , psoriasis or other skin condition.
The amount of compound or composition administered to a patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, the state of the patient, the manner of administration and the like. In therapeutic applications, compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient and the like.
The compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the compound preparations typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers or stabilizers will result in the formation of pharmaceutical salts.
The therapeutic dosage of a compound of the present invention can vary according to, e.g., the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of a compound of the invention in a
pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g. , hydrophobicity), and the route of administration. For example, the compounds of the invention can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1 μg/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
V. Labeled Compounds and Assay Methods
The compounds of the present disclosure can further be useful in investigations of biological processes in normal and abnormal tissues. Thus, another aspect of the present invention relates to labeled compounds of the invention (radio-labeled, fluorescent-labeled, etc.) that would be useful not only in imaging techniques but also in assays, both in vitro and in vivo, for localizing and quantitating PD-1 or PD-Ll protein in tissue samples, including human, and for identifying PD-Ll ligands by inhibition binding of a labeled compound. Accordingly, the present invention includes PD-1/PD-L1 binding assays that contain such labeled compounds.
The present invention further includes isotopically-substituted compounds of the disclosure. An "isotopically-substituted" compound is a compound of the invention where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e. , naturally occurring). It is to be understood that a "radio-labeled" is a compound that has incorporated at least one isotope that is radioactive (e.g., radionuclide). Suitable
radionuclides that may be incorporated in compounds of the present invention include but are not limited to ¾ (also written as T for tritium), nC, 1 C, 14C, 1 N, 15N, 150, 170, 180, 18F, 35S, 6C1, 82Br, 75Br, 76Br, 77Br, 12 I, 124I, 125I and 1 ll. The radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio-labeled compound. For example, for in vitro PD-Ll protein labeling and competition assays, compounds that incorporate H, 14C, 82Br, 125I, 1 11, 5S or will generally be most useful. For radio-imaging applications nC, 18F, 125I, 12 I, 124I, 1 XI, 75Br, 76Br or 77Br will generally be most useful. In some embodiments the radionuclide is selected from the group consisting of H, 14C, 1251, 5S and 82Br. Synthetic methods for incorporating radio-isotopes into organic compounds are known in the art.
Specifically, a labeled compound of the invention can be used in a screening assay to identify and/or evaluate compounds. For example, a newly synthesized or identified compound (i.e. , test compound) which is labeled can be evaluated for its ability to bind a PD- Ll protein by monitoring its concentration variation when contacting with the PD-Ll protein, through tracking of the labeling. For example, a test compound (labeled) can be evaluated for its ability to reduce binding of another compound which is known to bind to a PD-Ll protein (i.e., standard compound). Accordingly, the ability of a test compound to compete with the standard compound for binding to the PD-L1 protein directly correlates to its binding affinity. Conversely, in some other screening assays, the standard compound is labeled and test compounds are unlabeled. Accordingly, the concentration of the labeled standard compound is monitored in order to evaluate the competition between the standard compound and the test compound, and the relative binding affinity of the test compound is thus ascertained.
VI. Kits
The present disclosure also includes pharmaceutical kits useful, e.g., in the treatment or prevention of diseases or disorders associated with the activity of PD-L1 including its interaction with other proteins such as PD-1 and B7-1 (CD80), such as cancer or infections, which include one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I), or any of the embodiments thereof. Such kits can further include one or more of various conventional pharmaceutical kit components, such as, e.g. , containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, can also be included in the kit.
The invention will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes, and are not intended to limit the invention in any manner. Those of skill in the art will readily recognize a variety of non- critical parameters which can be changed or modified to yield essentially the same results. The compounds of the Examples have been found to inhibit the activity of PD-1/PD-L1 protein/protein interaction according to at least one assay described herein.
EXAMPLES
Experimental procedures for compounds of the invention are provided below. Open Access Preparative LCMS Purification of some of the compounds prepared was performed on Waters mass directed fractionation systems. The basic equipment setup, protocols and control software for the operation of these systems have been described in detail in literature. See, e.g. , Blom, "Two-Pump At Column Dilution Configuration for Preparative LC-MS", K. Blom, J. Combi. Chem., 2002, 4, 295-301 ; Blom et al, "Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification", J. Combi. Chem., 2003, 5, 670-83; and Blom et al, "Preparative LC-MS Purification: Improved Compound Specific Method Optimization", J. Combi. Chem., 2004, 6, 874-883.
Example 1
N-[2-cyano-3-(2,3-dihydro-l,4-benzodioxin-6-yl)phenyl]-4,5,6,7- tetrahydro [ 1,3] thiazolo [5,4-c
Figure imgf000077_0001
Step 1: 2-amino-6-(2, 3-dihydro-l, 4-benzodioxin-6-yl)benzonitrile
Figure imgf000077_0002
A mixture of 2-amino-6-bromobenzonitrile (1.5 g, 7.6 mmol) (Ark Pharm, cat#AK- 36350), 2,3-dihydro-l,4-benzodioxin-6-ylboronic acid (1.4 g, 7.6 mmol) (Combi-Blocks, cat#BB-8311), [l,r-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (1 : 1) (0.3 g, 0.4 mmol), Na2CCb (2.4 g, 22.8 mmol) in 1,4-dioxane (30.0 mL) and water (4.0 mL) was purged with nitrogen. The reaction mixture was heated to 100 °C for 4 h under vigorous stirring. After being cooled to room temperature, the reaction was quenched with saturated aqueous NaHCCb solution, and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2S04, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with 50% ethyl acetate in hexanes to afford the desired product (1.7 g, 88%). LCMS calculated for C15H13N2O2 (M+H)+: m/z = 253.1 ; found 253.1.
Step 2: tert-butyl 2-({[2-cyano-3-(2, 3-dihydro-l, 4-benzodioxin-6- yl)phenyl]amino}carbonyl)- -dihydro[ 1, 3] thiazolo [5, 4-c]pyridine-5(4H)-carboxylate
Figure imgf000077_0003
2-Amino-6-(2,3-dihydro-l ,4-benzodioxin-6-yl)benzonitrile (31 mg, 0.12 mmol) from Step 1 was added to a solution of 5-(tert-butoxycarbonyl)-4,5,6,7-tetrahydro[l ,3]thiazolo[5,4- c]pyridine-2-carboxylic acid (30 mg, 0.10 mmol) (J&W Pharmlab, cat#90R0423),
N,N,N',N'-tetramethyl-0-(7-azabenzotriazol-l-yl)uronium hexafluorophosphate (60 mg, 0.16 mmol) and N,N-diisopropylethylamine (55 xL, 0.32 mmol) in DMF (1.0 mL). The reaction mixture was stirred at room temperature for 24 h. The reaction was quenched with saturated aqueous NaHCC solution, and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2S04, filtered, and concentrated under reduced pressure. The crude product was used for next step without further purification. LCMS calculated for C27H27N4O5S (M+H)+: m/z = 519.2; found 519.2. Step 3: N-[ 2-cyano-3-(2, 3-dihydro-l, 4-benzodioxin-6-yl)phenyl ]-4, 5, 6, 7- tetrahydrof 1, 3 ] thiazolo- [ 5, 4-c ]pyridine-2-carboxamide
The crude product from Step 2 was dissolved in methanol (0.5 mL), and then treated with 4.0 M hydrogen chloride in 1,4-dioxane (0.5 mL). After being stirred at 50 °C for 2 h, the reaction mixture was concentrated and purified by prep-HPLC (pH = 2,
acetonitrile/water+TFA) to give the desired product as the TFA salt. LCMS calculated for
C22H19N4O3S (M+H)+: m/z = 419.1; found 419.2.
Example 2
N-(2-cyanobiphenyl-3-yl)-4,5,6 -tetrahydro [ 1,3] thiazolo [5,4-c] pyridine-2-carboxamide
Figure imgf000078_0001
Step 1: tert-butyl 2-{[(3-bromo-2-cyanophenyl)amino]carbonyl}-6, 7- dihydrof 1, 3 ] thiazolo [ 5, 4-c ]pyridine-5( 4H)-carboxylate
Figure imgf000078_0002
Potassium tert-butoxide (0.15 g, 1.3 mmol) was added to a solution of 5-tert-butyl 2- ethyl 6,7-dihydro[l,3]thiazolo[5,4-c]pyridine-2,5(4H)-dicarboxylate (0.26 g, 0.88 mmol) (Aurum Pharmatech, cat#Z-3884), and 2-amino-6-bromobenzonitrile (0.17 g, 0.88 mmol) (Ark Pharm, cat#AK-36350) in tetrahydrofuran (4 mL). After being stirred at room temperature for 3 h, the reaction mixture was quenched with water, and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2S04, filtered, and concentrated under reduced pressure. The crude product was used for next step without further purification. LCMS calculated for Ci9H2oBrN403S (M+H)+: m/z = 463.0; found 463.1. Step 2: N-( 3-bromo-2-cyanophenyl)-4, 5, 6, 7-tetrahydro[ 1, 3 Jthiazolof 5, 4-c ]pyridine-2- carboxamide
Figure imgf000079_0001
The crude product from Step 1 was dissolved in methanol (2.0 mL), and then treated with 4.0 M hydrogen chloride in 1,4-dioxane (2.0 mL). After being stirred at 50 °C for 2 h, the reaction mixture was neutralized with saturated aqueous Na2C03 solution, and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2S04, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with 5% methanol in dichloromethane to afford the desired product (0.20 g, 61% over 2 steps). LCMS calculated for Ci4Hi2BrN4OS (M+H)+: m/z = 363.0; found 363.1.
Step 3: N-(2-cyanobiphenyl-3-yl)-4, 5, 6, 7-tetrahydro[ 1, 3 Jthiazolof 5, 4-c ]pyridine-2- carboxamide
A mixture of N-(3-bromo-2-cyanophenyl)-4,5,6,7-tetrahydro[l,3]thiazolo[5,4- c]pyridine-2-carboxamide (8.0 mg, 0.02 mmol) from Step 2, phenylboronic acid (5.3 mg,
0.04 mmol), dichloro[l, -bis(dicyclohexylphosphino)ferrocene]palladium(II) (0.7 mg, 0.001 mmol), and Na2C03 (7.0 mg, 0.07 mmol) in tert-butyl alcohol (0.15 mL) and water (0.15 mL) was purged with nitrogen. The reaction mixture was heated to 100 °C for 2 h under vigorous stirring. After being cooled to room temperature, the mixture was diluted with methanol, and purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C20H17N4OS (M+H)+: m/z = 361.1; found 361.2.
Example 3
N-[2-cyano-3-(l-methyl-lH-indazol-4-yl)phenyl]-4,5,6,7-tetrahydro[l,3]thiazolo[5,4- c] pyridine-2-carboxamide
Figure imgf000080_0001
This compound was prepared using similar procedures as described for Example 2 with 1 -methyl- lH-indazole-4-boronic acid pinacol ester {Aldrich, Cat#: 725323) replacing phenylboronic acid in Step 3. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C22H19N6OS (M+H)+: m/z = 415.1; found 415.2.
Example 4
N-(2-cyano-2'-fluorobiphenyl-3-yl)-4,5,6,7-tetrahydro[l,3]thiazolo[5,4-c]pyridine-2- carboxamide
Figure imgf000080_0002
This compound was prepared using similar procedures as described for Example 2 with (2-fluorophenyl)boronic acid {Aldrich, Cat#: 445223) replacing phenylboronic acid in Step 3. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C20H16FN4OS (M+H)+: m/z = 379.1; found 379.2.
Example 5
N-(2-cyano-2'-fluoro-3'-methoxybiphenyl-3-yl)-4,5,6,7-tetrahydro[l,3]thiazolo[5,4- c]pyridine-2-carboxamide
Figure imgf000080_0003
This compound was prepared using similar procedures as described for Example 2 with (2-fluoro-3-methoxyphenyl)boronic acid {Combi-Blocks, Cat#:BB-2460) replacing phenylboronic acid in Step 3. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C21H18FN4O2S (M+H)+: m/z = 409.1; found 409.2.
Example 6 N-[2-cyano-3-(2,3-dihydro-l-benzofuran-6-yl)phenyl]-4,5,6,7- tetrahydro [ 1,3] thiazolo [5,4-c
Figure imgf000081_0001
This compound was prepared using similar procedures as described for Example 2 with 2,3-dihydro-l-benzofuran-6-ylboronic acid (ArkPharm, Cat#:AKl 43637) replacing phenylboronic acid in Step 3. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C22H19N4O2S (M+H)+: m/z = 403.1; found 403.2. Example 7
N-(2-cyano-3-cyclohex- 1-en- l-ylphenyl)-4,5,6,7-tetrahydro [ 1,3] thiazolo [5,4-c] pyridine- 2-carboxamide
Figure imgf000081_0002
This compound was prepared using similar procedures as described for Example 2 with cyclohex-l-en-l-ylboronic acid pinacol ester (Aldrich, Cat#: 650277) replacing phenylboronic acid in Step 3. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C20H21N4OS (M+H)+: m/z = 365.1; found 365.2. Example 8
N-(2-cyano-3-cyclohexylphenyl)-4,5,6,7-tetrahydro [1,3] thiazolo [5,4-c] pyridine-2- carboxamide
Figure imgf000081_0003
A suspension of N-(2-cyano-3-cyclohex-l-en-l-ylphenyl)-4,5,6,7- tetrahydro[l,3]thiazolo[5,4-c]pyridine-2-carboxamide (4.0 mg, 0.01 mmol) from Example 7 and 10% Pd/C (5.0 mg) in methanol (0.5 mL) was stirred under a hydrogen atmosphere (1 atm) at room temperature for 2 h. After the catalyst was filtered off, the filtrate was diluted with methanol, and purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C20H23N4OS (M+H)+: m/z = 367.2; found 367.2.
Example 9
N-(2-cyano-2',6'-difluorobiphenyl-3-yl)-4,5,6,7-tetrahydro[l,3]thiazolo[5,4-c]pyridine-2- carboxamide
Figure imgf000082_0001
A mixture of N-(3-bromo-2-cyanophenyl)-4,5,6,7-tetrahydro[l,3]thiazolo[5,4- c]pyridine-2-carboxamide (8.0 mg, 0.022 mmol) from Example 2, step 2, 2,6- difluorophenylboronic acid (6.2 mg, 0.026 mmol) (Aldrich, Cat#: 470791),
dicyclohexyl(2',4 6'-triisopropylbiphenyl-2-yl)phosphine-(2'-aminobiphenyl-2- yl)(chloro)palladium (1 : 1) (3.5 mg, 0.0044 mmol), and K3PO4 (12 mg, 0.055 mmol) in tetrahydrofuran (0.4 mL) and water (0.05 mL) was purged with nitrogen. The reaction mixture was stirred at room temperature for 2 h under vigorous stirring. After being cooled to room temperature, the mixture was diluted with methanol, and purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C20H15F2N4OS (M+H)+: m/z = 397.1; found 397.2.
Example 10
N- [2-cyano-3-(2,3-dihydro- l,4-benzodioxin-6-yl)phenyl] -4,5,6,7- tetrahydropyrazolo [1,5- a] pyrazine-2-carboxamide
Figure imgf000082_0002
This compound was prepared using similar procedures as described for Example 1 with 5-(tert-butoxycarbonyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazine-2-carboxylic acid (AstaTech, Cat#: 74720) replacing 5-(tert-butoxycarbonyl)-4,5,6,7- tetrahydro[l,3]thiazolo[5,4-c]pyridine-2-carboxylic acid in Step 2. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C22H20N5O3 (M+H)+: m/z = 402.2; found 402.2. Example 11 N-[2-cyano-3-(2,3-dihydro-l,4-benzodioxin-6-yl)phenyl]-5-(2-hydroxyethyl)-4,5,6,7- tetrahydropyrazolo [ 1,5-a] razine-2-carboxamide
Figure imgf000083_0001
A mixture of N-[2-cyano-3-(2,3-dihydro-l,4-benzodioxin-6-yl)phenyl]-4,5,6,7- tetrahydropyrazolo[l,5-a]pyrazine-2-carboxamide (5.0 mg, 0.01 mmol) from Example 10, 2- iodoethanol (6.4 mg, 0.04 mmol), and K2CO3 (8.6 mg, 0.06 mmol) in DMF (0.1 mL) was stirred at room temperature for 3 h. The reaction mixture was diluted with water, and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2S04, filtered, and concentrated under reduced pressure. The residue was purified by prep- HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C24H24N5O4 (M+H)+: m/z = 446.2; found 446.3.
Example 12
N-[2-cyano-3-(2,3-dihydro-l,4-benzodioxin-6-yl)phenyl]-l-methyl-4,5,6,7-tetrahyd lH-imidazo[4,5-c]pyridine-2-carboxamide
Figure imgf000083_0002
Step 1: tert-butyl l-methyl-l, 4, 6, 7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate
Figure imgf000083_0003
A solution of l-methyl-4,5,6,7-tetrahydro-lH-imidazo[4,5-c]pyridine (80 mg, 0.60 mmol) (Accela, Cat#:SY032476), di-tert-butyl dicarbonate (140 mg, 0.66 mmol) and triethylamine (0.10 mL, 0.72 mmol) in dichloromethane (4.0 mL) was stirred at room temperature for 1 h. The reaction was quenched with saturated aqueous NaHCC solution, and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2S04, filtered, and concentrated under reduced pressure. The crude product was used for next step without further purification. LCMS calculated for C12H20N3O2 (M+H)+: m/z = 238.2; found 238.2. Step 2: 5-tert-butyl 2-methyl l-methyl-6, 7-dihydro-lH-imidazo[4, 5-c]pyridine-2, 5(4H)- dicarboxylate
Figure imgf000084_0001
n-Butyllithium in hexanes (2.5 M, 0.29 mL, 0.72 mmol) was added to a cold (-78 °C) solution of the crude product from Step 1 in tetrahydrofuran (3.0 mL). The reaction mixture was stirred at -78 °C for 30 min prior to the addition of methyl chloroformate (46 μί, 0.60 mmol). After being stirred at -78 °C for 1 h, the reaction mixture was allowed to warm up to room temperature. The reaction was then quenched with saturated aqueous NaHCCb solution, and extracted with ethyl acetate, dried over Na2S04, filtered, and concentrated under reduced pressure. The crude product was used for next step without further purification. LCMS calculated for C14H22N3O4 (M+H)+: m/z = 296.2; found 296.3.
Step 3: tert-butyl 2-({[2-cyano-3-(2, 3-dihydro-l, 4-benzodioxin-6- yl)phenyl]amino}carbonyl)-l-methyl-l, 4, 6, 7-tetrahydro-5H-imidazo[4, 5-c]pyridine-5- carboxylate
Figure imgf000084_0002
Potassium tert-butoxide (52 mg, 0.50 mmol) was added to a solution of the crude product from Step 2, and 2-amino-6-(2,3-dihydro-l ,4-benzodioxin-6-yl)benzonitrile (25 mg, 0.10 mmol) from Example 1, step 1 in tetrahydrofuran (0.5 mL). After being stirred at room temperature for 3 h, the reaction mixture was quenched with water, and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2S04, filtered, and concentrated under reduced pressure. The crude product was used for next step without further purification. LCMS calculated for C28H30N5O5 (M+H)+: m/z = 516.2; found 516.2.
Step 4: N-[2-cyano-3-(2, 3-dihydro-l, 4-benzodioxin-6-yl)phenyl]-l-methyl-4, 5, 6, 7- tetrahydro-lH-imidazo[ 4, 5-c Jpyridine-2-carboxamide
The crude product from Step 3 was dissolved in methanol (0.2 mL), and then treated with 4.0 M hydrogen chloride in 1,4-dioxane (0.2 mL). After being stirred at 50 °C for 2 h, the reaction was neutralized with saturated aqueous Na2C03 solution, and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2S04, filtered, and concentrated under reduced pressure. The residue was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C23H22N5O3 (M+H)+: m/z = 416.2; found 416.3.
Example 13
N-(2-cyano-3-(2,3-dihydrobenzo[b] [l,4]dioxin-6-yl)phenyl)-5-(2-hydroxyethyl)-l- methyl-4,5,6,7-tetrahydro-lH-imidazo[4,5-c]pyridine-2-carboxamide
OH
Figure imgf000085_0001
This compound was prepared using similar procedures as described for Example 11, starting with N-[2-cyano-3-(2,3-dihydro-l,4-benzodioxin-6-yl)phenyl]-l-methyl-4,5, 6,7- tetrahydro-lH-imidazo[4,5-c]pyridine-2-carboxamide from Example 12. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C25H26N5O4 (M+H)+: m/z = 460.2; found 460.3.
Example 14
N-[2-cyano-3-(2,3-dihydro-l,4-benzodioxin-6-yl)phenyl]-5,6,7,8- tetrahydro [1,2,4] triazolo [ 1,5
Figure imgf000085_0002
This compound was prepared using similar procedures as described for Example 12 with 5,6,7,8-tetrahydro-[l,2,4]triazolo[l,5-a]pyrazine (Ark Pharm, Cat#:AK-25630) replacing l-methyl-4,5,6,7-tetrahydro-lH-imidazo[4,5-c]pyridine in Step 1. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C21H19N6O3 (M+H)+: m/z = 403.2; found 403.2.
Example 15
N-(2,3'-dicyano-2'-fluorobiphenyl-3-yl)-4,5,6,7-tetrahydro[l,3]thiazolo[5,4-c]pyridine-2- carboxamide
Figure imgf000086_0001
This compound was prepared using similar procedures as described for Example 2 with (3-cyano-2-fluorophenyl)boronic acid (Combi-Blocks, Cat#:BB-5008) replacing phenylboronic acid in Step 3. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C21H15FN5OS (M+H)+: m/z = 404.1 ; found 404.2.
Example 16
N-(2-cyano-3'-methoxybiphenyl-3-yl)-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2- carboxamide
Figure imgf000086_0002
This compound was prepared using similar procedures as described for Example 2 with 3-methoxyphenylboronic acid {Aldrich, Cat#: 441686) replacing phenylboronic acid in Step 3. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C21H19N4O2S (M+H)+: m/z = 391.1 ; found 391.2.
Example 17
N-(2-cyano-3'-fluoro-5'-methoxybiphenyl-3-yl)-4,5,6,7-tetrahydro[l,3]thiazolo[5,4- c] pyridine-2-carboxamide
Figure imgf000086_0003
This compound was prepared using similar procedures as described for Example 2 with (3-fluoro-5-methoxyphenyl)boronic acid {Combi-Blocks, Cat#:BB-2775) replacing phenylboronic acid in Step 3. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C21H18FN4O2S (M+H)+: m/z = 409.1; found 409.2.
Example 18
N-(2'-chloro-2-cyanobiphenyl-3-yl)-4,5,6,7-tetrahydro[l,3]thiazolo[5,4-c]pyridine-2- carboxamide
Figure imgf000087_0001
This compound was prepared using similar procedures as described for Example 2 with (2-chlorophenyl)boronic acid {Aldrich, Cat#: 445215) replacing phenylboronic acid in Step 3. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C20H16CIN4OS (M+H)+: m/z = 395.1 ; found 395.1.
Example 19
N-(2-cyano-2'-fluoro-3'-methoxybiphenyl-3-yl)-5,6,7,8-tetrahydroimidazo[l,2- a] pyrazine-2-carboxamide
Figure imgf000087_0002
This compound was prepared using similar procedures as described for Example 2 with ethyl 5,6,7,8-tetrahydroimidazo[l,2-a]pyrazine-2-carboxylate {AstaTech, Cat#: SC2741) replacing 5-tert-butyl 2-ethyl 6,7-dihydro[l,3]thiazolo[5,4-c]pyridine-2,5(4H)-dicarboxylate in Step 1, and (2-fluoro-3-methoxyphenyl)boronic acid {Combi-Blocks, Cat#: BB-2460) replacing phenylboronic acid in Step 3. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C21H19FN5O2 (M+H)+: m/z = 392.2; found 392.3.
Example 20
N-[3-(2,3-dihydro-l,4-benzodioxin-6-yl)-2-methylphenyl]-4,5,6,7- tetrahydro [ 1,3] thiazolo [5,4-c
Figure imgf000088_0001
Step 1: 3-(2, 3-dihydrobenzo [b ][ l,4]dioxin-6- l)-2-methylaniline
Figure imgf000088_0002
This compound was prepared using similar procedures as described for Example 1, step 1, starting with 3-bromo-2-methylaniline (460 mg, 2.5 mmol) (Combi-Blocks, Cat#:AN- 1321). The residue was purified by flash chromatography on a silica gel column eluting with 30% ethyl acetate in hexanes to afford the desired product (502 mg, 83%). LCMS calculated for CisHieNC (M+H)+: m/z = 242.1; found 242.2.
Step 2: tert-butyl 2-(3-(2, 3-dihydrobenzo[b] [l, 4]dioxin-6-yl)-2-methylphenylcarbamoyl)-6, 7- dihydrothiazolof 5,
Figure imgf000088_0003
This compound was prepared using similar procedures as described for Example 2, step 1 with 3-(2,3-dihydrobenzo[b][l,4]dioxin-6-yl)-2-methylaniline from Step 1 replacing 2- amino-6-bromobenzonitrile. The crude product was used for next step without further purification. LCMS calculated for C27H30N3O5S (M+H)+: m/z = 508.2; found 508.2.
Step 3: N-[3-(2, 3-dihydro-l,4-benzodioxin-6-yl)-2-methylphenyl]-4,5, 6, 7- tetrahydrof 1, 3 ] thiazolo [ 5, 4-c ]pyridine-2-carboxamide
This compound was prepared using similar procedures as described for Example 2, Step 2, starting with tert-butyl 2-(3-(2,3-dihydrobenzo[b] [l,4]dioxin-6-yl)-2- methylphenylcarbamoyl)-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate from Step 2. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C22H22N3O3S (M+H)+: m/z = 408.1; found 408.2. Example 21
N-(2'-fluoro-3'-methoxy-2-methylbiphenyl-3-yl)-4,5,6,7-tetrahydro[l,3]thiazolo[5,4- c] pyridine-2-carboxamide
Figure imgf000089_0001
This compound was prepared using similar procedures as described for Example 2 with 3-bromo-2-methylaniline replacing 2-amino-6-bromobenzonitrile in Step 1, and (2- fluoro-3-methoxyphenyl)boronic acid replacing phenylboronic acid in Step 3. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C21H21FN3O2S (M+H)+: m/z = 398.1; found 398.2.
Example 22
N-(2'-fluoro-3'-methoxy-2-methylbiphenyl-3-yl)-l-methyl-4,5,6,7-tetrahyd
imidazo[4,5-c]pyridine-2-carboxamide
Figure imgf000089_0002
This compound was prepared using similar procedures as described for Example 12, starting with 2'-fluoro-3'-methoxy-2-methylbiphenyl-3-amine, prepared using similar procedures for the synthesis of 2-amino-6-(2,3-dihydro-l,4-benzodioxin-6-yl)benzonitrile in Example 1, Step 1. The reaction mixture was purified by prep-HPLC (pH = 2,
acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C22H24FN4O2 (M+H)+: m/z = 395.2; found 395.3.
Example 23
N-[2-methyl-3-(l-methyl-lH-indazol-4-yl)phenyl]-4,5,6,7-tetrahydro[l,3]thiazolo[5,4- c]pyridine-2-carboxamide
Figure imgf000089_0003
This compound was prepared using similar procedures as described for Example 2 with 3-bromo-2-methylaniline replacing 2-amino-6-bromobenzonitrile in Step 1, and (1- methyl- lH-indazol-4-yl)boronic acid {Combi-Blocks; cat#BB-9017) replacing phenylboronic acid in Step 3. The reaction mixture was purified by prep-HPLC (pH = 2,
acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C22H22N5OS (M+H)+: m/z = 404.2; found 404.3.
Example 24
N-[2'-fluoro-3'-(hydroxymethyl)-2-methylbiphenyl-3-yl]-4,5,6,7- tetrahydro[l,3]thiazolo[5,4-
Figure imgf000090_0001
This compound was prepared using similar procedures as described for Example 2 with 3-bromo-2-methylaniline replacing 2-amino-6-bromobenzonitrile in Step 1, and [2- fluoro-3-(hydroxymethyl)phenyl]boronic acid {Combi-Blocks, Cat#: BB-6579) replacing phenylboronic acid in Step 3. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C21H21FN3O2S (M+H)+: m/z = 398.1; found 398.2.
Example 25
N-[3-(lH-indazol-4-yl)-2-methylphenyl]-4,5,6,7-tetrahydro[l,3]thiazolo[5,4-c]pyridine- -carboxamide
Figure imgf000090_0002
This compound was prepared using similar procedures as described for Example 2 with 3-bromo-2-methylaniline replacing 2-amino-6-bromobenzonitrile in Step 1, and indazole-4-boronic acid hydrochloride {Aldrich, Cat#: 709379) replacing phenylboronic acid in Step 3. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C21H20N5OS (M+H)+: m/z = 390.1; found 390.2.
Example 26
N-(2-methylbiphenyl-3-yl)-4,5,6,7-tetrahydro[l,3]thiazolo[5,4-c]pyridine-2- carboxamide
Figure imgf000091_0001
This compound was prepared using similar procedures as described for Example 2 with 3-bromo-2-methylaniline replacing 2-amino-6-bromobenzonitrile in Step 1. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C20H20N3OS (M+H)+: m/z = 350.1; found 350.2.
Example 27
5-(2-hydroxyethyl)-N-(2-methylbiphenyl-3-yl)-4,5,6,7-tetrahydrothiazolo[5,4- c] pyridine-2-carboxamide
Figure imgf000091_0002
This compound was prepared using similar procedures as described for Example 11, starting with N-(2-methylbiphenyl-3-yl)-4,5,6,7-tetrahydro[l,3]thiazolo[5,4-c]pyridine-2- carboxamide from Example 26. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C22H24N3O2S (M+H)+: m/z = 394.2; found 394.2.
Example 28
2-(2-(2-methylbiphenyl-3-ylcarbamoyl)-6,7-dihydrothiazolo[5,4-c]pyridin-5(4H)- yl)acetic acid
Figure imgf000091_0003
Gly oxalic acid monohydrate (9.9 mg, 0.11 rnmol) was added to a solution of N-(2- methylbiphenyl-3-yl)-4,5,6,74etrahydro[l,3]thiazolo[5,4-c]pyridine-2-carboxamide (17 mg, 0.05 rnmol) from Example 26, and N,N-diisopropylethylamine (19 \L, 0.11 rnmol) in dichloromethane (0.5 niL). After being stirred at room temperature for 15 min, sodium triacetoxyborohydride (33 mg, 0.15 rnmol) was added. The reaction mixture was stirred at room temperature for 2 h. The solvent was removed under reduced pressure, and the residue was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C22H22N3O3S (M+H)+: m/z = 408.1; found 408.2.
Example 29
N-[2-methyl-3-(2-methyl-2H-indazol-6-yl)phenyl]-4,5,6,7-tetrahydro[l,3]thiazolo[5,4- c]pyridine-2-carboxamide
Figure imgf000092_0001
This compound was prepared using similar procedures as described for Example 2 with 3-bromo-2-methylaniline replacing 2-amino-6-bromobenzonitrile in Step 1, and 2- methyl-2H-indazol-6-ylboronic acid pinacol ester {Combi-Blocks, Cat#:PN-9131) replacing phenylboronic acid in Step 3. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C22H22N5OS (M+H)+: m/z = 404.2; found 404.2.
Example 30
N-(2'-cyano-2-methylbiphenyl-3-yl)-4,5,6,7-tetrahydro[l,3]thiazolo[5,4-c]pyridine-2- carboxamide
Figure imgf000092_0002
This compound was prepared using similar procedures as described for Example 2 with 3-bromo-2-methylaniline replacing 2-amino-6-bromobenzonitrile in Step 1, and 2- cyanophenylboronic acid {Aldrich, Cat#:521396) replacing phenylboronic acid in Step 3. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C21H19N4OS (M+H)+: m/z = 375.1; found 375.2. Example 31
N-[2'-(cyanomethyl)-2-methylbiphenyl-3-yl]-4,5,6,7-tetrahydro[l,3]thiazolo[5,4- c] pyridine-2-carboxamide
Figure imgf000093_0001
This compound was prepared using similar procedures as described for Example 2 with 3-bromo-2-methylaniline replacing 2-amino-6-bromobenzonitrile in Step 1, and 2- (cyanomethyl)phenylboronic acid {Combi-Blocks, Cat#:BB-2136) replacing phenylboronic acid in Step 3. The reaction mixture was purified by prep-HPLC (pH = 2,
acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C22H21N4OS (M+H)+: m/z = 389.1; found 389.2.
Example 32
N-(2-chloro-2'-fluoro-3'-methoxybiphenyl-3-yl)-4,5,6,7-tetrahydro[l,3]thiazolo[5,4- c] pyridine-2-carboxamide
Figure imgf000093_0002
Step 1: tert-butyl 2-(3-bromo-2-chlorophenylcarbamoyl)-6, 7-dihydrothiazolo[5,4-c]pyridine- 5( 4H)-carboxylate
Figure imgf000093_0003
This compound was prepared using similar procedures as described for Example 2, Step 1, starting with 3-bromo-2-chloroaniline (206 mg, 0.10 mmol) (AstaTech,
Cat#:CL9068) and 5-tert-butyl 2-ethyl 6,7-dihydro[l,3]thiazolo[5,4-c]pyridine-2,5(4H)- dicarboxylate (312 mg, 0.10 mmol). The crude product was used for next step without further purification. LCMS calculated for CismoBrClNsCbS (M+H)+: m/z = 472.0; found 472.0.
Step 2: N-( 3-bromo-2-chlorophenyl)-4, 5, 6, 7-tetrahydrothiazolo[ 5, 4-c ]pyridine-2- carboxamide
Figure imgf000093_0004
This compound was prepared using similar procedures as described for Example 2, Step 2, starting with tert-butyl 2-(3-bromo-2-chlorophenylcarbamoyl)-6,7- dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate from Step 1. The residue was purified by flash chromatography on a silica gel column eluting with 5% methanol in dichloromethane to afford the desired product (238 mg, 64% over 2 steps). LCMS calculated for
Ci3Hi2BrClN3OS (M+H)+: m/z = 372.0; found 372.0.
Step 3: N-(2-chloro-2'-fluoro-3'-methoxybiphenyl-3-yl)-4, 5, 6, 7-tetrahydro[l, 3]thiazolo[5, 4- c ]pyridine-2-carboxamide
A mixture of N-(3-bromo-2-chlorophenyl)-4,5,6,7-tetrahydro[l,3]thiazolo[5,4- c]pyridine-2-carboxamide (10.0 mg, 0.027 mmol), (2-fluoro-3-methoxyphenyl)boronic acid (5.02 mg, 0.030 mmol), K3P04 (1 1 mg, 0.054 mmol) and
tetrakis(triphenylphosphine)palladium(0) (3.1 mg, 0.0027 mmol) in 1,4-dioxane (0.15 mL) and water (10 μί) was stirred at 100 °C for 1 h. After being cooled to room temperature, the mixture was diluted with methanol, and purified by prep-HPLC (pH = 2,
acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C20H18CIFN3O2S (M+H)+: m/z = 418.1 ; found 418.2.
Example 33
-(2-chlorobiphenyl-3-yl)-4,5,6,7-tetrahydro[l,3]thiazolo[5,4-c]pyridine-2-carboxamide
Figure imgf000094_0001
This compound was prepared using similar procedures as described for Example 32 with phenylboronic acid replacing (2-fluoro-3-methoxyphenyl)boronic acid in Step 3. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C19H17CIN3OS (M+H)+: m/z = 370.1 ; found 370.2.
Example 34
N-[2-chloro-3-(2,3-dihydro-l,4-benzodioxin-6-yl)phenyl]
tetrahydro[l,3]thiazolo[5,4-c
Figure imgf000094_0002
This compound was prepared using similar procedures as described for Example 32 with 2,3-dihydro-l ,4-benzodioxin-6-ylboronic acid replacing (2-fluoro-3- methoxyphenyl)boronic acid in Step 3. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C21H19CIN3O3S (M+H)+: m/z = 428.1 ; found 428.2.
Example 35
N-(2-chloro-3-(l-methyl-lH-indazol-4-yl)phenyl)-4,5,6,7-tetrahydrothiazolo[5,4-
Figure imgf000095_0001
This compound was prepared using similar procedures as described for Example 32 with 1 -methyl- lH-indazole-4-boronic acid (Combi-Blocks; cat#BB-9017) replacing (2- fluoro-3-methoxyphenyl)boronic acid in Step 3. The reaction mixture was purified by prep- HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C21H19CIN5OS (M+H)+: m/z = 424.1 ; found 424.2.
Example 36
N-[3-(2,3-dihydro-l,4-benzodioxin-6-yl)-5-fluoro-2-methylphenyl]-4,5,6,7- tetrahydro[l,3]thiazolo[5,4-c
Figure imgf000095_0002
This compound was prepared using similar procedures as described for Example 20 with 3-bromo-5-fluoro-2-methylaniline (Ark Pharm, Cat#:AK-82467) replacing 3-bromo-2- methylaniline in Step 1. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C22H21FN3O3S (M+H)+: m/z = 426.1 ; found 426.2.
Example 37
N- [2-(2,3-dihydro- l,4-benzodioxin-6-yl)-3-methylpyridin-4-yl] -4,5,6,7- tetrahydro [ 1,3] thiazolo [5,4-c] pyridine-2-carboxamide
Figure imgf000096_0001
This compound was prepared using similar procedures as described for Example 20 with 2-chloro-3-methylpyridin-4-amine (AstaTech, Cat#: 25664) replacing 3-bromo-2- methylaniline in Step 1. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C21H21N4O3S (M+H)+: m/z = 409.1; found 409.2.
Example 38
N- [5-(2,3-dihydro- l,4-benzodioxin-6-yl)-4-methylpyridin-3-yl] -4,5,6,7- tetrahydro [ 1,3] thiazolo [5,4-c
Figure imgf000096_0002
This compound was prepared using similar procedures as described for Example 20 with 5-bromo-4-methylpyridin-3-amine {AstaTech, Cat#: 36169) replacing 3-bromo-2- methylaniline in Step 1. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C21H21N4O3S (M+H)+: m/z = 409.1; found 409.2.
Example 39
N-(2-cyano-2'-fluoro-3'-methoxybiphenyl-3-yl)-l-methyl-4,5,6,7-tetrahyd
imidazo[4,5-c]pyridine-2-car xamide
Figure imgf000096_0003
This compound was prepared using similar procedures as described for Example 12, Step 3 to 4, starting with 5-tert-butyl 2-methyl l-methyl-6,7-dihydro-lH-imidazo[4,5- c]pyridine-2,5(4H)-dicarboxylate from Example 12, Step 2 and 3-amino-2'-fluoro-3'- methoxybiphenyl-2-carbonitrile, prepared using similar procedures for the synthesis of 2- amino-6-(2,3-dihydro-l,4-benzodioxin-6-yl)benzonitrile in Example 1, Step 1. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C22H21FN5O2 (M+H)+: m/z = 406.2; found
406.2.
Example 40
N-(2-cyano-2'-fluoro-3'-methoxybiphenyl-3-yl)-5-(2-hydroxyethyl)-l-methyl-4,5,6,7- tetrahydro- lH-imidazo [4,5-c] pyridine-2-carboxamide
Figure imgf000097_0001
This compound was prepared using similar procedures as described for Example 11, starting with N-(2-cyano-2'-fluoro-3'-methoxybiphenyl-3-yl)-l -methyl-4,5,6,7-tetrahydro- lH-imidazo[4,5-c]pyridine-2-carboxarnide from Example 39. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C24H25FN5O3 (M+H)+: m/z = 450.2; found 450.2.
Example 41
(2-{[(2-cyano-2'-fluoro-3'-methoxybiphenyl-3-yl)amino]carbonyl}-l-methyl-l,4,6,7- tetrahydro-5H-imidazo [4,5-c] ridin-5-yl)acetic acid
Figure imgf000097_0002
This compound was prepared using similar procedures as described for Example 28, starting with N-(2-cyano-2'-fluoro-3'-methoxybiphenyl-3-yl)-l -methyl-4,5,6,7-tetrahydro- lH-imidazo[4,5-c]pyridine-2-carboxarnide from Example 39. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C24H23FN5O4 (M+H)+: m/z = 464.2; found 464.2.
Example 42
N-(2-cyano-3-(l-methyl-lH-indazol-4-yl)phenyl)-l-methyl-4,5,6,7-tetrahyd
imidazo[4,5-c]pyridine-2-carboxamide
Figure imgf000098_0001
This compound was prepared using similar procedures as described for Example 12, Step 3 to 4, starting with 5-tert-butyl 2-methyl l-methyl-6,7-dihydro-lH-imidazo[4,5- c]pyridine-2,5(4H)-dicarboxylate from Example 12, Step 2 and 2-amino-6-(l-methyl-lH- indazol-4-yl)benzonitrile, prepared using similar procedures for the synthesis of 2-amino-6- (2,3-dihydro-l,4-benzodioxin-6-yl)benzonitrile in. Example 1, Step 1. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C23H22N7O (M+H)+: m/z = 412.2; found 412.2. Example A. PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) binding assay
The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 μί. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25° C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His- tag at the C-terminus was purchased from AcroBiosy stems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from
AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and \0 μΐ. was added to the plate well. Plates were centrifuged and proteins were
preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of \0 μΐ. of HTRF detection buffer supplemented with Europium cryptate-labeled anti -human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight®- Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25° C for 60 min. before reading on a PHERAstar FS plate reader
(665nm/620nm ratio). Final concentrations in the assay were - 3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin.ICso determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software. Compounds of the present disclosure, as exemplified in Examples 1-42, showed IC50 values in the following ranges: + = IC50≤ 100 nM; ++ = 100 nM < IC50≤ 500 nM; +++ = 500 nM < IC5o≤ 10000 nM
Data obtained for the Example compounds using the PD-l/PD-Ll homogenous time- resolved fluorescence (HTRF) binding assay described in Example A is provided in Table 1.
Table 1
Figure imgf000099_0001
PD-1/PD-L1 HTRF
Example
ICso (nM)
36 +
37 +++
38 +++
39 +
40 +
41 ++
42 ++
Various modifications of the invention, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference, including without limitation all patent, patent applications, and publications, cited in the present application is incorporated herein by reference in its entirety.

Claims

What is claimed is:
1. A compound of Formula I):
Figure imgf000101_0001
or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
(i) G1 is NR6 and G2 is CR7R7; or
(ii) G1 is CR6R6 and G2 is NR7;
X1 is N or CR1;
X2 is N or CR2;
X3 is N or CR3;
Z is O, S, N, NR4 or CR4;
Y1 and Y2 are each independently N or C, provided Y1 and Y2 are not simultaneously
N;
Cy is Ce-ιο aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R8 substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C3-10 cycloalkyl, C3- 10 cycloalkyl-Ci-4 alkyl-, Ce-ιο aryl, Ce-ιο aryl-Ci-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OR10, Ci-4 haloalkyl, Ci-4 haloalkoxy, NH2, -NHR10, -NR10R10, NHOR10, C(0)R10, C(O)NR10R10, C(0)OR10,
OC(0)R10, OC(O)NR10R10, NR10C(O)R10, NR10C(O)OR10, NR10C(O)NR10R10, C(=NR10)R10, C(=NR10)NR10R10, NR10C(=NR10)NR10R10, NR10S(O)R10, NR10S(O)2R10,
NR10S(O)2NR10R10, S(0)R10, S(O)NR10R10, S(0)2R10, and S(O)2NR10R10, wherein each R10 is independently selected from H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C 1-4 alkoxy, C3-10 cycloalkyl, C3-10 cycloalkyl-Ci-4 alkyl-, Ce-ιο aryl, Ce-ιο aryl-Ci-4 alkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4- 10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, Ci-4 alkoxy, C3-10 cycloalkyl, C3-io cycloalkyl-Ci-4 alkyl-, Ce-ιο aryl, Ce-io aryl-Ci-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R1, R2, R3 and R10 are each optionally substituted with 1, 2 or 3 independently selected Rd substituents;
R4, R5, R6, R7 and R8 are each independently selected from H, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, Ce-ιο aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered
heterocycloalkyl)-Ci-4 alkyl-, CN, NO2, ORa, SRa, NHORa, C(0)Ra, C(0)NRaRa, C(0)ORa, OC(0)Ra, OC(0)NRaRa, NHRa, NRaRa, NRaC(0)Ra, NRaC(0)ORa, NRaC(0)NRaRa, C(=NRa)Ra, C(=NRa)NRaRa, NRaC(=NRa)NRaRa, NRaC (=NOH)NRaRa,
NRaC(=NCN)NRaRa, NRaS(0)Ra, NRaS(0)2Ra, NRaS(0)2NRaRa, S(0)Ra, S(0)NRaRa, S(0)2Ra, and S(0)2NRaRa, wherein the Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-io aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R4, R5, R6, R7 and R8 are each optionally substituted with 1, 2, 3, 4 or 5 Rb substituents;
or two adjacent R8 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
or two R5 substituents attached to the same carbon atom, taken together with the carbon atom to which they are attached, form a C3-6 cycloalkyl ring or 4-, 5-, 6- or 7- membered heterocycloalkyl ring, wherein the C3-6 cycloalkyl ring and 4-, 5-, 6- or 7- membered heterocycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R9 is halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, Ce-ιο aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, NO2, OR11, SR11, NH2, NHR11, NRnRn, NHOR11, C(0)Rn, C(0)NRnRn, C(0)ORn, OC(0)Rn, OC(0)NRnRn, NRnC(0)Rn, NRHC^OR!!^RHC^NRHR11, C(=NR11)R11, C(=NR11)NR11R11, NR11C(=NR11)NR11R11, NR11C(=NOH)NR11R11, NR11C(=NCN)NR11R11, NRnS(0)Rn, NRHS^R11, NRHS^NRHR11, S(0)Rn, S(0)NRnRn, S(0)2Rn, or S^NRHR1 1, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, C6-io aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R9 are each optionally substituted with 1 , 2 or 3 Rb substituents;
each R11 is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-C 1-4 alkyl-, C3-io cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R11 are each optionally substituted with 1 , 2 or 3 Rb substituents;
each Ra is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Ra are each optionally substituted with 1 , 2 or 3 Rd substituents;
each Rb substituent is independently selected from halo, Ci-6 alkyl, Ci-6 haloalkyl, Ci- 6 haloalkoxy, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRcC(=NOH)NRcRc, NRCC(=NCN)NRCRC, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc,
S(0)NRcRc, S(0)2Rc and S(0)2NRcRc; wherein the Ci-e alkyl, Ci-e haloalkyl, Ci-e haloalkoxy, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- 10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-and (4- 10 membered heterocycloalkyl)-Ci-4 alkyl- of Rb are each further optionally substituted with 1-3 independently selected Rd substituents;
each Rc is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rc are each optionally substituted with 1, 2 or 3 Rf substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, halo, CN, NHOR , ORg, SRg, C(0)Rg, C(0)NRgRg, C(0)ORg, OC(0)Rg, OC(0)NRgRg, NHRg, NRgRg, NRgC(0)Rg, NRgC(0)NRgRg, NRgC(0)ORg, C(=NRg)NRgRg, NRgC(=NRg)NRgRg, NRgC(=NOH)NRgRg, NRgC(=NCN)NRgRg, S(0)Rg, S(0)NRgRg, S(0)2Rg, NRgS(0)2Rg, NRgS(0)2NRgRg, and S(0)2NRgRg; wherein the Ci-e alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rf are each optionally substituted with 1, 2 or 3 Rn substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, halo, CN, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, NHOR0, OR0, SR°, C(O)R0, C(O)NR0R°, C(O)OR0, OC(0)R°, OC(0)NR°R°, NHR°, NR°R°, NR0C(O)R°, NR0C(O)NR°R°, NR°C(0)OR°, C(=NR°)NR°R°, NR0C(=NR°)NR°R0, S(O)R0, S(O)NR0R°, S(O)2R0, NR0S(O)2R°,
NR0S(O)2NR0R°, and S(O)2NR0R°, wherein the Ci-e alkyl, Ci-e haloalkyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of Rn is optionally substituted with 1, 2 or 3 Rq substituents;
each Rd is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, halo, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, NH2, NHORe, ORe, SRe, C(0)Re, C(0)NReRe, C(0)ORe, OC(0)Re, OC(0)NReRe, NHRe, NReRe, NReC(0)Re, NReC(0)NReRe, NReC(0)ORe, C(=NRe)NReRe, NReC (=NRe)NReRe, NReC(=NOH)NReRe, NReC(=NCN)NReRe, S(0)Re, S(0)NReRe, S(0)2Re, NReS(0)2Re, NReS(0)2NReRe, and S(0)2NReRe, wherein the Ci-e alkyl, Ci-6 haloalkyl, Ce-ιο aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rd are each optionally substituted with 1-3 independently selected Rf substituents;
each Re is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Re are each optionally substituted with 1, 2 or 3 independently selected Rf substituents;
each R is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-C 1-4 alkyl-, C3-io cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R are each optionally substituted with 1-3 Rp substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10
cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered
heterocycloalkyl)-Ci-4 alkyl-, halo, CN, NHORr, ORr, SRr, C(0)Rr, C(0)NRrRr, C(0)ORr, OC(0)Rr, OC(0)NRrRr, NHRr, NRrRr, NRrC(0)Rr, NRrC(0)NRrRr, NRrC(0)ORr,
C(=NRr)NRrRr, NRrC(=NRr)NRrRr, NRrC(=NOH)NRrRr, NRrC (=NCN)NRrRr, S(0)Rr, S(0)NRrRr, S(0)2Rr, NRrS(0)2Rr, NRrS(0)2NRrRr and S(0)2NRrRr, wherein the Ci-e alkyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10
cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rp are each optionally substituted with 1 , 2 or 3 Rq substituents; or any two Ra substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 Rh substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-7 membered heterocycloalkyl, Ce-ιο aryl, 5-6 membered heteroaryl, Ce-ιο aryl- C1-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-6 membered heteroaryl)-Ci-4 alkyl-, (4-7 membered heterocycloalkyl)-Ci-4 alkyl-, Ci-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, halo, CN, OR1, SR NHOR1, C(0)R C^NR^, 0(0)0^, 00(0)^, 00(0)Ν^^, NHR', NR'R1, NR^C R1, Ν^0(Ο)Ν^^, NR'C C OR1, C^NR NR'R1, NR'C^NR NR'R1,
Ν^(=ΝΟΗ)Ν^, NR'C^NCTvONR'R1, S(0)R S^N^R1, 8(0)Λ\ NR^O^R1, NR^O^NRiR1, and SCO^NR , wherein the Ci-e alkyl, Ci-e haloalkyl, C3-10 cycloalkyl, 4-7 membered heterocycloalkyl, Ce-ιο aryl, 5-6 membered heteroaryl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-6 membered heteroaryl)-C 1-4 alkyl-, (4-7 membered
heterocycloalkyl)-Ci-4 alkyl- of Rh are each optionally substituted by 1, 2, or 3 RJ substituents independently selected from C1-4 alkyl, C3-6 cycloalkyl, Ce-ιο aryl, 5- or 6-membered heteroaryl, 4-6 membered heterocycloalkyl, C2-4 alkenyl, C2-4 alkynyl, halo, Ci-4 haloalkyl, Ci-4haloalkoxy, CN, NHORk, 0Rk, SRk, C(0)Rk, C(0)NRkRk, C(0)ORk, OC(0)Rk,
OC(0)NRkRk, NHRk, NRkRk, NRkC(0)Rk, NRkC(0)NRkRk, NRkC(0)ORk, C(=NRk)NRkRk, NRkC(=NRk)NRkRk, S(0)Rk, S(0)NRkRk, S(0)2Rk, NRkS(0)2Rk, NRkS(0)2NRkRk, and S(0)2NRkRk- wherein the C1-4 alkyl, C3-6 cycloalkyl, Ce-ιο aryl, 5- or 6-membered heteroaryl, 4-6 membered heterocycloalkyl, C2-4 alkenyl, C2-4 alkynyl, Ci-4 haloalkyl, and Ci-4haloalkoxy of Ri are each optionally substituted with 1, 2 or 3 Rq substituents;
or two Rh groups attached to the same carbon atom of the 4- to 10-membered heterocycloalkyl, taken together with the carbon atom to which they are attached, form a C3-6 cycloalkyl or 4- to 6-membered heterocycloalkyl having 1-2 heteroatoms as ring members selected from O, N or S;
each R1 or Rk is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R1 or Rk are each optionally substituted with 1-3 independently selected Rp substituents; or any two Rc substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Re substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R1 substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rk substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R° substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rr substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
each R° or Rr is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, Ce-ιο aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the C1-4 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, Ce-ιο aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C2-4 alkenyl, and C2-4 alkynyl of R° or Rr are each optionally substituted with 1, 2 or 3 Rq substituents;
each Rq is independently selected from OH, CN, -COOH, NH2, halo, C 1-6 haloalkyl, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 haloalkoxy, Ci-6 alkylthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C3-6 cycloalkyl, NHR12 and NR12R12, wherein the Ci-6 alkyl, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl of Rq are each optionally substituted with halo, OH, CN, -COOH, NH2, C1-4 alkoxy, C1-4 haloalkyl, Ci-4 haloalkoxy, phenyl, C3-10 cycloalkyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl and each R12 is independently Ci-6 alkyl; = is a single bond or a double bond to maintain ring A being aromatic; and the subscript n is an integer of 1 , 2, 3 or 4.
2. The compound of claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
(i) G1 is NR6 and G2 is CR7R7; or
(ii) G1 is CR6R6 and G2 is NR7;
X1 is N or CR1;
X2 is N or CR2;
X3 is N or CR3;
Z is O, S, N, NR4 or CR4;
Y1 and Y2 are each independently N or C, provided Y1 and Y2 are not simultaneously
N;
Cy is Ce-ιο aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R8 substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C3-6 cycloalkyl, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OH, Ci-4 alkoxy, Ci-4 haloalkyl, Ci-4 haloalkoxy, NH2, -NH- Ci-4 alkyl, -N(Ci-4 alkyl)2, NHOR10, C(0)R10, C(O)NR10R10, C(0)OR10, OC(0)R10, OC(O)NR10R10, NR10C(O)R10, NR10C(O)OR10, NR10C(O)NR10R10, C(=NR10)R10,
C(=NR10)NR10R10, NR10C(=NR10)NR10R10, NR10S(O)R10, NR10S(O)2R10,
NR10S(O)2NR10R10, S(0)R10, S(O)NR10R10, S(0)2R10, and S(O)2NR10R10, wherein each R10 is independently selected from H and C1-4 alkyl optionally substituted with 1 or 2 groups independently selected from halo, OH, CN and C1-4 alkoxy; and wherein the C1-4 alkyl, C3-6 cycloalkyl, C2-4 alkenyl, C2-4 alkynyl and C1-4 alkoxy of R1, R2 and R3 are each optionally substituted with 1 or 2 substituents independently selected from halo, OH, CN and C1-4 alkoxy;
R4, R5, R6, R7 and R8 are each independently selected from H, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, Ce-ιο aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered
heterocycloalkyl)-Ci-4 alkyl-, CN, N02, ORa, SRa, NHORa, C(0)Ra, C(0)NRaRa, C(0)ORa, OC(0)Ra, OC(0)NRaRa, NHRa, NRaRa, NRaC(0)Ra, NRaC(0)ORa, NRaC(0)NRaRa, C(=NRa)Ra, C(=NRa)NRaRa, NRaC(=NRa)NRaRa, NRaC (=NOH)NRaRa, NRaC(=NCN)NRaRa, NRaS(0)Ra, NRaS(0)2Ra, NRaS(0)2NRaRa, S(0)Ra, S(0)NRaRa, S(0)2Ra, and S(0)2NRaRa, wherein the Ci-e alkyl, C2-e alkenyl, C2-e alkynyl, Ce-io aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R4, R5, R6, R7 and R8 are each optionally substituted with 1 , 2, 3, 4 or 5 Rb substituents;
or two adjacent R8 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
or two R5 substituents attached to the same carbon atom, taken together with the carbon atom to which they are attached, form a C3-6 cycloalkyl ring or 4-, 5-, 6- or 7- membered heterocycloalkyl ring, wherein the C3-6 cycloalkyl ring and 4-, 5-, 6- or 7- membered heterocycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R9 is halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, Ce-ιο aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, N02, OR11, SR.11, NH2, NHR11, NRnRn, NHOR11, C(0)Rn, C(0)NRnRn, C(0)ORn, OC(0)Rn, OC(0)NRnRn, NRnC(0)Rn, NR11C(0)OR11, NR11C(0)NR11R11, C(=NR11)R11, C(=NR11)NR11R11,
NR11C(=NR11)NR11R11, NR11C(=NOH)NR11R11, NR11C(=NCN)NR11R11, NRnS(0)Rn, NRnS(0)2Rn, NR11 S(0)2NR1 Κη, S(0)Rn, S(0)NRnRn, S(0)2Rn, or S(0)2NRnRn, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, C6-io aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-14 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R9 are each optionally substituted with 1 , 2 or 3 Rb substituents;
each R11 is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-C 1-4 alkyl-, C3-io cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R11 are each optionally substituted with 1 , 2 or 3 Rb substituents;
each Ra is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Ra are each optionally substituted with 1 , 2 or 3 Rd substituents;
each Rb substituent is independently selected from halo, Ci-6 alkyl, Ci-6 haloalkyl, Ci- 6 haloalkoxy, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRcC(=NOH)NRcRc, NRCC(=NCN)NRCRC, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRCS(0)2RC, NRCS(0)2NRCRC, S(0)Rc,
S(0)NRcRc, S(0)2Rc and S(0)2NRcRc; wherein the Ci-e alkyl, Ci-e haloalkyl, Ci-e haloalkoxy, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce- 10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-and (4- 10 membered heterocycloalkyl)-Ci-4 alkyl- of Rb are each further optionally substituted with 1-3 independently selected Rd substituents;
each Rc is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rc are each optionally substituted with 1 , 2 or 3 Rf substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered
heterocycloalkyl)-Ci-4 alkyl-, halo, CN, NHOR , ORg, SRg, C(0)Rg, C(0)NRgRg, C(0)ORg, OC(0)Rg, OC(0)NRgRg, NHRg, NRgRg, NRgC(0)Rg, NRgC(0)NRgRg, NRgC(0)ORg, C(=NR )NR R , NR C(=NR )NR R , NR C(=NOH)NR R , NR C (=NCN)NR R , S(0)Rg, S(0)NRgRg, S(0)2Rg, NRgS(0)2Rg, NRgS(0)2NRgRg, and S(0)2NRgRg; wherein the Ci-e alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rf are each optionally substituted with 1 , 2 or 3 Rn substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, halo, CN, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, NHOR0, OR0, SR°, C(O)R0, C(O)NR0R°, C(O)OR0, OC(0)R°, OC(0)NR°R°, NHR°, NR°R°, NR0C(O)R°, NR0C(O)NR°R°, NR°C(0)OR°, C(=NR°)NR°R°, NR0C(=NR°)NR°R0, S(O)R0, S(O)NR0R°, S(O)2R0, NR0S(O)2R°,
NR°S(0)2NR°R°, and S(O)2NR0R°, wherein the Ci-e alkyl, Ci-e haloalkyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of Rn is optionally substituted with 1, 2 or 3 Rq substituents;
each Rd is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, halo, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, NH2, NHORe, ORe, SRe, C(0)Re, C(0)NReRe, C(0)ORe, OC(0)Re, OC(0)NReRe, NHRe, NReRe, NReC(0)Re, NReC(0)NReRe, NReC(0)ORe, C(=NRe)NReRe, NReC (=NRe)NReRe, NReC(=NOH)NReRe, NReC(=NCN)NReRe, S(0)Re, S(0)NReRe, S(0)2Re, NReS(0)2Re, NReS(0)2NReRe, and S(0)2NReRe, wherein the Ci-e alkyl, Ci-6 haloalkyl, Ce-ιο aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rd are each optionally substituted with 1-3 independently selected Rf substituents;
each Re is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Re are each optionally substituted with 1, 2 or 3 independently selected Rf substituents;
each Rg is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-C 1-4 alkyl-, C3-io cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rg are each optionally substituted with 1-3 Rp substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-C 1-4 alkyl-, (4-10 membered heterocycloalkyl)-C 1-4 alkyl-, halo, CN, NHORr, ORr, SRr, C(0)Rr, C(0)NR¾r, C(0)ORr, OC(0)Rr, OC(0)NR¾r, NHRr, NRrRr, NRrC(0)Rr, NRrC(0)NRrRr, NRrC(0)ORr, C(=NRr)NRrRr, NRrC(=NRr)NRrRr, NRrC(=NOH)NRrRr, NRrC(=NCN)NRrRr, S(0)Rr, S(0)NRrRr, S(0)2Rr, NRrS(0)2Rr, NRrS(0)2NRrRr and S(0)2NRrRr, wherein the Ci-e alkyl, Ci-e haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl- and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rp is optionally substituted with 1, 2 or 3 Rq substituents;
or any two Ra substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 Rh substituents independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-7 membered heterocycloalkyl, Ce-ιο aryl, 5-6 membered heteroaryl, C3-10 cycloalkyl-C 1-4 alkyl-, (5-6 membered heteroaryl)-C 1-4 alkyl-, (4-7 membered
heterocycloalkyl)-Ci-4 alkyl-, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, halo, CN, OR1, SR NHOR1, C(0)R C C NR'R1, 0(0)0^, ΟΟ(Ο)^, Ο0(Ο)Ν^^, NHR', NR'R1, NR^C R1, NR'C C NR'R1, NR'C^C OR1, C^NR NR'R1, NR'C^NR NR'R1, Ν^Ο(=ΝΟΗ)Ν^, Ν^Ο(=ΝΟΝ)Ν^^, S(0)R 8(0)Ν^^, 8(0)2^, NR^O^R1, Ν^8(0)2Ν^^, and
S(0)2NR1R1, wherein the Ci-6 alkyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-7 membered heterocycloalkyl, Ce-ιο aryl, 5-6 membered heteroaryl, C3-10 cycloalkyl-Ci-4 alkyl-, (5-6 membered heteroaryl)-Ci-4 alkyl-, (4-7 membered heterocycloalkyl)-Ci-4 alkyl- of Rh are each optionally substituted by 1, 2, or 3 RJ substituents independently selected from Ci-4 alkyl, C3-6 cycloalkyl, Ce-ιο aryl, 5- or 6-membered heteroaryl, C2-4 alkenyl, C2-4 alkynyl, halo, C1-4 haloalkyl, Ci-4haloalkoxy, CN, NHORk, ORk, SRk, C(0)Rk, C(0)NRkRk, C(0)ORk,
OC(0)Rk, OC(0)NRkRk, NHRk, NRkRk, NRkC(0)Rk, NRkC(0)NRkRk, NRkC(0)ORk, C(=NRk)NRkRk, NRkC(=NRk)NRkRk, S(0)Rk, S(0)NRkRk, S(0)2Rk, NRkS(0)2Rk,
NRkS(0)2NRkRk, and S(0)2NRkRk;
or two Rh groups attached to the same carbon atom of the 4- to 10-membered heterocycloalkyl, taken together with the carbon atom to which they are attached, form a C3-6 cycloalkyl or 4- to 6-membered heterocycloalkyl having 1-2 heteroatoms as ring members selected from O, N or S;
or any two Rc substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Re substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R1 substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rk substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R° substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rr substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
each R1, Rk, R° or Rr is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, Ce-ιο aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the C1-4 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, Ce-ιο aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C2-4 alkenyl, and C2-4 alkynyl of R1, Rk, R° or Rr are each optionally substituted with 1, 2 or 3 Rq substituents;
each R¾ is independently selected from OH, CN, -COOH, NH2, halo, Ci-6 haloalkyl, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 haloalkoxy, Ci-6 alkylthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C3-6 cycloalkyl, NHR12 and NR12R12, wherein the Ci-6 alkyl, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl of Rq are each optionally substituted with halo, OH, CN, -COOH, NH2, C1-4 alkoxy, C1-4 haloalkyl, Ci-4 haloalkoxy, phenyl, C3-10 cycloalkyl and 4-6 membered heterocycloalkyl and each R12 is independently Ci-6 alkyl;
= is a single bond or a double bond to maintain ring A being aromatic; and the subscript n is an integer of 1, 2, 3 or 4.
3. The compound of claim 1 having Formula (II):
Figure imgf000114_0001
or a pharmaceutically acceptable salt or a stereoisomer thereof.
4. The compound of claim 1 having Formula (III):
Figure imgf000114_0002
or a pharmaceutically acceptable salt or a stereoisomer thereof.
5. The compound of claim 1, having Formula (IV):
Figure imgf000115_0001
pharmaceutically acceptable salt or a stereoisomer thereof. The compound of claim 1 having Formula (V):
Figure imgf000115_0002
pharmaceutically acceptable salt or a stereoisomer thereof. The compound of claim 1 having Formula (VI):
Figure imgf000115_0003
pharmaceutically acceptable salt or a stereoisomer thereof. The compound of claim 1 having Formula (VII):
Figure imgf000115_0004
harmaceutically acceptable salt or a stereoisomer thereof.
9. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R1, R2 and R3 are each independently selected from H, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OH, Ci-4 alkoxy, Ci-4 haloalkyl, or Ci-4 haloalkoxy.
10. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R1 is H, R2 is H or halo, and R3 is H.
11. The compound of any one of claims 1-10, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein Cy is phenyl, 5- or 6-membered heteroaryl, C3-6 cycloalkyl or
5- or 6-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R8 substituents; or two adj acent R8 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or
6- membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents.
12. The compound of any one of claims 1-10, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein Cy is phenyl, 2-thiophenyl, 3-thiophenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 3,6-dihydro-2H-pyran-4-yl, cyclohexyl, cyclohexenyl, 2,3-dihydro-l ,4- benzodioxin-6-yl, l,3-benzodioxin-5-yl, 2-methylindazol-6-yl or 1 -methylindazol-4-yl, each of which is optionally substituted with 1 to 5 R8 substituents.
13. The compound of any one of claims 1-12, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R9 is halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, CN, NO2, and NH2.
14. The compound of any one of claims 1-12, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R9 is halo, Ci-6 alkyl, or CN.
15. The compound of any one of claims 1-12, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R9 is CH3, CN or halo.
16. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein Z is S, CR4, NR4, or N and R4 is independently H or Ci-6 alkyl
17. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein Z is S, CH, NCH3 or N.
18. The compound of any one of claims 1-17, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein Y1 is C or N and Y2 is C.
19. The compound of any one of claims 1-17, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein Y1 is C and Y2 is N.
20. The com ound of any one of claims 1-15, or a pharmaceutically acceptable salt or a
Figure imgf000117_0001
21. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein (i) Y1 is N, Y2 is C and Z is N; (ii) Y1 is N, Y2 is C and Z is CR4; (iii) Y1 is C, Y2 is N and Z is N; (iv) Y1 is C, Y2 is N and Z is CR4; (v) Y1 is C, Y2 is C and Z is S; or (vi) Y1 is C, Y2 is C and Z is O.
22. The compound of any one of claims 1-21, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R5 is H.
23. The compound of any one of claims 1-22, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein G1 is NR6 and G2 is CR7R7.
24. The compound of any one of claims 1-22, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein G1 is CR6R6 and G2 is NR7.
25. The compound of claims 23 or 24, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R6 is H or Ci-6 alkyl optionally substituted with 1, 2 or 3 Rb substituents.
26. The compound of claims 23 or 24, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R7 is H or Ci-6 alkyl optionally substituted with 1, 2 or 3 Rb substituents.
27. The compound of any one of claims 1-26, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein each Rb substituent is independently selected from halo, Ci-6 alkyl, Ci-e haloalkyl, Ci-e haloalkoxy, CN, OH, NH2, ORc, C(0)Rc, C(0)NRcRc, and C(0)ORc.
28. The compound of any one of claims 1-26, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein each Rb substituent is independently selected from Ci-6 alkyl, CN, OH, and C(0)ORc.
29. The compound of claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
(i) G1 is NR6 and G2 is CR7R7; or
(ii) G1 is CR6R6 and G2 is NR7;
X1 is N or CR1; X2 is N or CR2;
X3 is N or CR3;
Z is O, S, N, NR4 or CR4;
Y1 and Y2 are each independently N or C, provided Y1 and Y2 are not simultaneously
N;
Cy is Ce-ιο aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R8 substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C3-6 cycloalkyl, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OH, Ci-4 alkoxy, Ci-4 haloalkyl, Ci-4 haloalkoxy, NH2, -NH- Ci-4 alkyl, -N(Ci-4 alkyl)2, C(0)R10, C(O)NR10R10, C(0)OR10, OC(0)R10, OC(O)NR10R10, NR10C(O)R10, NR10C(O)OR10, NR10S(O)R10, NR10S(O)2R10, NR10S(O)2NR10R10, S(0)R10, S(O)NR10R10, S(0)2R10, and S(O)2NR10R10, wherein each R10 is independently selected from H and C1-4 alkyl optionally substituted with 1 or 2 groups independently selected from halo, OH, CN and C1-4 alkoxy; and wherein the C1-4 alkyl, C3-6 cycloalkyl, C2-4 alkenyl, C2-4 alkynyl and Ci-4 alkoxy of R1, R2 and R3 are each optionally substituted with 1 or 2 substituents independently selected from halo, OH, CN and C1-4 alkoxy;
R4, R5, R6, R7 and R8 are each independently selected from H, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, Ci-e haloalkoxy, CN, NO2, ORa, SRa, C(0)Ra,
C(0)NRaRa, C(0)ORa, OC(0)Ra, OC(0)NRaRa, NHRa, NRaRa, NRaC(0)Ra, NRaC(0)ORa, NRaS(0)Ra, NRaS(0)2Ra, NRaS(0)2NRaRa, S(0)Ra, S(0)NRaRa, S(0)2Ra, and S(0)2NRaRa, wherein the Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl of R4, R5, R6, R7 and R8 are each optionally substituted with 1, 2, 3, 4 or 5 Rb substituents;
or two adjacent R8 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R9 is halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, CN, NO2, OR11, SR.11, NH2, NHR11, NRnRn, NHOR11, C(0)Rn, C(0)NRnRn, C(0)ORn, OC(0)Rn, OC(0)NRnRn, NRnC(0)Rn, NRnC(0)ORn, NR11C(0)NR11R11, NRnS(0)Rn, NRHSCCXhR11, NRHS^NRHR11, S(0)Rn, S(0)NRnRn, S(0)2Rn, or S^NRHR1 1, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, and Ci-6 haloalkoxy of R9 are each optionally substituted with 1, 2 or 3 Rb substituents;
each R11 is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
each Ra is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
each Rb substituent is independently selected from halo, Ci-6 alkyl, Ci-6 haloalkyl, Ci- e haloalkoxy, CN, OH, NH2, NO2, NHORc, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, NHRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc, S(0)NRcRc, S(0)2Rc and S(0)2NRcRc; wherein the Ci-6 alkyl, Ci-6 haloalkyl, and Ci-6 haloalkoxy of Rb are each further optionally substituted with 1-3 independently selected Rd substituents;
each Rc is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl, wherein the Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl of Rc are each optionally substituted with 1, 2 or 3 Rf substituents independently selected from Ci-6 alkyl, Ci-e haloalkyl, C2-6 alkenyl, C2-6 alkynyl, halo, CN, ORg, SRg, C(0)Rg, C(0)NRgRg, C(0)ORg, OC(0)Rg, OC(0)NRgRg, NHRg, NRgRg, NRgC(0)Rg, NRgC(0)NRgRg,
NRgC(0)ORg, S(0)Rg, S(0)NRgRg, S(0)2Rg, NRgS(0)2Rg, NRgS(0)2NRgRg, and
S(0)2NRgRg;
each Rd is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, halo, CN, NH2, ORe, SRe, C(0)Re, C(0)NReRe, C(0)ORe, OC(0)Re, OC(0)NReRe, NHRe, NReRe, NReC(0)Re, NReC(0)NReRe, NReC(0)ORe, S(0)Re, S(0)NReRe, S(0)2Re, NReS(0)2Re, NReS(0)2NReRe, and S(0)2NReRe;
each Re is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-;
each R is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-;
= is a single bond or a double bond to maintain ring A being aromatic; and the subscript n is an integer of 1 , 2, 3 or 4.
30. The compound of claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
(i) G1 is NR6 and G2 is CR7R7; or
(ii) G1 is CR6R6 and G2 is NR7;
X1 is N or CR1;
X2 is N or CR2;
X3 is N or CR3;
Z is S, N, NR4 or CR4;
Y1 and Y2 are each independently N or C, provided Y1 and Y2 are not simultaneously
N;
Cy is Ce-ιο aryl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R8 substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C3-6 cycloalkyl, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OH, Ci-4 alkoxy, Ci-4 haloalkyl, Ci-4 haloalkoxy, NH2, -NH- Ci-4 alkyl, and -N(Ci-4 alkyl)2;
R4, R5, R6, R7 and R8 are each independently selected from H, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, Ci-e haloalkoxy, CN, NO2, ORa, SRa, C(0)Ra,
C(0)NRaRa, and C(0)ORa, wherein the Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl of R4, R5, R6, R7 and R8 are each optionally substituted with 1, 2, 3, 4 or 5 Rb substituents;
or two adjacent R8 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected Rb substituents;
R9 is halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, CN, NO2, or NH2, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, and Ci-6 haloalkoxy of R9 are each optionally substituted with 1, 2 or 3 Rb substituents;
each Ra is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl; each Rb substituent is independently selected from halo, Ci-6 alkyl, Ci-6 haloalkyl, Ci- 6 haloalkoxy, CN, OH, NH2, N02, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, NHRC, NRCRC, and NRcC(0)Rc; wherein the Ci-6 alkyl, Ci-6 haloalkyl, and Ci-6 haloalkoxy of Rb are each further optionally substituted with 1-3 independently selected Rd substituents;
each Rc is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
each Rd is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, halo, CN, NH2, ORe, SRe, C(0)Re, C(0)NReRe, C(0)ORe, NHRe, NReRe, and NReC(0)Re;
each Re is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
= is a single bond or a double bond to maintain ring A being aromatic; and the subscript n is an integer of 1 or 2.
31. The compound of claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
(i) G1 is NR6 and G2 is CR7R7; or
(ii) G1 is CR6R6 and G2 is NR7;
X1 is N or CR1;
X2 is N or CR2;
X3 is N or CR3;
Z is S, N, NR4 or CR4;
Y1 and Y2 are each independently N or C, provided Y1 and Y2 are not simultaneously
N;
Cy is phenyl, C3-10 cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each of which is optionally substituted with 1 to 5 independently selected R8 substituents;
R1, R2 and R3 are each independently selected from H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, halo, CN, OH, C1-4 alkoxy, C1-4 haloalkyl, or C 1-4 haloalkoxy;
R4, R5, R6, R7 and R8 are each independently selected from H, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, Ci-e haloalkoxy, CN, NO2, ORa, and C(0)ORa, wherein the Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl of R4, R5, R6, R7 and R8 are each optionally substituted with 1 or 2 Rb substituents;
or two adjacent R8 substituents on the Cy ring, taken together with the atoms to which they are attached, form a fused 5-, 6- or 7-membered heterocycloalkyl ring, or a fused 5- or 6-membered heteroaryl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring are each optionally substituted with 1 or 2 independently selected Rb substituents;
R9 is halo, Ci-e alkyl, or CN;
each Ra is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
each Rb substituent is independently selected from halo, Ci-6 alkyl, Ci-6 haloalkyl, Ci- e haloalkoxy, CN, OH, NH2, ORc, C(0)Rc, C(0)NRcRc, and C(0)ORc;
each Rc is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
= is a single bond or a double bond to maintain ring A being aromatic; and the subscript n is an integer of 1 or 2.
32. The compound of claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein the compound is selected from:
N-[2-cyano-3-(2,3-dihydro-l,4-benzodioxin-6-yl)phenyl]-4,5,6,7- tetrahydro[l,3]thiazolo[5,4-c]pyridine-2-carboxamide;
N-(2-cyanobiphenyl-3-yl)-4,5,6,7-tetrahydro[l,3]thiazolo[5,4-c]pyridine-2- carboxamide;
N-[2-cyano-3-(l-methyl-lH-indazol-4-yl)phenyl]-4,5,6,7- tetrahydro[l,3]thiazolo[5,4-c]pyridine-2-carboxamide;
N-(2-cyano-2'-fluorobiphenyl-3-yl)-4,5,6,7-tetrahydro[l,3]thiazolo[5,4-c]pyridine-2- carboxamide;
N-(2-cyano-2'-fluoro-3'-methoxybiphenyl-3-yl)-4,5,6,7-tetrahydro[l,3]thiazolo[5,4- c]pyridine-2-carboxamide;
N-[2-cyano-3-(2,3-dihydro-l-benzofuran-6-yl)phenyl]-4,5,6,7- tetrahydro[l,3]thiazolo[5,4-c]pyridine-2-carboxamide;
N-(2-cyano-3-cyclohex-l-en-l-ylphenyl)-4,5,6,7-tetrahydro[l,3]thiazolo[5,4- c]pyridine-2-carboxamide;
N-(2-cyano-3-cyclohexylphenyl)-4,5,6,7-tetrahydro[l,3]thiazolo[5,4-c]pyridine-2- carboxamide; N-(2-cyano-2',6'-difluorobiphenyl-3-yl)-4,5,6,7-tetrahydro[l,3]thiazolo[5,4- c]pyridine-2-carboxamide;
N-[2-cyano-3-(2,3-dihydro-l,4-benzodioxin-6-yl)phenyl]-4,5,6,7- tetrahydropyrazolo[l,5-a]pyrazine-2-carboxamide;
N-[2-cyano-3-(2,3-dihydro-l,4-benzodioxin-6-yl)phenyl]-5-(2 -hydroxy ethyl)-4,5,6,7- tetrahydropyrazolo[l,5-a]pyrazine-2-carboxamide;
N-[2-cyano-3-(2,3-dihydro-l,4-benzodioxin-6-yl)phenyl]-l-methyl-4,5,6,7- tetrahydro-lH-imidazo[4,5-c]pyridine-2-carboxamide;
N-(2-cyano-3-(2,3-dihydrobenzo[b][l,4]dioxin-6-yl)phenyl)-5-(2 -hydroxy ethyl)-l - methyl-4,5,6 -tetrahydro-lH-imidazo[4,5-c]pyridine-2-carboxamide;
N-[2-cyano-3-(2,3-dihydro-l,4-benzodioxin-6-yl)phenyl]-5,6,7,8- tetrahydro[l,2,4]triazolo[l,5-a]pyrazine-2-carboxamide;
N-(2,3'-dicyano-2'-fluorobiphenyl-3-yl)-4,5,6,7-tetrahydro[l,3]thiazolo[5,4- c]pyridine-2-carboxamide;
N-(2-cyano-3'-methoxybiphenyl-3-yl)-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2- carboxamide;
N-(2-cyano-3'-fluoro-5'-methoxybiphenyl-3-yl)-4,5,6,7-tetrahydro[l,3]thiazolo[5,4- c]pyridine-2-carboxamide;
N-(2'-chloro-2-cyanobiphenyl-3-yl)-4,5,6,7-tetrahydro[l,3]thiazolo[5,4-c]pyridine-2- carboxamide;
N-(2-cyano-2'-fluoro-3'-methoxybiphenyl-3-yl)-5,6 ,8-tetrahydroimidazo[l,2- a]pyrazine-2-carboxamide;
N-[3-(2,3-dihydro-l,4-benzodioxin-6-yl)-2-methylphenyl]-4,5,6,7- tetrahydro[l,3]thiazolo[5,4-c]pyridine-2-carboxamide;
N-(2'-fluoro-3'-methoxy-2-methylbiphenyl-3-yl)-4,5,6,7-tetrahydro[l,3]thiazolo[5,4- c]pyridine-2-carboxamide;
N-(2'-fluoro-3'-methoxy-2-methylbiphenyl-3-yl)-l-methyl-4,5,6,7-tetrahydro-lH- imidazo[4,5-c]pyridine-2-carboxamide;
N-[2-methyl-3-(l-methyl-lH-indazol-4-yl)phenyl]-4,5,6,7- tetrahydro[l,3]thiazolo[5,4-c]pyridine-2-carboxamide;
N-[2'-fluoro-3'-(hydroxymethyl)-2-methylbiphenyl-3-yl]-4,5,6,7- tetrahydro[l,3]thiazolo[5,4-c]pyridine-2-carboxamide;
N-[3-(lH-indazol-4-yl)-2-methylphenyl]-4,5,6,7-tetrahydro[l,3]thiazolo[5,4- c]pyridine-2-carboxamide;
N-(2-methylbiphenyl-3-yl)-4,5,6,7-tetrahydro[l,3]thiazolo[5,4-c]pyridine-2- carboxamide;
5-(2-hydroxyethyl)-N-(2-methylbiphenyl-3-yl)-4,5,6,7-tetrahydrothiazolo[5,4- c]pyridine-2-carboxamide;
2-(2-(2-methylbiphenyl-3-ylcarbamoyl)-6,7-dihydrothiazolo[5,4-c]pyridin-5(4H)- yl)acetic acid;
N-[2-methyl-3-(2-methyl-2H-indazol-6-yl)phenyl]-4,5,6,7- tetrahydro[l,3]thiazolo[5,4-c]pyridine-2-carboxamide;
N-(2'-cyano-2-methylbiphenyl-3-yl)-4,5,6,7-tetrahydro[l,3]thiazolo[5,4-c]pyridine-2- carboxamide;
N-[2'-(cyanomethyl)-2-methylbiphenyl-3-yl]-4,5,6,7-tetrahydro[l,3]thiazolo[5,4- c]pyridine-2-carboxamide;
N-(2-chloro-2'-fluoro-3'-methoxybiphenyl-3-yl)-4,5,6,7-tetrahydro[l,3]thiazolo[5,4- c]pyridine-2-carboxamide;
N-(2-chlorobiphenyl-3-yl)-4,5,6,7-tetrahydro[l,3]thiazolo[5,4-c]pyridine-2- carboxamide;
N-[2-chloro-3-(2,3-dihydro-l,4-benzodioxin-6-yl)phenyl]-4,5,6,7- tetrahydro[l,3]thiazolo[5,4-c]pyridine-2-carboxamide;
N-(2-chloro-3-(l-methyl-lH-indazol-4-yl)phenyl)-4,5,6,7-tetrahydrothiazolo[5,4- c]pyridine-2-carboxamide;
N- [3 -(2,3 -dihy dro- 1 ,4-benzodioxin-6-y l)-5-fluoro-2-methy lpheny 1] -4,5 , 6,7- tetrahydro[l,3]thiazolo[5,4-c]pyridine-2-carboxamide;
N-[2-(2,3-dihydro-l,4-benzodioxin-6-yl)-3-methylpyridin-4-yl]-4,5,6,7- tetrahydro[l,3]thiazolo[5,4-c]pyridine-2-carboxamide;
N-[5-(2,3-dihydro-l,4-benzodioxin-6-yl)-4-methylpyridin-3-yl]-4,5,6,7- tetrahydro[l,3]thiazolo[5,4-c]pyridine-2-carboxamide;
N-(2-cyano-2'-fluoro-3'-methoxybiphenyl-3-yl)-l-methyl-4,5,6,7-tetrahydro-lH- imidazo[4,5-c]pyridine-2-carboxamide;
N-(2-cyano-2'-fluoro-3'-methoxybiphenyl-3-yl)-5-(2 -hydroxy ethyl)-l-methyl-4,5,6,7- tetrahydro-lH-imidazo[4,5-c]pyridine-2-carboxamide;
(2-{[(2-cyano-2'-fluoro-3'-methoxybiphenyl-3-yl)amino]carbonyl}-l-methyl-l,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)acetic acid; and N-(2-cyano-3-(l-methyl-lH-indazol-4-yl)phenyl)-l-methyl-4,5,6,7-tetrahydro-lH- imidazo[4,5-c]pyridine-2-carboxamide.
33. A pharmaceutical composition comprising a compound of any one of claims 1-32, or a pharmaceutically acceptable salt or a stereoisomer thereof, and at least one
pharmaceutically acceptable carrier or excipient.
34. A method of inhibiting PD-1/PD-L1 interaction, said method comprising administering to a patient a compound of any one of claims 1-32, or a pharmaceutically acceptable salt or a stereoisomer thereof.
35. A method of treating a disease or disorder associated with inhibition of PD-1/PD-L1 interaction, said method comprising administering to a patient in need thereof a
therapeutically effective amount of a compound of any one of claims 1-32, or a
pharmaceutically acceptable salt or a stereoisomer thereof.
36. A method of enhancing, stimulating and/or increasing the immune response in a patient, said method comprising administering to the patient in need thereof a therapeutically effective amount of a compound of any one of claims 1-32, or a pharmaceutically acceptable salt or a stereoisomer thereof.
PCT/US2017/038120 2016-06-19 2017-06-19 Heterocyclic compounds as immunomodulators WO2017222976A1 (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
MA45392A MA45392B1 (en) 2016-06-20 2017-06-19 Heterocyclic compounds used as immunomodulators
SG11201811414TA SG11201811414TA (en) 2016-06-20 2017-06-19 Heterocyclic compounds as immunomodulators
DK17734589.9T DK3472167T3 (en) 2016-06-20 2017-06-19 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
CN201780049752.9A CN109890819B (en) 2016-06-20 2017-06-19 Heterocyclic compounds as immunomodulators
JP2018566514A JP7000357B2 (en) 2016-06-20 2017-06-19 Heterocyclic compounds as immunomodulators
EA201990074A EA201990074A1 (en) 2016-09-19 2017-06-19 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
PL17734589.9T PL3472167T3 (en) 2016-06-20 2017-06-19 Heterocyclic compounds as immunomodulators
SI201731245T SI3472167T1 (en) 2016-06-20 2017-06-19 Heterocyclic compounds as immunomodulators
AU2017281285A AU2017281285C1 (en) 2016-06-20 2017-06-19 Heterocyclic compounds as immunomodulators
EP22184212.3A EP4137489A1 (en) 2016-06-20 2017-06-19 Heterocyclic compounds as immunomodulators
BR112018076534-1A BR112018076534A2 (en) 2016-06-20 2017-06-19 heterocyclic compounds as immunomodulators
UAA201900525A UA125391C2 (en) 2016-06-20 2017-06-19 Heterocyclic compounds as immunomodulators
EP17734589.9A EP3472167B1 (en) 2016-06-20 2017-06-19 Heterocyclic compounds as immunomodulators
HRP20221030TT HRP20221030T1 (en) 2016-06-20 2017-06-19 Heterocyclic compounds as immunomodulators
MYPI2018002678A MY197280A (en) 2016-06-20 2017-06-19 Heterocyclic compounds as immunomodulators
CR20190028A CR20190028A (en) 2016-06-19 2017-06-19 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
RS20220907A RS63673B1 (en) 2016-06-20 2017-06-19 Heterocyclic compounds as immunomodulators
MX2018016273A MX2018016273A (en) 2016-06-20 2017-06-19 Heterocyclic compounds as immunomodulators.
ES17734589T ES2927984T3 (en) 2016-06-20 2017-06-19 Heterocyclic compounds as immunomodulators
LTEPPCT/US2017/038120T LT3472167T (en) 2016-06-20 2017-06-19 Heterocyclic compounds as immunomodulators
CA3028685A CA3028685A1 (en) 2016-06-20 2017-06-19 Heterocyclic compounds as immunomodulators
KR1020197001807A KR102685249B1 (en) 2016-06-20 2017-06-19 Heterocyclic Compounds as Immunomodulators
IL263825A IL263825B (en) 2016-06-20 2017-06-19 Heterocyclic compounds as immunomodulators
MDE20190506T MD3472167T2 (en) 2016-06-20 2017-06-19 Heterocyclic compounds as immunomodulators
PH12018502710A PH12018502710A1 (en) 2016-06-20 2018-12-20 Heterocyclic compounds as immunomodulators
CONC2019/0000386A CO2019000386A2 (en) 2016-06-20 2019-01-15 Heterocyclic compounds as immunomodulators
AU2021250978A AU2021250978B2 (en) 2016-06-20 2021-10-15 Heterocyclic compounds as immunomodulators
JP2021209731A JP7394824B2 (en) 2016-06-20 2021-12-23 Heterocyclic compounds as immunomodulators

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662352485P 2016-06-20 2016-06-20
US62/352,485 2016-06-20
US201662396353P 2016-09-19 2016-09-19
US62/396,353 2016-09-19

Publications (1)

Publication Number Publication Date
WO2017222976A1 true WO2017222976A1 (en) 2017-12-28

Family

ID=59258383

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/038120 WO2017222976A1 (en) 2016-06-19 2017-06-19 Heterocyclic compounds as immunomodulators

Country Status (30)

Country Link
US (4) US20170362253A1 (en)
EP (2) EP4137489A1 (en)
JP (2) JP7000357B2 (en)
KR (1) KR102685249B1 (en)
CN (1) CN109890819B (en)
AU (2) AU2017281285C1 (en)
BR (1) BR112018076534A2 (en)
CA (1) CA3028685A1 (en)
CL (1) CL2018003701A1 (en)
CO (1) CO2019000386A2 (en)
DK (1) DK3472167T3 (en)
EC (1) ECSP19003773A (en)
ES (1) ES2927984T3 (en)
HR (1) HRP20221030T1 (en)
HU (1) HUE060256T2 (en)
IL (1) IL263825B (en)
LT (1) LT3472167T (en)
MD (1) MD3472167T2 (en)
MX (2) MX2018016273A (en)
MY (1) MY197280A (en)
PE (1) PE20190731A1 (en)
PH (1) PH12018502710A1 (en)
PL (1) PL3472167T3 (en)
PT (1) PT3472167T (en)
RS (1) RS63673B1 (en)
SG (2) SG10202012828TA (en)
SI (1) SI3472167T1 (en)
TW (1) TWI771305B (en)
UA (1) UA125391C2 (en)
WO (1) WO2017222976A1 (en)

Cited By (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119224A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
WO2018195321A1 (en) 2017-04-20 2018-10-25 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019032547A1 (en) 2017-08-08 2019-02-14 Chemocentryx, Inc. Macrocyclic immunomodulators
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2019149183A1 (en) * 2018-02-05 2019-08-08 上海和誉生物医药科技有限公司 Biaryl derivative, preparation method thereof and pharmaceutical application thereof
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019165374A1 (en) 2018-02-26 2019-08-29 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
WO2019165043A2 (en) 2018-02-22 2019-08-29 Chemocentryx, Inc. Indane-amines as pd-l1 antagonists
WO2019193533A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'2'-cyclic dinucleotides
WO2019193542A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides
WO2019193543A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
WO2019200247A1 (en) 2018-04-12 2019-10-17 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
WO2019204609A1 (en) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
WO2019217821A1 (en) * 2018-05-11 2019-11-14 Incyte Corporation Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
WO2020014643A1 (en) 2018-07-13 2020-01-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
WO2020092621A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
WO2020088357A1 (en) 2018-11-02 2020-05-07 上海再极医药科技有限公司 Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof
US10662416B2 (en) 2016-10-14 2020-05-26 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome
US10669271B2 (en) 2018-03-30 2020-06-02 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2020156564A1 (en) * 2019-02-02 2020-08-06 南京明德新药研发有限公司 Vinylpyridine carboxamide compound as pd-l1 immunomodulator
WO2020178770A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020178769A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
WO2020192570A1 (en) 2019-03-22 2020-10-01 上海再极医药科技有限公司 Small-molecule inhibitor of pd-1/pd-l1, pharmaceutical composition thereof with pd-l1 antibody, and application of same
US10793565B2 (en) 2016-12-22 2020-10-06 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2020214652A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2020214663A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2021007386A1 (en) 2019-07-10 2021-01-14 Chemocentryx, Inc. Indanes as pd-l1 inhibitors
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
US10919852B2 (en) 2017-07-28 2021-02-16 Chemocentryx, Inc. Immunomodulator compounds
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2021067181A1 (en) 2019-09-30 2021-04-08 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
WO2021138512A1 (en) 2020-01-03 2021-07-08 Incyte Corporation Combination therapy comprising a2a/a2b and pd-1/pd-l1 inhibitors
WO2021136354A1 (en) 2020-01-03 2021-07-08 上海翰森生物医药科技有限公司 Biphenyl derivative inhibitor, preparation method therefor and use thereof
WO2021147940A1 (en) * 2020-01-21 2021-07-29 上海华汇拓医药科技有限公司 Pd-1/pd-l1 inhibitor, preparation method therefor, and use thereof
JP2021520342A (en) * 2018-04-03 2021-08-19 ベータ ファーマシューティカルズ カンパニー リミテッド Immunomodulators, compositions and methods thereof
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
WO2021226206A2 (en) 2020-05-05 2021-11-11 Teon Therapeutics, Inc. Cannabinoid receptor type 2 (cb2) modulators and uses thereof
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
US11266643B2 (en) 2019-05-15 2022-03-08 Chemocentryx, Inc. Triaryl compounds for treatment of PD-L1 diseases
WO2022052926A1 (en) 2020-09-09 2022-03-17 广州再极医药科技有限公司 Aromatic ethylene compound and preparation method therefor, and intermediate, pharmaceutical composition, and application thereof
RU2768830C9 (en) * 2018-02-05 2022-06-17 Aббиско Тхерaпеутицс Цо., Лтд. Biaryl derivative, method for production thereof and pharmaceutical application thereof
WO2022147092A1 (en) 2020-12-29 2022-07-07 Incyte Corporation Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
US11401279B2 (en) 2019-09-30 2022-08-02 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
US11407749B2 (en) 2015-10-19 2022-08-09 Incyte Corporation Heterocyclic compounds as immunomodulators
US11426364B2 (en) 2016-06-27 2022-08-30 Chemocentryx, Inc. Immunomodulator compounds
US11465981B2 (en) 2016-12-22 2022-10-11 Incyte Corporation Heterocyclic compounds as immunomodulators
US11485708B2 (en) 2019-06-20 2022-11-01 Chemocentryx, Inc. Compounds for treatment of PD-L1 diseases
WO2022241134A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
WO2022261301A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
WO2022261310A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
US11535615B2 (en) 2015-12-22 2022-12-27 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11572366B2 (en) 2015-11-19 2023-02-07 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2023034530A1 (en) 2021-09-02 2023-03-09 Teon Therapeutics, Inc. Methods of improving growth and function of immune cells
US11608337B2 (en) 2016-05-06 2023-03-21 Incyte Corporation Heterocyclic compounds as immunomodulators
US11613536B2 (en) 2016-08-29 2023-03-28 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2023081730A1 (en) 2021-11-03 2023-05-11 Teon Therapeutics, Inc. 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
WO2023097211A1 (en) 2021-11-24 2023-06-01 The University Of Southern California Methods for enhancing immune checkpoint inhibitor therapy
US11673883B2 (en) 2016-05-26 2023-06-13 Incyte Corporation Heterocyclic compounds as immunomodulators
US11673894B2 (en) 2018-02-27 2023-06-13 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
US11713307B2 (en) 2019-10-16 2023-08-01 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
US11718605B2 (en) 2016-07-14 2023-08-08 Incyte Corporation Heterocyclic compounds as immunomodulators
US11753406B2 (en) 2019-08-09 2023-09-12 Incyte Corporation Salts of a PD-1/PD-L1 inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
US11866451B2 (en) 2019-11-11 2024-01-09 Incyte Corporation Salts and crystalline forms of a PD-1/PD-L1 inhibitor
US11866434B2 (en) 2020-11-06 2024-01-09 Incyte Corporation Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
US11866429B2 (en) 2019-10-16 2024-01-09 Chemocentryx, Inc. Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases
US11873304B2 (en) 2018-05-18 2024-01-16 Incyte Corporation Fused pyrimidine derivatives as A2A/A2B inhibitors
US11873309B2 (en) 2016-06-20 2024-01-16 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2024015372A1 (en) 2022-07-14 2024-01-18 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
US11884665B2 (en) 2019-01-29 2024-01-30 Incyte Corporation Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors
US11999740B2 (en) 2018-07-05 2024-06-04 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
DK2861595T5 (en) 2012-06-13 2018-01-15 Incyte Holdings Corp Substituted tricyclic compounds as FGFR inhibitors
KR102269032B1 (en) 2013-04-19 2021-06-24 인사이트 홀딩스 코포레이션 Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
EA038045B1 (en) 2015-02-20 2021-06-28 Инсайт Корпорейшн Bicyclic heterocycles as fgfr inhibitors
WO2018200571A1 (en) 2017-04-25 2018-11-01 Arbutus Biopharma Corporation Substituted 2,3-dihydro-1h-indene analogs and methods using same
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
WO2019098682A1 (en) 2017-11-14 2019-05-23 앱클론(주) Anti-her2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CA3093851A1 (en) 2018-03-29 2019-10-03 Arbutus Biopharma Corporation Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same
MX2020011718A (en) 2018-05-04 2021-02-15 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same.
PE20210919A1 (en) 2018-05-04 2021-05-19 Incyte Corp SALTS FROM A FGFR INHIBITOR
TW202017569A (en) 2018-05-31 2020-05-16 美商佩樂敦治療公司 Compositions and methods for inhibiting cd73
US11111247B2 (en) 2018-09-25 2021-09-07 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
MX2021007426A (en) 2018-12-20 2021-09-08 Incyte Corp Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2.
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
AU2020221293A1 (en) 2019-02-15 2021-09-02 Incyte Corporation Cyclin-dependent kinase 2 biomarkers and uses thereof
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20220064369A (en) 2019-08-14 2022-05-18 인사이트 코포레이션 Imidazolyl Pyridimidinylamine Compounds as CDK2 Inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
JOP20220083A1 (en) 2019-10-14 2023-01-30 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021093817A1 (en) * 2019-11-15 2021-05-20 杭州和正医药有限公司 Immunomodulatory compounds, composition and application thereof
MX2022006691A (en) 2019-12-04 2022-09-19 Incyte Corp Derivatives of an fgfr inhibitor.
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN110950886A (en) * 2019-12-13 2020-04-03 苏州莱克施德药业有限公司 Method for synthesizing 1-methyl-imidazole-2-methyl formate derivative
TW202126653A (en) * 2020-01-07 2021-07-16 大陸商上海和譽生物醫藥科技有限公司 Biphenyl fluorine double bond derivative, preparation method therefor, and pharmaceutical application thereof
AU2021206240A1 (en) 2020-01-10 2022-08-25 Incyte Corporation Tricyclic compounds as inhibitors of KRAS
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021150613A1 (en) 2020-01-20 2021-07-29 Incyte Corporation Spiro compounds as inhibitors of kras
WO2021158891A1 (en) 2020-02-06 2021-08-12 Incyte Corporation Salts and solid forms and processes of preparing a pi3k inhibitor
CN115697343A (en) 2020-03-06 2023-02-03 因赛特公司 Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
CN115702025A (en) 2020-04-16 2023-02-14 因赛特公司 Fused tricyclic KRAS inhibitors
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
CN115956081A (en) 2020-06-12 2023-04-11 因赛特公司 Imidazopyridazine compounds having activity as ALK2 inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
TW202216713A (en) 2020-07-02 2022-05-01 美商英塞特公司 Tricyclic urea compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11999752B2 (en) 2020-08-28 2024-06-04 Incyte Corporation Vinyl imidazole compounds as inhibitors of KRAS
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
EP4298099A1 (en) 2021-02-25 2024-01-03 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
WO2022204112A1 (en) 2021-03-22 2022-09-29 Incyte Corporation Imidazole and triazole kras inhibitors
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
EP4352060A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
JP2024522189A (en) 2021-06-09 2024-06-11 インサイト・コーポレイション Tricyclic Heterocycles as FGFR Inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
EP4367117A1 (en) 2021-07-07 2024-05-15 Incyte Corporation Tricyclic compounds as inhibitors of kras
CA3224841A1 (en) 2021-07-14 2023-01-19 Zhenwu Li Tricyclic compounds as inhibitors of kras
JP2024534187A (en) 2021-08-31 2024-09-18 インサイト・コーポレイション Naphthyridine Compounds as Inhibitors of KRAS - Patent application
US12030883B2 (en) 2021-09-21 2024-07-09 Incyte Corporation Hetero-tricyclic compounds as inhibitors of KRAS
US12030884B2 (en) 2021-10-01 2024-07-09 Incyte Corporation Pyrazoloquinoline KRAS inhibitors
AU2022367432A1 (en) 2021-10-14 2024-05-02 Incyte Corporation Quinoline compounds as inhibitors of kras
WO2023091746A1 (en) 2021-11-22 2023-05-25 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a kras inhibitor
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
EP4452982A1 (en) 2021-12-22 2024-10-30 Incyte Corporation Salts and solid forms of an fgfr inhibitor and processes of preparing thereof
WO2023178285A1 (en) 2022-03-17 2023-09-21 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US20230399342A1 (en) 2022-06-08 2023-12-14 Incyte Corporation Tricyclic triazolo compounds as dgk inhibitors
WO2024015731A1 (en) 2022-07-11 2024-01-18 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants
TW202416968A (en) 2022-10-21 2024-05-01 美商英塞特公司 Tricyclic urea compounds as jak2 v617f inhibitors
US20240217989A1 (en) 2022-11-18 2024-07-04 Incyte Corporation Heteroaryl Fluoroalkenes As DGK Inhibitors
TW202428575A (en) 2023-01-12 2024-07-16 美商英塞特公司 Heteroaryl fluoroalkenes as dgk inhibitors
WO2024191996A1 (en) 2023-03-13 2024-09-19 Incyte Corporation Bicyclic ureas as kinase inhibitors
WO2024220532A1 (en) 2023-04-18 2024-10-24 Incyte Corporation Pyrrolidine kras inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000196A2 (en) 2000-06-28 2002-01-03 Smithkline Beecham P.L.C. Wet milling process
WO2009039397A2 (en) * 2007-09-20 2009-03-26 Cgi Pharmaceuticals, Inc. Substituted amides, methods of making, use thereof for the treatment of diseases such as cancer
WO2013157021A1 (en) * 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof

Family Cites Families (356)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3272781A (en) 1963-08-07 1966-09-13 American Potash & Chem Corp Boroureas of phosphinoborine polymers
FR1425700A (en) 1965-02-22 1966-01-24 Basf Ag Compounds forming metal complexes and method of preparing and using them
US4208328A (en) 1978-04-27 1980-06-17 General Electric Company Alkyl 3,5-dihydroxy-4-(2-benzothiazolyl)benzoates
US4789711A (en) 1986-12-02 1988-12-06 Ciba-Geigy Corporation Multifunctional epoxide resins
DE3828535A1 (en) 1988-08-23 1990-03-08 Basf Ag BENZIMIDAZOLE-2-CARBON-ACIDANILIDE, THEIR USE AS ANTI-LIGHTING AGENT FOR ORGANIC MATERIAL AND ORGANIC MATERIAL STABILIZED THEREOF
US5077164A (en) 1989-06-21 1991-12-31 Minolta Camera Kabushiki Kaisha Photosensitive member containing an azo dye
EP0644460B1 (en) 1993-09-20 1999-12-08 Fuji Photo Film Co., Ltd. Positive working photoresist composition
JP3461397B2 (en) 1995-01-11 2003-10-27 富士写真フイルム株式会社 Positive photoresist composition
EP0946587A2 (en) 1996-12-16 1999-10-06 Fujisawa Pharmaceutical Co., Ltd. New amide compounds
JPH10316853A (en) 1997-05-15 1998-12-02 Sumitomo Bakelite Co Ltd Resin composition for interlaminar insulating membrane for multilayer interconnection of semiconductor, and production of the insulating membrane
WO1999018096A1 (en) 1997-10-02 1999-04-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU2745899A (en) 1998-03-05 1999-09-20 Nissan Chemical Industries Ltd. Anilide compounds and herbicide
JP2000128987A (en) 1998-10-28 2000-05-09 Sumitomo Bakelite Co Ltd Polybenzoxazole precursor and polybenzoxazole
JP2000128984A (en) 1998-10-28 2000-05-09 Sumitomo Bakelite Co Ltd Polybenzoxazole precursor and resin
JP2000128986A (en) 1998-10-28 2000-05-09 Sumitomo Bakelite Co Ltd Polybenzoxazole precursor and polybenzoxazole
US6297351B1 (en) 1998-12-17 2001-10-02 Sumitomo Bakelite Company Limited Polybenzoxazole resin and precursor thereof
UA70976C2 (en) 1998-12-18 2004-11-15 Аксіз Фармасьютікелз, Інк. (hetero)arylbicyclic and heteroaryl derivatives, preparation thereof and application as proteases inhibitors
JP2000212281A (en) 1999-01-27 2000-08-02 Sumitomo Bakelite Co Ltd Polybenzoxazole precursor and polybenzoxazole resin
WO2001007409A1 (en) 1999-07-23 2001-02-01 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
JP2001114893A (en) 1999-10-15 2001-04-24 Sumitomo Bakelite Co Ltd Polybenzoxazole resin and its precursor
US6372907B1 (en) 1999-11-03 2002-04-16 Apptera Corporation Water-soluble rhodamine dye peptide conjugates
JP2001163975A (en) 1999-12-03 2001-06-19 Sumitomo Bakelite Co Ltd Polybenzoxazole resin and its precursor
CN1167680C (en) 1999-12-27 2004-09-22 日本烟草产业株式会社 Fused-ring compounds and use thereof as drugs
DE50112961D1 (en) 2000-02-01 2007-10-18 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as PARP inhibitors
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
AU2001249679A1 (en) 2000-03-31 2001-10-15 Ortho-Mcneil Pharmaceutical, Inc. Phenyl-substituted imidazopyridines
CA2405170A1 (en) 2000-04-24 2001-11-01 Merck Frosst Canada & Co. Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
WO2002014321A1 (en) 2000-08-11 2002-02-21 The Regents Of The University Of California Use of stat-6 inhibitors as therapeutic agents
AU2002224927A1 (en) 2000-12-13 2002-06-24 Basf Aktiengesellschaft Use of substituted imidazoazines, novel imidazoazines, methods for the production thereof, and agents containing these compounds
EP1341788B1 (en) 2000-12-15 2005-08-10 Glaxo Group Limited Pyrazolopyridines
SE0100567D0 (en) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
CA2438586A1 (en) 2001-03-14 2002-09-19 Eli Lilly And Company Retinoid x receptor modulators
JP4237497B2 (en) 2001-03-30 2009-03-11 スミスクライン ビーチャム コーポレーション Pyrazolopyridines, their preparation and their use as therapeutic compounds
EP1377575B1 (en) 2001-04-10 2006-07-05 SmithKline Beecham Corporation Antiviral pyrazolopyridine compounds
JP2002316966A (en) 2001-04-19 2002-10-31 Ueno Seiyaku Oyo Kenkyusho:Kk Binaphthol derivative and method for producing the same
US6962914B2 (en) 2001-04-27 2005-11-08 Smithkline Beecham Corporation Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds
AR035543A1 (en) 2001-06-26 2004-06-16 Japan Tobacco Inc THERAPEUTIC AGENT FOR HEPATITIS C THAT INCLUDES A CONDENSED RING COMPOUND, CONDENSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS, BENZIMIDAZOL, THIAZOL AND BIFENYL COMPOUNDS USED AS INTERMEDIARY COMPARTMENTS OF COMPARTMENTS
WO2003022845A1 (en) 2001-09-07 2003-03-20 Smithkline Beecham Corporation Pyrazolo-pyridines for the treatment of herpes infections
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
CA2461369A1 (en) 2001-10-09 2003-04-17 Pharmacia & Upjohn Company Arylsulphonyl-substituted tetrahydro-and-hexahydro-carbazoles as 5-ht-6 receptor ligands
AU2002334969A1 (en) 2001-10-09 2003-04-22 Sylvie Barchechath Use of stat-6 inhibitors as therapeutic agents
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
JP4024579B2 (en) 2002-01-22 2007-12-19 住友ベークライト株式会社 Plastic optical waveguide material and optical waveguide
US7273885B2 (en) 2002-04-11 2007-09-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
CN100343255C (en) 2002-04-23 2007-10-17 盐野义制药株式会社 Pyrazolo (1,5-a) pyrimidine derivative and nad(p)h oxidase inhibitor containing the same
EP1541563A4 (en) 2002-07-10 2007-11-07 Ono Pharmaceutical Co Ccr4 antagonist and medicinal use thereof
AU2003249244A1 (en) 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
JP2004059761A (en) 2002-07-30 2004-02-26 Sumitomo Bakelite Co Ltd Polybenzoxazole resin, its precursor, and optical waveguide material and optical waveguide using these
JP2004091369A (en) * 2002-08-30 2004-03-25 Sumitomo Pharmaceut Co Ltd New biphenyl compound
EP1547996A4 (en) 2002-08-30 2006-08-02 Bf Res Inst Inc Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein
JP2006504728A (en) 2002-10-03 2006-02-09 スミスクライン ビーチャム コーポレーション Pyrazolopyridine derivative therapeutic compounds
AU2003301302A1 (en) 2002-10-15 2004-05-04 Smithkline Beecham Corporation Pyradazine compounds as gsk-3 inhibitors
US7521051B2 (en) 2002-12-23 2009-04-21 Medimmune Limited Methods of upmodulating adaptive immune response using anti-PD-1 antibodies
KR100624406B1 (en) 2002-12-30 2006-09-18 삼성에스디아이 주식회사 Biphenyl derivatives and organo-electroluminescent device employing the same
US7320989B2 (en) 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
US7078419B2 (en) 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
JP4595288B2 (en) 2003-03-25 2010-12-08 住友ベークライト株式会社 Polybenzoxazole resin, precursor thereof, optical waveguide material using the same, and optical waveguide
ATE427308T1 (en) 2003-04-11 2009-04-15 Glenmark Pharmaceuticals Sa NEW HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES: METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
WO2005000833A1 (en) 2003-05-19 2005-01-06 Irm, Llc Immunosuppressant compounds and compositions
JP2005002330A (en) 2003-05-19 2005-01-06 Sumitomo Electric Ind Ltd Optical resin material, optical element, optical module, precursor of fluorinated polymer, and fluorinated polymer
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US20060183746A1 (en) 2003-06-04 2006-08-17 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
US20050014786A1 (en) 2003-07-11 2005-01-20 Chongqing Sun Tetrahydroquinoline derivatives as cannabinoid receptor modulators
JP5001650B2 (en) 2003-07-11 2012-08-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Benzimidazole carboxamide
JPWO2005012221A1 (en) 2003-08-04 2006-09-14 小野薬品工業株式会社 Diphenyl ether compound, its production method and use
WO2005014543A1 (en) 2003-08-06 2005-02-17 Japan Tobacco Inc. Condensed ring compound and use thereof as hcv polymerase inhibitor
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
CN102060806A (en) 2003-09-11 2011-05-18 iTherX药品公司 Cytokine inhibitors
JP4758349B2 (en) 2003-10-08 2011-08-24 アイアールエム・リミテッド・ライアビリティ・カンパニー Compounds and compositions as protein kinase inhibitors
US20070099938A1 (en) 2003-10-24 2007-05-03 Ono Pharmaceutical Co., Ltd. Antistress drug and medical use thereof
US20050288295A1 (en) 2003-11-11 2005-12-29 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
WO2005063710A1 (en) 2003-12-23 2005-07-14 Basf Aktiengesellschaft 3-trifluoromethyl picolinic acid anilides, and use thereof as fungicides
US20070149547A1 (en) 2004-02-12 2007-06-28 Celine Bonnefous Bipyridyl amides as modulators of metabotropic glutamate receptor-5
JPWO2005077948A1 (en) 2004-02-16 2008-01-10 第一製薬株式会社 Antifungal heterocyclic compounds
GB0403864D0 (en) 2004-02-20 2004-03-24 Ucl Ventures Modulator
JP2005248082A (en) 2004-03-05 2005-09-15 Sumitomo Electric Ind Ltd Manufacturing process of polybenzoxazole resin precursor and manufacturing process of polybenzoxazole resin
AU2005220882A1 (en) 2004-03-08 2005-09-22 Georgia State University Research Foundation, Inc Novel dicationic imidazo(1,2-a)pyridines and 5,6,7,8-tetrahydro-imidazo(1,2a)pyridines as antiprotozoal agents
US20050250820A1 (en) 2004-03-08 2005-11-10 Amgen Inc. Therapeutic modulation of PPARgamma activity
JP2007531753A (en) 2004-03-31 2007-11-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Non-imidazole heterocyclic compounds
JP2005290301A (en) 2004-04-02 2005-10-20 Sumitomo Electric Ind Ltd Method for manufacturing polybenzoxazol resin precursor and polybenzoxazol resin
WO2005099656A2 (en) 2004-04-06 2005-10-27 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
JP4879165B2 (en) 2004-04-20 2012-02-22 トランス テック ファーマ，インコーポレイテッド Substituted thiazole and pyrimidine derivatives as modulators of melanocortin receptors
DE102004021716A1 (en) 2004-04-30 2005-12-01 Grünenthal GmbH Substituted imidazo [1,2-a] pyridine compounds and drugs containing substituted imidazo [1,2-a] pyridine compounds
WO2005108387A2 (en) 2004-05-03 2005-11-17 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
PE20060748A1 (en) 2004-09-21 2006-10-01 Smithkline Beecham Corp INDOLCARBOXAMIDE DERIVATIVES AS KINASE INHIBITORS IKK2
WO2006034337A2 (en) 2004-09-23 2006-03-30 Wyeth Carbazole and cyclopentaindole derivatives to treat infection with hepatitis c virus
DE602005023333D1 (en) 2004-10-15 2010-10-14 Takeda Pharmaceutical KINASE INHIBITORS
WO2006053121A2 (en) 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
DE102004054665A1 (en) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituted bicyclic and tricyclic pyrazole derivatives Methods for the preparation and use as herbicides and plant growth regulators
US7998974B2 (en) 2005-03-03 2011-08-16 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
TW200716551A (en) 2005-03-10 2007-05-01 Cgi Pharmaceuticals Inc Certain substituted amides, method of making, and method of use thereof
JP2006290883A (en) 2005-03-17 2006-10-26 Nippon Nohyaku Co Ltd Substituted heterocycle carboxylic anilide derivative, its intermediate and chemical for agriculture and horticulture and method for using the same
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
US7566716B2 (en) 2005-05-20 2009-07-28 Array Biopharma Inc. Imidazopyrazines as Raf inhibitor compounds
EP1907424B1 (en) 2005-07-01 2015-07-29 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US20080220968A1 (en) 2005-07-05 2008-09-11 Ge Healthcare Bio-Sciences Ab [1, 2, 4] Triazolo [1, 5-A] Pyrimidine Derivatives as Chromatographic Adsorbent for the Selective Adsorption of Igg
WO2007034282A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2007049532A1 (en) 2005-10-25 2007-05-03 Shionogi & Co., Ltd. Aminodihydrothiazine derivative
ES2390135T3 (en) 2005-11-22 2012-11-06 Merck Sharp & Dohme Corp. Tricyclic compounds useful as kinase inhibitors
WO2007067711A2 (en) 2005-12-08 2007-06-14 Amphora Discovery Corporation Certain chemical entities, compositions, and methods for modulating trpv1
JPWO2007069565A1 (en) 2005-12-12 2009-05-21 小野薬品工業株式会社 Bicyclic heterocyclic compounds
US20090281075A1 (en) 2006-02-17 2009-11-12 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
WO2007096764A2 (en) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
EP1992348A4 (en) 2006-03-08 2009-09-23 Takeda Pharmaceutical Pharmaceutical combination
CA2644963A1 (en) 2006-03-31 2007-10-11 Novartis Ag Organic compounds
US7700616B2 (en) 2006-05-08 2010-04-20 Molecular Neuroimaging, Llc. Compounds and amyloid probes thereof for therapeutic and imaging uses
WO2007146712A2 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
CA2658764A1 (en) 2006-07-20 2008-01-24 Mehmet Kahraman Benzothiophene inhibitors of rho kinase
DE102006035018B4 (en) 2006-07-28 2009-07-23 Novaled Ag Oxazole triplet emitter for OLED applications
WO2008021745A2 (en) 2006-08-16 2008-02-21 Itherx Pharmaceuticals, Inc. Hepatitis c virus entry inhibitors
TWI389895B (en) 2006-08-21 2013-03-21 Infinity Discovery Inc Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
US7563797B2 (en) 2006-08-28 2009-07-21 Forest Laboratories Holding Limited Substituted imidazo(1,2-A)pyrimidines and imidazo(1,2-A) pyridines as cannabinoid receptor ligands
PE20080839A1 (en) 2006-09-11 2008-08-23 Cgi Pharmaceuticals Inc CERTAIN AMIDAS SUBSTITUTED, METHOD OF PREPARATION AND METHOD OF USE OF THE SAME
JP2010502751A (en) 2006-09-11 2010-01-28 シージーアイ ファーマシューティカルズ，インコーポレイティド Kinase inhibitors and methods of using and identifying kinase inhibitors
US7838523B2 (en) 2006-09-11 2010-11-23 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
AR063707A1 (en) 2006-09-11 2009-02-11 Cgi Pharmaceuticals Inc CERTAIN AMIDAS REPLACED, THE USE OF THE SAME FOR THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF THE ACTIVITY OF BTK AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM.
US8263648B2 (en) 2006-09-11 2012-09-11 Mylan Laboratories Ltd. Diebenzofuran derivatives as inhibitors of PDE-4 and PDE-10
FR2906250B1 (en) 2006-09-22 2008-10-31 Sanofi Aventis Sa DERIVATIVES OF 2-ARYL-6PHENYL-IMIDAZO (1,2-A) PYRIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
CA2667644A1 (en) 2006-10-27 2008-05-15 Wyeth Tricyclic compounds as matrix metalloproteinase inhibitors
PL2089364T3 (en) 2006-11-08 2013-11-29 Bristol Myers Squibb Co Pyridinone compounds
GB0623209D0 (en) 2006-11-21 2007-01-03 F2G Ltd Antifungal agents
WO2008064317A1 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Lipophilic opioid receptor active compounds
WO2008064318A2 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Peripheral opioid receptor active compounds
US20100004301A1 (en) 2006-12-14 2010-01-07 Benjamin Pelcman Benzoxazoles Useful in the Treatment of Inflammation
WO2008079965A1 (en) 2006-12-22 2008-07-03 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
EP1964840A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]pyridines and their use as pharmaceuticals
EP1964841A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]azine and their use as pharmaceuticals
JP2008218327A (en) 2007-03-07 2008-09-18 Hitachi Ltd Electrolyte, electrolyte film, film-electrode assembly using the same, fuel cell power supply, and fuel cell power supply system
JP2010120852A (en) * 2007-03-09 2010-06-03 Daiichi Sankyo Co Ltd New diamide derivative
CA2680761A1 (en) 2007-03-22 2008-09-25 Astrazeneca Ab Quinoline derivatives for the treatment of inflammatory diseases
WO2008133274A1 (en) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with cyclic groups
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co Pharmaceutical composition for treatment of alzheimer's disease
WO2008134553A1 (en) 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using bicyclic compounds in treating sodium channel-mediated diseases
WO2008141239A1 (en) 2007-05-10 2008-11-20 Acadia Pharmaceuticals Inc. Imidazol [1,2-a] pyridines and related compounds with activity at cannabinoid cb2 receptors
KR20100054780A (en) 2007-06-18 2010-05-25 엔.브이.오가논 Antibodies to human programmed death receptor pd-1
WO2009027733A1 (en) 2007-08-24 2009-03-05 Astrazeneca Ab (2-pyridin-3-ylimidazo[1,2-b]pyridazin-6-yl) urea derivatives as antibacterial agents
US8080542B2 (en) 2007-09-20 2011-12-20 Amgen, Inc. S1P receptor modulating compounds and use thereof
DE102007048716A1 (en) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo [1,2-a] pyrimidine derivatives
TW200932219A (en) 2007-10-24 2009-08-01 Astellas Pharma Inc Oxadiazolidinedione compound
CA2703653A1 (en) 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives -083
US7868001B2 (en) 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
WO2009062059A2 (en) 2007-11-08 2009-05-14 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
JP5489296B2 (en) 2007-12-13 2014-05-14 メルク・シャープ・アンド・ドーム・コーポレーション JANUS kinase inhibitors
RU2364597C1 (en) 2007-12-14 2009-08-20 Андрей Александрович Иващенко HETEROCYCLIC INHIBITORS OF Hh-SYGNAL CASCADE, BASED ON THEM MEDICINAL COMPOSITIONS AND METHOD OF TREATING DISEASES INDUCED BY ABBARANT ACTIVITY OF Hh-SIGNAL SYSTEM
US8410145B2 (en) 2007-12-19 2013-04-02 Syngenta Crop Protection Llc Insecticidal compounds
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CA2710016A1 (en) 2007-12-21 2009-07-02 The University Of Sydney Translocator protein ligands
JP4520533B2 (en) 2008-01-18 2010-08-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 Condensed aminodihydrothiazine derivatives
JP5381718B2 (en) 2008-01-31 2014-01-08 コニカミノルタ株式会社 Halopolycyclic aromatic compound and method for producing the same
WO2009106539A1 (en) 2008-02-26 2009-09-03 Novartis Ag Heterocyclic compounds as inhibitors of cxcr2
EP2095818A1 (en) 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
FR2928924B1 (en) 2008-03-21 2010-04-23 Sanofi Aventis POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYL-IMIDAZO-1,2-A! PYRIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR2928921B1 (en) 2008-03-21 2010-04-23 Sanofi Aventis POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO-1,2-A! PYRIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
FR2928922B1 (en) 2008-03-21 2010-04-23 Sanofi Aventis DERIVATIVES OF POLYSUBSTITUTED 2-ARYL-6-PHENYL-IMIDAZO-1,2-A! PYRIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
US8461163B2 (en) 2008-03-31 2013-06-11 Takeda Pharmaceutical Company Limited Substituted N-(pyrazolo[1,5-a]pyrimidin-5-yl)amides as inhibitors of apoptosis signal-regulating kinase 1
KR101034351B1 (en) 2008-05-14 2011-05-16 한국화학연구원 Novel benzoxazole-pyridine derivatives or pharmaceutically acceptable salt thereof, preparation method thereof and pharmaceutical composition for the prevention and treatment of abnormal cell growth diseases containing the same as an active ingredient
WO2009143156A2 (en) 2008-05-19 2009-11-26 Sepracor Inc. IMIDAZO[1,2-a]PYRIDINE COMPOUNDS
KR20110019385A (en) 2008-05-29 2011-02-25 서트리스 파마슈티컬즈, 인코포레이티드 Imidazopyridine and related analogs as sirtuin modulators
WO2009147187A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
US8476430B2 (en) 2008-07-24 2013-07-02 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
JP2011231017A (en) 2008-09-09 2011-11-17 Nissan Chem Ind Ltd Process for producing optically active epoxy compound and optically active sulfoxide compound, ligand and complex for use in the process, and process for producing the complex
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
EP2365970B1 (en) 2008-11-12 2018-03-21 Gilead Connecticut, Inc. Pyridazinones and their use as btk inhibitors
EP2376490B1 (en) 2008-12-04 2013-01-23 Proximagen Limited Imidazopyridine compounds
KR20200047793A (en) 2008-12-09 2020-05-07 제넨테크, 인크. Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2010071885A1 (en) 2008-12-19 2010-06-24 Cephalon, Inc. Pyrrolotriazines as alk and jak2 inhibitors
CN102325753B (en) 2008-12-19 2014-09-10 百时美施贵宝公司 Carbazole carboxamide compounds useful as kinase inhibitors
EP2370407B1 (en) 2008-12-19 2014-06-18 Bristol-Myers Squibb Company Carbazole and carboline kinase inhibitors
JP5624275B2 (en) 2008-12-22 2014-11-12 ユー・ディー・シー アイルランド リミテッド Organic electroluminescence device
MX2011006332A (en) 2008-12-23 2011-06-27 Abbott Lab Anti-viral compounds.
WO2010074284A1 (en) 2008-12-26 2010-07-01 味の素株式会社 Pyrazolopyrimidine compound
EP2393835B1 (en) 2009-02-09 2017-04-05 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
JP2010202530A (en) 2009-02-27 2010-09-16 Tokyo Institute Of Technology Heterocycle-containing aromatic compound, and optical material
WO2010104306A2 (en) 2009-03-07 2010-09-16 주식회사 메디젠텍 Pharmaceutical compositions for treating or preventing diseases caused by the translocation of gsk3 from the cell nucleus to the cytoplasm, containing compounds for inhibiting the translocation of gsk3 from the cell nucleus to the cytoplasm
ES2882797T3 (en) 2009-04-02 2021-12-02 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
US8778935B2 (en) 2009-04-16 2014-07-15 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazopyrazines for use as kinase inhibitors
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
BRPI1009034A2 (en) 2009-06-30 2019-09-24 Siga Tech Inc pharmaceutical composition and method for the treatment or prophylaxis of a viral infection or disease associated with it
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
TWI625121B (en) 2009-07-13 2018-06-01 基利科學股份有限公司 Apoptosis signal-regulating kinase inhibitors
JP2011057661A (en) 2009-08-14 2011-03-24 Bayer Cropscience Ag Pesticidal carboxamides
UA108363C2 (en) 2009-10-08 2015-04-27 IMINOTIADIASIADIOXIDE OXIDES AS BACE INHIBITORS, COMPOSITIONS THEREOF AND THEIR APPLICATIONS
WO2011047129A1 (en) 2009-10-15 2011-04-21 Southern Research Institute Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such
EA201270566A1 (en) 2009-10-16 2012-11-30 Риб-Экс Фармасьютикалз, Инк. ANTIMICROBIAL COMPOUNDS AND METHODS FOR THEIR PRODUCTION AND APPLICATION
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
JP2013512251A (en) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Simultaneous inhibition of PD-L1 / PD-L2
WO2011078221A1 (en) 2009-12-24 2011-06-30 味の素株式会社 Imidazopyridazine compounds
WO2011082400A2 (en) * 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
WO2011097607A1 (en) 2010-02-08 2011-08-11 Southern Research Institute Anti-viral treatment and assay to screen for anti-viral agent
TW201136919A (en) 2010-03-02 2011-11-01 Merck Sharp & Amp Dohme Corp Inhibitors of hepatitis C virus NS5B polymerase
JP5995728B2 (en) 2010-03-04 2016-09-21 メルク・シャープ・エンド・ドーム・コーポレイション Inhibitors of catechol O-methyltransferase and their use in the treatment of mental disorders
RU2576662C2 (en) 2010-03-18 2016-03-10 Энститю Пастер Корея Antiinfective compounds
US8410117B2 (en) 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
EP2582668B1 (en) 2010-06-16 2016-01-13 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
CA2802344C (en) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CN102295642B (en) 2010-06-25 2016-04-06 中国人民解放军军事医学科学院毒物药物研究所 2-Aryimidazole is [1,2-a] pyridine-3-acetamide, Preparation Method And The Use also
EP2402345A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazole fused bicyclic compounds
CN101891895B (en) 2010-07-28 2011-11-30 南京航空航天大学 Benzothiazole derivatives metal coordination polymer based on bridged bis-salicylaldehyde structure as well as manufacture method and application thereof
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
US8633200B2 (en) 2010-09-08 2014-01-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
CN101993415B (en) 2010-09-15 2013-08-14 北京韩美药品有限公司 Compound as Hedgehog path inhibitor, medicine composition containing same and application thereof
WO2012047856A2 (en) 2010-10-04 2012-04-12 Institute For Hepatitis And Virus Research Novel inhibitors of secretion of hepatitis b virus antigens
WO2012052745A1 (en) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
CN103282034A (en) 2010-11-18 2013-09-04 利亘制药公司 Use of hematopoietic growth factor mimetics
UY33808A (en) 2010-12-17 2012-07-31 Syngenta Participations Ag INSECTICIDE COMPOUNDS
TWI617559B (en) 2010-12-22 2018-03-11 江蘇恆瑞醫藥股份有限公司 2-arylimidazo[1,2-b]pyridazine, 2-phenylimidazo[1,2-a]pyridine, and 2-phenylimidazo[1,2-a]pyrazine derivatives
AU2012204920B2 (en) 2011-01-04 2014-08-07 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD)
US9018395B2 (en) 2011-01-27 2015-04-28 Université de Montréal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
US8921368B2 (en) 2011-03-17 2014-12-30 Bristol-Myers Squibb Company Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2012139425A1 (en) 2011-04-13 2012-10-18 Schering Corporation 5-substituted iminothiazines and their mono-and dioxides as bace inhibitors,compositions,and their use
CN102796103A (en) 2011-05-23 2012-11-28 南京英派药业有限公司 6-(aryl formyl) imidazo [1,2-a] pyrimidine and 6-(aryl formyl) [1,2,4] triazol [4,3-a] pyrimidine serving as Hedgehog inhibitors and application thereof
DK2713722T3 (en) 2011-05-31 2017-07-03 Celgene Int Ii Sarl Newly known GLP-1 receptor stabilizers and modulators
GB201109763D0 (en) 2011-06-10 2011-07-27 Ucl Business Plc Compounds
WO2012175991A1 (en) 2011-06-24 2012-12-27 Pharminox Limited Fused pentacyclic anti - proliferative compounds
MX2014000338A (en) 2011-07-08 2014-05-01 Novartis Ag Novel pyrrolo pyrimidine derivatives.
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013040528A1 (en) 2011-09-16 2013-03-21 Microbiotix, Inc. Antimicrobial compounds
US9351973B2 (en) 2011-09-22 2016-05-31 Merck Sharp & Dohme Corp. Pyrazolopyridyl compounds as aldosterone synthase inhibitors
JP6040677B2 (en) 2011-09-29 2016-12-07 東洋インキＳｃホールディングス株式会社 Resin composition for solar cell encapsulant
US9284284B2 (en) 2011-10-13 2016-03-15 Novartis Ag Oxazine derivatives and their use in the treatment of disease
CN103998451A (en) 2011-10-20 2014-08-20 葛兰素史密斯克莱有限责任公司 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
CN104024260A (en) 2011-10-21 2014-09-03 托伦特药物有限公司 Novel substituted imidazopyrimidines as gpbar1 receptor modulators
WO2013120040A1 (en) 2012-02-10 2013-08-15 Children's Medical Center Corporation Targeted pathway inhibition to improve muscle structure, function and activity in muscular dystrophy
US9034882B2 (en) 2012-03-05 2015-05-19 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
EP2824099A4 (en) 2012-03-09 2015-11-11 Carna Biosciences Inc Novel triazine derivative
CN105121418A (en) 2012-04-20 2015-12-02 吉利德科学公司 Benzothiazol- 6 -yl acetic acid derivatives and their use for treating an hiv infection
US20150105433A1 (en) 2012-04-27 2015-04-16 The Uab Research Foundation TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM
CN104379567A (en) 2012-06-18 2015-02-25 住友化学株式会社 Fused heterocyclic compound
WO2014007228A1 (en) 2012-07-03 2014-01-09 小野薬品工業株式会社 Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes
ES2689429T3 (en) 2012-07-13 2018-11-14 Ucb Biopharma Sprl Imidazopyridine derivatives as modulators of TNF activity
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
JP2015178457A (en) 2012-07-25 2015-10-08 杏林製薬株式会社 Pyrazolopyridine derivative and pharmacologically permissible salt of the same
WO2014039595A1 (en) 2012-09-06 2014-03-13 Bristol-Myers Squibb Company Imidazopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
CN104640858B (en) 2012-09-26 2018-11-06 霍夫曼-拉罗奇有限公司 Cyclic ethers pyrazoles -4- bases-heterocycle-benzamide compound and application method
WO2014061693A1 (en) 2012-10-17 2014-04-24 塩野義製薬株式会社 Novel non-aromatic carbocyclic or non-aromatic heterocyclic derivative
US9163027B2 (en) 2012-11-21 2015-10-20 Stategics, Inc. Substituted triazolo-pyrimidine compounds for modulating cell proliferation differentiation and survival
JP6037804B2 (en) 2012-12-03 2016-12-07 富士フイルム株式会社 Gas separation membrane
PE20151448A1 (en) 2013-01-15 2015-09-28 Incyte Corp THIAZOLCARBOXAMIDES AND PYRIDINACARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS
CA2896185A1 (en) 2013-01-22 2014-07-31 F. Hoffmann-La Roche Ag Fluoro-[1,3]oxazines as bace1 inhibitors
CN103933036B (en) 2013-01-23 2017-10-13 中国人民解放军军事医学科学院毒物药物研究所 2 Aryimidazoles simultaneously the acetamide derivative of [1,2 α] pyridine 3 prepare preventing and treating PTSD medicine in purposes
WO2014121085A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Pd-l1 and pd-l2-based fusion proteins and uses thereof
CN105189493B (en) 2013-02-27 2017-04-12 持田制药株式会社 Novel pyrazole derivative
AU2014225604B2 (en) 2013-03-08 2018-05-17 Amgen Inc. Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
CN104045552B (en) 2013-03-13 2019-06-11 江苏先声药业有限公司 Medicinal compound as neuroprotective agent
CA2905565A1 (en) 2013-03-13 2014-09-18 Australian Nuclear Science And Technology Organisation Transgenic non-human organisms with non-functional tspo genes
ES2623904T3 (en) 2013-03-14 2017-07-12 VIIV Healthcare UK (No.5) Limited Human immunodeficiency virus replication inhibitors
RU2690489C2 (en) 2013-03-14 2019-06-04 Селтакссис, Инк. Leukotriene a4-hydrolase inhibitors
EP2968304B1 (en) 2013-03-14 2018-10-10 The Trustees of Columbia University in the City of New York 4-phenylpiperidines, their preparation and use
AU2014265957A1 (en) 2013-03-14 2015-09-10 Curadev Pharma Private Ltd. Inhibitors of the kynurenine pathway
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
KR102273997B1 (en) 2013-06-26 2021-07-08 애브비 인코포레이티드 Primary carboxamides as btk inhibitors
HUE049733T2 (en) 2013-07-02 2020-10-28 Syngenta Participations Ag Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents
AU2014291142B2 (en) 2013-07-17 2018-10-11 Otsuka Pharmaceutical Co., Ltd. Cyanotriazole compounds
JP2016531113A (en) 2013-07-25 2016-10-06 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Inhibitors of transcription factors and uses thereof
EP2835375A1 (en) 2013-08-09 2015-02-11 Fundació Institut Català d'Investigació Química Bis-salphen compounds and carbonaceous material composites comprising them
KR101715090B1 (en) 2013-08-28 2017-03-13 한국화학연구원 Novel compound or pharmaceutically acceptable salt thereof and pharmaceutical composition for prevention or treatment of disease caused by influenza virus infection containing the same as an active ingredient
MX2016002544A (en) 2013-09-04 2016-06-17 Squibb Bristol Myers Co Compounds useful as immunomodulators.
CA2922607C (en) 2013-09-06 2022-08-30 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole derivatives as immunomodulators
CA2922655A1 (en) 2013-09-06 2015-03-12 Aurigene Discovery Technologies Limited 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
WO2015036927A1 (en) 2013-09-10 2015-03-19 Aurigene Discovery Technologies Limited Immunomodulating peptidomimetic derivatives
JP6336870B2 (en) 2013-09-30 2018-06-06 日本ポリプロ株式会社 Biphenol compound, olefin polymerization catalyst using the same, and process for producing olefin polymer
FR3012140B1 (en) 2013-10-18 2016-08-26 Arkema France UNIT AND PROCESS FOR THE PURIFICATION OF RAW METHYL METHACRYLATE
GB201321733D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321743D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321736D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2015095337A2 (en) 2013-12-18 2015-06-25 The Rockefeller University PYRAZOLO[1,5-a]PYRIMIDINECARBOXAMIDE DERIVATIVES FOR TREATING COGNITIVE IMPAIRMENT
WO2015101622A1 (en) 2014-01-03 2015-07-09 Bayer Cropscience Ag Novel pyrazolyl-heteroarylamides as pesticides
JP2017512056A (en) 2014-02-10 2017-05-18 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Antibody binding to human tau and assay for quantifying human tau using the antibody
AU2015223084B2 (en) 2014-02-25 2019-11-07 Achillion Pharmaceuticals, Inc. Compounds for treatment of complement mediated disorders
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
JP6490464B2 (en) 2014-03-26 2019-03-27 三井化学株式会社 Transition metal compound, catalyst for olefin polymerization, and process for producing olefin polymer
JP6554117B2 (en) 2014-04-04 2019-07-31 イオメット ファーマ リミテッド Indole derivatives used in medicine
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
WO2015175678A1 (en) 2014-05-14 2015-11-19 President And Fellows Of Harvard College Organic light-emitting diode materials
WO2015197028A1 (en) 2014-06-28 2015-12-30 Sunshine Lake Pharma Co., Ltd. Compounds as hepatitis c virus (hcv) inhibitors and uses thereof in medicine
CN104211726B (en) 2014-08-11 2017-06-16 中南民族大学 The tooth double-core titanium complex of non-luxuriant class three, Preparation method and use
US20170305922A1 (en) 2014-09-17 2017-10-26 Epizyme, Inc. Carm1 inhibitors and uses thereof
AU2015317566B2 (en) 2014-09-19 2019-10-10 Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital Benzo-heterocyclic compounds and their applications
ES2907622T3 (en) 2014-10-06 2022-04-25 Merck Patent Gmbh Heteroaryl Compounds as BTK Inhibitors and Uses of These
US10017520B2 (en) 2014-12-10 2018-07-10 Massachusetts Institute Of Technology Myc modulators and uses thereof
JP6853619B2 (en) 2015-01-16 2021-03-31 大塚製薬株式会社 Pharmaceutical use of cyanotriazole compounds
WO2016116525A1 (en) 2015-01-20 2016-07-28 Cynora Gmbh Organic molecules, in particular for use in optoelectronic components
EP3261442B1 (en) 2015-01-20 2020-04-01 Merck Sharp & Dohme Corp. Iminothiadiazine dioxides bearing an amine-linked substituent as bace inhibitors, compositions, and their use
WO2016156282A1 (en) 2015-04-02 2016-10-06 Bayer Cropscience Aktiengesellschaft Novel triazole compounds for controlling phytopathogenic harmful fungi
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
US10745382B2 (en) 2015-10-15 2020-08-18 Bristol-Myers Squibb Company Compounds useful as immunomodulators
TW201718581A (en) 2015-10-19 2017-06-01 英塞特公司 Heterocyclic compounds as immunomodulators
WO2017070320A1 (en) 2015-10-21 2017-04-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Phenyl indole allosteric inhibitors of p97 atpase
US9603950B1 (en) 2015-10-25 2017-03-28 Institute Of Nuclear Energy Research Compounds of imaging agent with HDAC inhibitor for treatment of Alzheimer syndrome and method of synthesis thereof
KR101717601B1 (en) 2015-11-10 2017-03-20 한국화학연구원 Novel compound or pharmaceutically acceptable salt thereof and pharmaceutical composition for prevention or treatment of disease caused by influenza virus infection containing the same as an active ingredient
EP4141002A1 (en) 2015-11-19 2023-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2916874T3 (en) 2015-12-17 2022-07-06 Incyte Corp N-phenyl-pyridine-2-carboxamide derivatives and their use as modulators of the PD-1/PD-L1 protein/protein interaction
US20170174679A1 (en) 2015-12-22 2017-06-22 Incyte Corporation Heterocyclic compounds as immunomodulators
AU2016378482A1 (en) 2015-12-22 2018-07-12 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant
SG10202111399YA (en) 2015-12-22 2021-11-29 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
WO2017108569A1 (en) 2015-12-22 2017-06-29 Syngenta Participations Ag Pesticidally active pyrazole derivatives
WO2017107052A1 (en) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase stimulators
KR101653560B1 (en) 2016-02-02 2016-09-12 한국화학연구원 Novel compound or pharmaceutically acceptable salt thereof and pharmaceutical composition for prevention or treatment of disease caused by influenza virus infection containing the same as an active ingredient
MX2018012901A (en) 2016-04-22 2019-06-06 Incyte Corp Formulations of an lsd1 inhibitor.
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2793773T3 (en) 2016-06-20 2020-11-16 Elanco Us Inc PEGYLATED PORCINE INTERFERON AND METHODS OF USING IT
ES2975263T3 (en) 2016-06-20 2024-07-04 Novartis Ag Crystalline forms of a triazolopyrimidine compound
MD3472167T2 (en) 2016-06-20 2023-02-28 Incyte Corp Heterocyclic compounds as immunomodulators
JP7054529B2 (en) 2016-06-21 2022-04-14 エックス４ ファーマシューティカルズ， インコーポレイテッド CXCR4 inhibitor and its use
MA45669A (en) 2016-07-14 2019-05-22 Incyte Corp HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS
AU2017305399A1 (en) 2016-08-03 2019-01-31 Arising International, Inc. Symmetric or semi-symmetric compounds useful as immunomodulators
EP3504198B1 (en) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclic compounds as immunomodulators
MA46102A (en) 2016-08-30 2019-07-10 Tetraphase Pharmaceuticals Inc TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT
CN110291080B (en) 2016-12-21 2022-07-08 安塞塔制药公司 Imidazopyrazine inhibitors of bruton's tyrosine kinase
TWI795381B (en) 2016-12-21 2023-03-11 比利時商健生藥品公司 Pyrazole derivatives as malt1 inhibitors
US10287303B2 (en) 2016-12-22 2019-05-14 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
US20180179202A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
PL3558990T3 (en) 2016-12-22 2022-12-19 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
WO2018119266A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Benzooxazole derivatives as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
JOP20180040A1 (en) 2017-04-20 2019-01-30 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
JP7185681B2 (en) 2017-07-28 2022-12-07 ケモセントリックス，インコーポレイティド immunomodulatory compounds
EP3664793B1 (en) 2017-08-08 2022-06-29 ChemoCentryx, Inc. Macrocyclic immunomodulators
EP3669872A4 (en) 2017-08-18 2021-05-05 Shanghai Ennovabio Pharmaceuticals Co., Ltd. Compound having pd-l1 inhibitory activity, preparation method therefor and use thereof
LT3774791T (en) 2018-03-30 2023-04-11 Incyte Corporation Heterocyclic compounds as immunomodulators
US20210040118A1 (en) 2018-04-03 2021-02-11 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof
WO2019204609A1 (en) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
EP3790877B1 (en) 2018-05-11 2023-03-01 Incyte Corporation Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
EP3870566A1 (en) 2018-10-24 2021-09-01 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
EP3875458A4 (en) 2018-11-02 2022-08-24 Shanghai Maxinovel Pharmaceuticals Co., Ltd. Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
US20220098183A1 (en) 2019-01-31 2022-03-31 Betta Pharmaceuticals Co.,Ltd Immunomodulators, compositions and methods thereof
GB201911210D0 (en) 2019-08-06 2019-09-18 Amlo Biosciences Ltd Clinical management of oropharyngeal squamous cell carcinoma
CA3150434A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
CA3155090A1 (en) 2019-09-20 2021-03-25 Transgene Combination of a poxvirus encoding hpv polypeptides and il-2 with an anti-pd-l1 antibody
AU2020357514A1 (en) 2019-09-30 2022-04-07 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
JP2023500395A (en) 2019-11-11 2023-01-05 インサイト・コーポレイション Salts and Crystal Forms of PD-1/PD-L1 Inhibitors
EP4146216A4 (en) 2020-05-04 2024-05-29 Beyondspring Pharmaceuticals Inc. Triple combination therapy for enhancing cancer cell killing in cancers with low immunogenicity
CN116670114A (en) 2020-11-06 2023-08-29 因赛特公司 Methods for preparing PD-1/PD-L1 inhibitors, and salts and crystalline forms thereof
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
TW202233615A (en) 2020-11-06 2022-09-01 美商英塞特公司 Crystalline form of a pd-1/pd-l1 inhibitor
US20220193050A1 (en) 2020-12-18 2022-06-23 Incyte Corporation Oral formulation for a pd-l1 inhibitor
WO2023049831A1 (en) 2021-09-24 2023-03-30 Incyte Corporation Treatment of human papillomavirus-associated cancers by pd-l1 inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000196A2 (en) 2000-06-28 2002-01-03 Smithkline Beecham P.L.C. Wet milling process
WO2009039397A2 (en) * 2007-09-20 2009-03-26 Cgi Pharmaceuticals, Inc. Substituted amides, methods of making, use thereof for the treatment of diseases such as cancer
WO2013157021A1 (en) * 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof

Non-Patent Citations (32)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY, pages: 1418
BARBER ET AL., NATURE, vol. 439, 2006, pages 682 - 7
BERGE ET AL., J. PHARM. SCI., vol. 66, no. 1, 1977, pages 1 - 19
BLANK ET AL., CANCER RES, vol. 64, no. 3, 2004, pages 1140 - 5
BLOM ET AL.: "Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification", J. COMBI. CHEM., vol. 5, 2003, pages 670 - 83
BLOM ET AL.: "Preparative LC-MS Purification: Improved Compound Specific Method Optimization", J. COMBI. CHEM, vol. 6, 2004, pages 874 - 883
BLOM: "Two-Pump At Column Dilution Configuration for Preparative LC-MS", J. COMBI. CHEM., vol. 4, 2002, pages 295 - 301
CARTER ET AL., EUR J IMMUNOL, vol. 32, no. 3, 2002, pages 634 - 43
FREEMAN ET AL., J EXP MED, vol. 192, no. 7, 2000, pages 1027 - 34
GREENWALD ET AL., ANNU. REV. IMMUNOL, vol. 23, 2005, pages 515 - 548
HUANG ET AL., ONCOL REP, 2015
IWAI ET AL., PNAS, vol. 99, no. 19, 2002, pages 12293 - 7
KOCIENSKI: "Protecting Groups", 2007, THIEME
LATCHMAN ET AL., NAT IMMUNOL, vol. 2, 2001, pages 261 - 268
M. A. POSTOW ET AL: "Immune Checkpoint Blockade in Cancer Therapy", JOURNAL OF CLINICAL ONCOLOGY, vol. 33, no. 17, 20 January 2015 (2015-01-20), US, pages 1974 - 1982, XP055320016, ISSN: 0732-183X, DOI: 10.1200/JCO.2014.59.4358 *
NAKAE ET AL., J IMMUNOL, vol. 177, 2006, pages 566 - 73
NISHIMURA ET AL., IMMUNITY, vol. 11, 1999, pages 141 - 151
NISHIMURA ET AL., SCIENCE, vol. 291, 2001, pages 319 - 322
OKAZAKI; HONJO, TRENDS IMMUNOL, 2006, pages 195 - 201
PARRY ET AL., MOL CELL BIOL, 2005, pages 9543 - 9553
PETURSSION ET AL.: "Protecting Groups in Carbohydrate Chemistry", J. CHEM. EDUC., vol. 74, no. 11, 1997, pages 1297
POSTOW ET AL., J. CLINICAL ONCOL, 2015, pages 1 - 9
POSTOW ET AL., J. CLINICAL ONCOLOGY, 2015, pages 1 - 9
ROBERTSON: "Protecting Group Chemistry", 2000, OXFORD UNIVERSITY PRESS
SABATIER ET AL., ONCOTARGET, vol. 6, no. 7, 2015, pages 5449 - 5464
SHARPE ET AL., NAT IMMUNOL, vol. 8, 2007, pages 239 - 245
SMITH ET AL.: "March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 2007, WILEY
STAHL ET AL.: "Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002, WILEY
WANG ET AL., EUR J SURG ONCOL, 2015
WUTS ET AL.: "Protective Groups in Organic Synthesis", 2006, WILEY
YOUNG WENDY B ET AL: "Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 26, no. 2, January 2016 (2016-01-01), pages 575 - 579, XP029380242, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2015.11.076 *
YOUNG, W.B. ET AL.: "Potent and selective Bruton's tyrosine kinase inhibbitors: Discovery of GDC-0834", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 25, 2015, pages 1333 - 1337, XP002772334 *

Cited By (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11407749B2 (en) 2015-10-19 2022-08-09 Incyte Corporation Heterocyclic compounds as immunomodulators
US11572366B2 (en) 2015-11-19 2023-02-07 Incyte Corporation Heterocyclic compounds as immunomodulators
US11535615B2 (en) 2015-12-22 2022-12-27 Incyte Corporation Heterocyclic compounds as immunomodulators
US11866435B2 (en) 2015-12-22 2024-01-09 Incyte Corporation Heterocyclic compounds as immunomodulators
US11608337B2 (en) 2016-05-06 2023-03-21 Incyte Corporation Heterocyclic compounds as immunomodulators
US11673883B2 (en) 2016-05-26 2023-06-13 Incyte Corporation Heterocyclic compounds as immunomodulators
US11873309B2 (en) 2016-06-20 2024-01-16 Incyte Corporation Heterocyclic compounds as immunomodulators
US11793771B2 (en) 2016-06-27 2023-10-24 Chemocentryx, Inc. Immunomodulator compounds
US11426364B2 (en) 2016-06-27 2022-08-30 Chemocentryx, Inc. Immunomodulator compounds
US11718605B2 (en) 2016-07-14 2023-08-08 Incyte Corporation Heterocyclic compounds as immunomodulators
US11613536B2 (en) 2016-08-29 2023-03-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US11274285B2 (en) 2016-10-14 2022-03-15 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the Hepatitis B virus genome
US10662416B2 (en) 2016-10-14 2020-05-26 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome
WO2018119224A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
US11787793B2 (en) 2016-12-22 2023-10-17 Incyte Corporation Heterocyclic compounds as immunomodulators
EP4223369A1 (en) * 2016-12-22 2023-08-09 Incyte Corporation Immunomodulator compounds and methods of use
US10806785B2 (en) 2016-12-22 2020-10-20 Incyte Corporation Immunomodulator compounds and methods of use
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
US10800768B2 (en) 2016-12-22 2020-10-13 Incyte Corporation Heterocyclic compounds as immunomodulators
US11566026B2 (en) 2016-12-22 2023-01-31 Incyte Corporation Heterocyclic compounds as immunomodulators
US10793565B2 (en) 2016-12-22 2020-10-06 Incyte Corporation Heterocyclic compounds as immunomodulators
US11465981B2 (en) 2016-12-22 2022-10-11 Incyte Corporation Heterocyclic compounds as immunomodulators
US11339149B2 (en) 2016-12-22 2022-05-24 Incyte Corporation Heterocyclic compounds as immunomodulators
EP4026835A2 (en) 2017-04-20 2022-07-13 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2018195321A1 (en) 2017-04-20 2018-10-25 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US11708326B2 (en) 2017-07-28 2023-07-25 Chemocentryx, Inc. Immunomodulator compounds
US10919852B2 (en) 2017-07-28 2021-02-16 Chemocentryx, Inc. Immunomodulator compounds
US11691985B2 (en) 2017-08-08 2023-07-04 Chemocentryx, Inc. Macrocyclic immunomodulators
US11059834B2 (en) 2017-08-08 2021-07-13 Chemocentryx, Inc. Macrocyclic immunomodulators
US10392405B2 (en) 2017-08-08 2019-08-27 Chemocentryx, Inc. Macrocyclic immunomodulators
WO2019032547A1 (en) 2017-08-08 2019-02-14 Chemocentryx, Inc. Macrocyclic immunomodulators
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
RU2768830C2 (en) * 2018-02-05 2022-03-24 Аббиско Тхерапеутицс Цо., Лтд. Biaryl derivative, method for production thereof and pharmaceutical application thereof
RU2768830C9 (en) * 2018-02-05 2022-06-17 Aббиско Тхерaпеутицс Цо., Лтд. Biaryl derivative, method for production thereof and pharmaceutical application thereof
EP3750887A4 (en) * 2018-02-05 2021-10-20 Abbisko Therapeutics Co., Ltd. Biaryl derivative, preparation method thereof and pharmaceutical application thereof
WO2019149183A1 (en) * 2018-02-05 2019-08-08 上海和誉生物医药科技有限公司 Biaryl derivative, preparation method thereof and pharmaceutical application thereof
US11459339B2 (en) 2018-02-05 2022-10-04 Abbisko Therapeutics Co., Ltd. Biaryl derivative, preparation method thereof and pharmaceutical application thereof
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
EP4227302A1 (en) 2018-02-13 2023-08-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US10710986B2 (en) 2018-02-13 2020-07-14 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US11555029B2 (en) 2018-02-13 2023-01-17 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US11135210B2 (en) 2018-02-22 2021-10-05 Chemocentryx, Inc. Indane-amines as PD-L1 antagonists
WO2019165043A2 (en) 2018-02-22 2019-08-29 Chemocentryx, Inc. Indane-amines as pd-l1 antagonists
US10568874B2 (en) 2018-02-22 2020-02-25 Chemocentryx, Inc. Indane-amines as PD-L1 antagonists
US11759458B2 (en) 2018-02-22 2023-09-19 Chemocentryx, Inc. Indane-amines as PD-L1 antagonists
WO2019165374A1 (en) 2018-02-26 2019-08-29 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
US11673894B2 (en) 2018-02-27 2023-06-13 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
US10669271B2 (en) 2018-03-30 2020-06-02 Incyte Corporation Heterocyclic compounds as immunomodulators
US11124511B2 (en) 2018-03-30 2021-09-21 Incyte Corporation Heterocyclic compounds as immunomodulators
JP2021520342A (en) * 2018-04-03 2021-08-19 ベータ ファーマシューティカルズ カンパニー リミテッド Immunomodulators, compositions and methods thereof
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
WO2019193542A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides
US11292812B2 (en) 2018-04-06 2022-04-05 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotides
WO2019193543A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides
WO2019193533A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'2'-cyclic dinucleotides
US11149052B2 (en) 2018-04-06 2021-10-19 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′-cyclic dinucleotides
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
US11788077B2 (en) 2018-04-12 2023-10-17 Precision Biosciences, Inc. Polynucleotides encoding optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
WO2019200247A1 (en) 2018-04-12 2019-10-17 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2019204609A1 (en) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
AU2019267824B2 (en) * 2018-05-11 2023-10-05 Incyte Corporation Tetrahydro-imidazo(4,5-C)pyridine derivatives as PD-L1 immunomodulators
WO2019217821A1 (en) * 2018-05-11 2019-11-14 Incyte Corporation Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
CN112752756B (en) * 2018-05-11 2024-06-25 因赛特公司 Tetrahydro-imidazo [4,5-c ] pyridine derivatives as PD-L1 immunomodulators
JP2021524842A (en) * 2018-05-11 2021-09-16 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Tetrahydro-imidazole [4,5-C] pyridine derivative as PD-L1 immunomodulator
TWI821288B (en) * 2018-05-11 2023-11-11 美商英塞特公司 Heterocyclic compounds as immunomodulators
US10618916B2 (en) 2018-05-11 2020-04-14 Incyte Corporation Heterocyclic compounds as immunomodulators
CN112752756A (en) * 2018-05-11 2021-05-04 因赛特公司 Tetrahydro-imidazo [4,5-c ] pyridine derivatives as PD-L1 immunomodulators
JP7328995B2 (en) 2018-05-11 2023-08-17 インサイト・コーポレイション Tetrahydro-imidazo[4,5-C]pyridine derivatives as PD-L1 immunomodulators
EP4219492A1 (en) * 2018-05-11 2023-08-02 Incyte Corporation Heterocyclic compounds as immunomodulators
US10906920B2 (en) 2018-05-11 2021-02-02 Incyte Corporation Heterocyclic compounds as immunomodulators
US11414433B2 (en) 2018-05-11 2022-08-16 Incyte Corporation Heterocyclic compounds as immunomodulators
US11873304B2 (en) 2018-05-18 2024-01-16 Incyte Corporation Fused pyrimidine derivatives as A2A/A2B inhibitors
US11999740B2 (en) 2018-07-05 2024-06-04 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
US10774071B2 (en) 2018-07-13 2020-09-15 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2020014643A1 (en) 2018-07-13 2020-01-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
EP4234030A2 (en) 2018-07-13 2023-08-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2020092621A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
EP4371987A1 (en) 2018-10-31 2024-05-22 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
WO2020088357A1 (en) 2018-11-02 2020-05-07 上海再极医药科技有限公司 Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof
US11884665B2 (en) 2019-01-29 2024-01-30 Incyte Corporation Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors
WO2020156564A1 (en) * 2019-02-02 2020-08-06 南京明德新药研发有限公司 Vinylpyridine carboxamide compound as pd-l1 immunomodulator
KR102668124B1 (en) 2019-02-02 2024-05-23 노바온코 제이에스 테라퓨틱스 컴퍼니 리미티드 Vinyl pyridine carboxamide compounds, PD-L1 immunomodulators
KR20210124329A (en) * 2019-02-02 2021-10-14 메드샤인 디스커버리 아이엔씨. Vinyl pyridine carboxamide compound as a PD-L1 immunomodulator
WO2020178770A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020178769A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020192570A1 (en) 2019-03-22 2020-10-01 上海再极医药科技有限公司 Small-molecule inhibitor of pd-1/pd-l1, pharmaceutical composition thereof with pd-l1 antibody, and application of same
WO2020214663A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2020214652A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
US11266643B2 (en) 2019-05-15 2022-03-08 Chemocentryx, Inc. Triaryl compounds for treatment of PD-L1 diseases
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
US11485708B2 (en) 2019-06-20 2022-11-01 Chemocentryx, Inc. Compounds for treatment of PD-L1 diseases
US11872217B2 (en) 2019-07-10 2024-01-16 Chemocentryx, Inc. Indanes as PD-L1 inhibitors
WO2021007386A1 (en) 2019-07-10 2021-01-14 Chemocentryx, Inc. Indanes as pd-l1 inhibitors
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
US11753406B2 (en) 2019-08-09 2023-09-12 Incyte Corporation Salts of a PD-1/PD-L1 inhibitor
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
US11401279B2 (en) 2019-09-30 2022-08-02 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
WO2021067181A1 (en) 2019-09-30 2021-04-08 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
US11866429B2 (en) 2019-10-16 2024-01-09 Chemocentryx, Inc. Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases
US11713307B2 (en) 2019-10-16 2023-08-01 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
US11866451B2 (en) 2019-11-11 2024-01-09 Incyte Corporation Salts and crystalline forms of a PD-1/PD-L1 inhibitor
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
WO2021138512A1 (en) 2020-01-03 2021-07-08 Incyte Corporation Combination therapy comprising a2a/a2b and pd-1/pd-l1 inhibitors
WO2021136354A1 (en) 2020-01-03 2021-07-08 上海翰森生物医药科技有限公司 Biphenyl derivative inhibitor, preparation method therefor and use thereof
WO2021147940A1 (en) * 2020-01-21 2021-07-29 上海华汇拓医药科技有限公司 Pd-1/pd-l1 inhibitor, preparation method therefor, and use thereof
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
WO2021226206A2 (en) 2020-05-05 2021-11-11 Teon Therapeutics, Inc. Cannabinoid receptor type 2 (cb2) modulators and uses thereof
WO2022052926A1 (en) 2020-09-09 2022-03-17 广州再极医药科技有限公司 Aromatic ethylene compound and preparation method therefor, and intermediate, pharmaceutical composition, and application thereof
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
US12084443B2 (en) 2020-11-06 2024-09-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
US11866434B2 (en) 2020-11-06 2024-01-09 Incyte Corporation Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
WO2022147092A1 (en) 2020-12-29 2022-07-07 Incyte Corporation Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
WO2022241134A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
US11931424B2 (en) 2021-06-11 2024-03-19 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-body drug conjugates
WO2022261310A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
WO2022261301A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
US11957693B2 (en) 2021-06-11 2024-04-16 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-cancer agents
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023034530A1 (en) 2021-09-02 2023-03-09 Teon Therapeutics, Inc. Methods of improving growth and function of immune cells
WO2023081730A1 (en) 2021-11-03 2023-05-11 Teon Therapeutics, Inc. 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
WO2023097211A1 (en) 2021-11-24 2023-06-01 The University Of Southern California Methods for enhancing immune checkpoint inhibitor therapy
WO2024015372A1 (en) 2022-07-14 2024-01-18 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof

Also Published As

Publication number Publication date
JP7000357B2 (en) 2022-01-19
US20190040082A1 (en) 2019-02-07
EP4137489A1 (en) 2023-02-22
HUE060256T2 (en) 2023-02-28
EP3472167A1 (en) 2019-04-24
DK3472167T3 (en) 2022-09-05
US11873309B2 (en) 2024-01-16
CL2018003701A1 (en) 2019-04-05
AU2021250978A1 (en) 2021-11-11
AU2017281285C1 (en) 2022-05-12
BR112018076534A2 (en) 2019-04-02
CO2019000386A2 (en) 2019-04-30
IL263825A (en) 2019-01-31
KR20190035694A (en) 2019-04-03
CN109890819A (en) 2019-06-14
AU2021250978B2 (en) 2023-11-09
HRP20221030T1 (en) 2022-11-11
US20210317139A1 (en) 2021-10-14
SG10202012828TA (en) 2021-01-28
JP7394824B2 (en) 2023-12-08
PH12018502710A1 (en) 2019-04-15
SG11201811414TA (en) 2019-01-30
PT3472167T (en) 2022-11-11
PE20190731A1 (en) 2019-05-23
AU2017281285A1 (en) 2019-01-31
LT3472167T (en) 2022-11-10
US20190062345A1 (en) 2019-02-28
MD3472167T2 (en) 2023-02-28
EP3472167B1 (en) 2022-08-03
TWI771305B (en) 2022-07-21
CA3028685A1 (en) 2017-12-28
IL263825B (en) 2022-08-01
CN109890819B (en) 2022-11-22
AU2017281285B2 (en) 2021-11-04
PL3472167T3 (en) 2022-12-19
UA125391C2 (en) 2022-03-02
RS63673B1 (en) 2022-11-30
MX2018016273A (en) 2019-07-04
TW201800409A (en) 2018-01-01
JP2022058400A (en) 2022-04-12
MX2022000789A (en) 2022-02-14
JP2019523231A (en) 2019-08-22
KR102685249B1 (en) 2024-07-17
ES2927984T3 (en) 2022-11-14
ECSP19003773A (en) 2019-04-30
MY197280A (en) 2023-06-09
SI3472167T1 (en) 2022-11-30
US20170362253A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
AU2017281285B2 (en) Heterocyclic compounds as immunomodulators
US11407749B2 (en) Heterocyclic compounds as immunomodulators
US11866435B2 (en) Heterocyclic compounds as immunomodulators
US11566026B2 (en) Heterocyclic compounds as immunomodulators
EP3558973B1 (en) Pyridine derivatives as immunomodulators
EP3452476B1 (en) Heterocyclic compounds as immunomodulators
AU2016358100B2 (en) Heterocyclic compounds as immunomodulators
WO2017106634A1 (en) N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators
NZ788114A (en) Heterocyclic compounds as immunomodulators

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17734589

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2018566514

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3028685

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018076534

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: NC2019/0000386

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 20197001807

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017734589

Country of ref document: EP

Effective date: 20190121

ENP Entry into the national phase

Ref document number: 2017281285

Country of ref document: AU

Date of ref document: 20170619

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112018076534

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20181219